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Abstract 
 
 Stress is defined as a challenge to homeostatic equilibrium by physical or 
psychological events, generating a coping response consisting of central and 
peripheral changes, with the aim of exerting control over the threatening events. 
Corticotropin-releasing factor (CRF) is well known as a hypothalamic factor 
which controls the hypothalamic-pituitary-adrenocortical (HPA) axis during basal 
activity and stress. CRF also serves a neurotransmitter function in the brain, 
where it is implicated in a range of stress-related behaviours. 
 
 The measurement of local cerebral glucose utilisation (LCGU) using 
radiolabelled 2-deoxy-D-glucose (2DG) provides an estimate of cellular activity in 
the brain. 2DG competes with glucose in its metabolic pathway, but is not fully 
metabolised, instead accumulating within astrocytes where it can be quantified. 
 
 After consideration of available modifications to the LCGU technique, the 
effect of manipulating the CRF system on LCGU was studied, in order to test the 
hypothesis that CRF and other endogenously expressed CRF-related peptides 
would induce different patterns of LCGU, and to examine the involvement of 
CRF receptors in any response. The CRF1 receptor has been implicated in the 
mediation of stress- and anxiety-related behaviour, while recent evidence has 
suggested a role for CRF2 in mediating the delayed effects of stress, although it 
has previously been postulated that CRF2 may be involved in the attenuation of 
stress-related behaviour. 
 
 CRF and the endogenous CRF-related peptide Urocortin 1 both induced 
increases in LCGU in a number of brain regions associated with the CRF 
system, with concomitant activation of the HPA axis. CRF induced increases in 
LCGU in the dissected hypothalamus, thalamus, cerebellum and hippocampus, 
while Urocortin 1 induced a significant increase in LCGU in a dissected hindbrain 
region, with trend-like effects in frontal cortex and hippocampus. These regions 
contain components of the CRF system, or receive projections from regions 
involved in the CRF system, and have been implicated in stress-related function. 
The effects of CRF on LCGU appear to be mediated by the CRF2 receptor, as 
 xix 
they were abolished by the selective CRF2 antagonist antisauvagine-30, but 
persisted in mice lacking CRF1 and were unaffected by a selective CRF1 
antagonist. However, neither of the endogenous CRF-related peptides selective 
for CRF2, Urocortin 2 and Stresscopin, affected LCGU, which may indicate 
ligand-specific effects within the CRF system. 
  
 In contrast to the effects of CRF, restraint stress reduced LCGU, while 
activating the HPA axis, and this response was unaffected by a selective CRF1 
antagonist. This data suggests that the role of CRF receptors in restraint-induced 
LCGU changes may be overshadowed by effects on other neurotransmitter 
systems. 
 
 These studies support the hypothesis that CRF and other endogenously 
expressed CRF-related peptides would induce different patterns of LCGU, and 
highlight the involvement of particular brain regions in the response to CRF 
receptor stimulation. Furthermore, these studies provide evidence suggesting 
ligand-specific effects within the CRF system. 
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Corticotropin-Releasing Factor: An Overview 
 
Corticotropin-releasing factor (CRF), a 41-residue staight-chain peptide 
isolated initially in 1981 from ovine hypothalamus by Vale and colleagues at the 
Salk Institute (Vale et al., 1981), is most well known for its role in the 
hypothalamic-pituitary-adrenocortical (HPA) axis, one of the main effector 
systems that are activated in numerous species upon exposure to an acute 
stressor.  
 
Stress is defined as a challenge to homeostatic equilibrium by physical or 
psychological events (McEwen, 2003), generating a coping response consisting 
of central and peripheral changes, with the aim of exerting control over the 
threatening events. Effective coping implies that a stress response is effectively 
triggered when required and is terminated appropriately (de Kloet et al., 2005). 
However, if the stress response is inadequate or prolonged excessively, a series 
of pathophysiological changes may occur in the brain, immune system and 
viscera (Musselman and Nemeroff, 2000; Sapolsky, 2000; Mayer and Fanselow, 
2003; Sorrells and Sapolsky, 2007), that may ultimately contribute to the 
development of disorders including depression and post-traumatic stress 
disorder. 
 
CRF is also expressed throughout the brain, and dysfunction of the CRF 
system has been implicated in a number of stress-related disorders. Since its 
discovery, CRF has been linked to numerous endogenous functions, both 
centrally and peripherally mediated. CRF is implicated in a range of functions 
that may be affected by stress, including cognitive processes, regulation of food 
intake and satiety, gastrointestinal motility, vascular tone and development, 
hearing and cardiac function, demonstrating the vast importance of the CRF 
family (Bale and Vale, 2004). The CRF system and its hypothesised role in the 
brain will be discussed in more detail below. 
 
In response to acute physical or psychological stress, parvocellular 
neurons of the paraventricular hypothalamic nucleus (PVN) produce increased 
amounts of CRF. CRF enters the portal circulation to regulate 
proopiomelanocortin (POMC)-derived peptide (mainly adrenocorticotropic 
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hormone (ACTH) and beta-endorphin) synthesis and secretion from the anterior 
pituitary (Rivier and Plotsky, 1986). In turn ACTH enters the circulation and 
stimulates glucocorticoid (e.g. corticosterone, the glucocorticoid most associated 
with the stress response in rodents; cortisol in humans) release from the adrenal 
gland. This extended pathway constitutes the HPA axis (illustrated in Figure 1). 
Glucocorticoids readily penetrate the blood-brain barrier and exert feedback on 
the HPA axis.  
 
Figure 1: The HPA axis, with examples of both effects mediated by increased 
circulating glucocorticoids, and central CRF (Adapted from Holsboer, 1999). 
 
CRF
PVN
Anterior Pituitary
↑ACTH
Circulation
Adrenal Glands
↑Glucocorticoids
↑ Gluconeogenesis
↑ Lipolysis
↑ Proteolysis
↑ Insulin Resistance
↑ Arousal
↑ ↓ Cognition
↑ Stress/Anxiety/Fear
↑ ↓ Autonomic Effects
 
 
A stress-related CRF pathway has been suggested (Lee and Davis, 
1997). It includes CRF input into the central nucleus of the amygdala (CeA), 
originating in the lateral hypothalamus, dorsal raphe and intrinsic cells of the CeA 
(Gray, 1993). CRF neurons in the CeA project to the bed nucleus of the stria 
terminalis (BNST) (Sakanaka et al., 1986), from where there are CRF projections 
to the PVN, leading to activation of the HPA axis. HPA axis activation results in 
corticosterone release from the adrenal gland which self-regulates through three 
major feedback mechanisms: 1) negative feedback at the level of PVN neurons 
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and anterior pituitary (Swanson and Simmons, 1989); 2) positive feedback at the 
CeA and the dorsal PVN, from where spinal projections of CRF neurons emerge 
(Swanson and Simmons, 1989; Gray and Bingaman, 1996) and 3) negative 
feedback through the ventral hippocampus, which projects to the BNST via the 
fimbria/fornix (Herman et al., 1992; Cullinan et al., 1993). Negative feedback on 
the HPA axis may also exist at the level of the medial prefrontal cortex (mPFC), 
as corticosterone administered directly into the mPFC has been shown to 
attenuate stress-induced HPA activation (Diorio et al., 1993). 
 
 However, CRF, its receptors and related peptides, are not restricted to the 
pathways of the HPA axis, and its function via these other regions has been 
linked to a number of behaviours and pathological states. The extended 
distribution of the CRF system and its postulated roles will be discussed below. 
 
The Distribution of CRF 
 
The hypothalamic PVN is the major site of CRF-containing cell bodies 
(Merchenthaler, 1984; Swanson and Simmons, 1989) (Figure 2b). These cell 
bodies send axon terminals to the capillaries of the median eminence, from 
where CRF enters the portal circulation to regulate pituitary ACTH release. Other 
CRF neurons of PVN origin project to the brainstem and spinal cord, both of 
which contain CRF cell bodies and influence behavioural activity and autonomic 
function (Vale et al., 1981; De Souza, 1995). 
 
In addition to CRF in the PVN, in the rat there are large and discrete 
populations of CRF neurons in the CeA, the BNST, the hippocampus, the 
accumbens, the posteromedial thalamic nuclei such as the mediodorsal nuclei, 
the substantia nigra, the locus coeruleus (LC), the dorsal and the medial raphe 
nuclei, the periaqueductal grey, the olfactory bulbs, the parabrachial nuclei, the 
nucleus of the solitary tract (NTS) and the cerebellum (Swanson et al., 1983; 
Merchenthaler et al., 1984; Merchenthaler, 1984; Sakanaka et al., 1987; Van 
Bockstaele et al., 1996; Morin et al., 1999). Particularly high densities of CRF-
containing neurons are found in the prefrontal and cingulate cortices, and 
throughout the neocortex, emphasising a possible role of CRF in cognitive 
processes (Swanson et al., 1983). In humans, CRF-immunoreactivity has been 
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found in the frontal cortex, temporal cortex, occipital cortex, thalamus, 
hypothalamus, medulla oblongata, and in the cerebellum and low CRF 
concentrations were also found in the pons (Takahashi et al., 1998).  
 
CRF neurons located in the PVN project to the LC (Valentino et al., 1992) 
(Figure 2a). Another CRF projection to the LC originates in the BNST (Van 
Bockstaele et al., 1998), which also sends projections to noradrenergic neurons 
in the NTS (Gray and Magnuson, 1987). CRF cell bodies and fibres are also 
associated with the serotonergic neurons at the level of the raphe nuclei 
(Cummings et al., 1983; Sakanaka et al., 1986; Austin et al., 1997; Ruggiero et 
al., 1999). However, most extrahypothalamic CRF neurons are located within the 
CeA, from where CRF neurons project to areas including the PVN (Gray, 1993), 
BNST (Sakanaka et al., 1986) and the LC (Valentino et al., 1993; Koegler-Muly 
et al., 1993). Finally, another CRF projection originates in the medial amygdala 
and innervates the ventromedial hypothalamic nucleus (VMH) (Sakanaka et al., 
1986; Gray, 1993). 
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Figure 2: (a) CRF pathways, (b) CRF peptide, (c) CRF receptor mRNA, and (d) 
Urocortin 1, 2, 3 mRNA distributions in the rodent brain; adapted from (Holmes et 
al., 2003);  
Abbreviations: 7, facial nucleus, 12, hypoglossal nucleus, A1, A5, noradrenaline-
containing cell groups, ac, anterior commissure, Amb, ambiguus nucleus, AON, 
anterior olfactory nucleus, APit, anterior pituitary, Arc, arcuate nucleus, Basal G, 
basal ganglia, BLA, basolateral amygdala, BNST, bed nucleus of the stria 
terminalis, CA1, 2, 3, fields CA1, 2, 3, of the hippocampus, cc, corpus callosum, 
CeA, central nucleus of the amygdala, CG, central grey matter, CingCx, 
cingulate cortex, CoA, cortical nucleus of the amygdala, DBB, diagonal band of 
broca, DeepN, deep nuclei, DG, dentate gyrus, DR, dorsal raphe, DVC, dorsal 
motor nucleus of the vagus, EW, edinger westphal nucleus, FrCx, frontal cortex, 
Hipp, hippocampus, IC, inferior colliculi, LC, locus coeruleus, LDTg, laterodorsal 
tegemental nucleus, LH, lateral hypothalamus, LS, lateral septum, LSO, lateral 
superior olive, MeA, medial nucleus of the amygdala, MePO, median preoptic 
nucleus, mfb, median forebrain bundle, MPO, median preoptic area, MR, median 
raphe, MS, medial septum, MVN, medial vestibular nucleus, NTS, nucleus of the 
solitary tract, OB, olfactory bulb, OccCx, occipital cortex, PAG, periaqueductal 
grey, ParCx, parietal cortex, PB, parabrachial nucleus, PFA, perifornical area, 
POR, perioculomotor nucleus, PPit, posterior pituitary, PPTg, pendunculopontine 
tegmental nucleus, PVN, paraventicular nucleus of the hypothalamus, R, red 
nucleus, RN, raphe nuclei, SC, superior colliculi, SI, substantia inominata, SN, 
substantia nigra, SON, supraoptic nucleus, Sp5n, spinal trigeminus nucleus, 
SPO, superior paraolivary nucleus, Thal, thalamus, VMH, ventromedial 
hypothalamus. 
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CRF receptors 
 
Two primary subtypes of CRF receptor have been discovered, CRF1, the 
most abundant in the brain, and CRF2, of which two major splice-variants have 
been reported, CRF2(a), the primary variant in the brain and CRF2(b), 
predominantly expressed in the periphery. CRF is a non-specific agonist at both 
receptors, although it has a greater affinity for CRF1 (Table 2). 
 
The CRF1 receptor has been cloned from a variety of species, including 
human (Chen et al., 1993; Vita et al., 1993), mouse (Vita et al., 1993), rat (Perrin 
et al., 1993; Chang et al., 1993), chicken (Yu et al., 1996), frog (Dautzenberg et 
al., 1997), sheep (Myers et al., 1998), tree shrew (Palchaudhuri et al., 1998) and 
fish (Arai et al., 2001; Pohl et al., 2001).  
 
A number of splice variants of the CRF1 receptor cDNA have been 
identified (Chen et al., 1993; Chang et al., 1993; Ross et al., 1994; Myers et al., 
1998; Grammatopoulos et al., 1999), but these have not been shown to encode 
functional receptors in vivo due to their low binding affinity or lack of activation in 
recombinant systems (Hauger et al., 2003). 
 
Expression of CRF1 has been observed in frontal cortical areas, the 
cholinergic basal forebrain (medial septum and ventral and horizontal limbs of 
the diagonal band of Broca), the brainstem cholinergic nuclei (laterodorsal 
tegmental nucleus and the pendunculopontine tegmental nucleus), the ventral 
tegmental area, the superior colliculus, the basolateral nucleus of the amygdala 
(BLA), the cerebellum, the red nucleus, the trigeminal nuclei, the anterior 
pituitary (Steckler and Holsboer, 1999), the hippocampus, substantia nigra pars 
compacta and pars reticularis, the LC and at the level of the substantia 
innominata (Sauvage and Steckler, 2001) (Figure 2c). 
 
The CRF2 receptor has been cloned from man (Liaw et al., 1996; 
Valdenaire et al., 1997; Kostich et al., 1998), mouse (Perrin et al., 1995; 
Kishimoto et al., 1995; Stenzel et al., 1995), rat (Lovenberg et al., 1995b), frog 
(Dautzenberg et al., 1997), tree shrew (Dautzenberg et al., 1997; Palchaudhuri 
et al., 1999) and fish (Arai et al., 2001; Pohl et al., 2001). 
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Three functional splice variants of the CRF2 receptor have so far been 
identified: CRF2(a) (Lovenberg et al., 1995b), CRF2(b) (Lovenberg et al., 1995b) 
and CRF2(c) (Kostich et al., 1998).  
 
CRF2(a) is a 411 amino acid protein with approximately 71% identity to the 
CRF1 receptor (Lovenberg et al., 1995b), and is the dominant CRF2 splice 
variant expressed in the mammalian brain (Hauger et al., 2003).  
 
CRF2(b) is 431 amino acids in length and differs from CRF2(a) in that the 
first 34 amino acids in the N-terminal extracellular domain are replaced by 54 
different amino acids (Perrin et al., 1995). This receptor is primarily expressed in 
the periphery, and may be involved in some of the effects of CRF which are not 
centrally mediated. 
 
Expression of the 397-amino acid CRF2(c) receptor has only been detected 
in limbic regions of the human central nervous system, and it shows similar 
pharmacological characteristics to CRF2(a) (Kostich et al., 1998). 
 
CRF2(a) is localised to subcortical regions, including the lateral septum, the 
PVN and VMH, the cortical and medial nuclei of the amygdala, and the 
serotonergic Raphé nuclei (Lovenberg et al., 1995b; Steckler and Holsboer, 
1999) (Figure 2c). 
 
Combined populations of both CRF1 and CRF2(a) have been reported in 
the olfactory bulb, the hippocampus, the entorhinal cortex, the BNST and the 
PAG (Lovenberg et al., 1995b) 
 
CRF2(b) is primarily localised to the heart, skeletal muscle, and in the brain 
to cerebral arterioles and choroid plexus (Lovenberg et al., 1995a). Due to this 
lack of expression in the brain, the CRF2(b) receptor has not been implicated in 
stress related conditions, or the stress response. 
 
 The most recently described novel CRF2 receptor is a truncated variant of 
CRF2(a), cloned from the rat amygdala (Miyata et al., 1999). Compared to the 
CRF2(a) receptor, this new subtype is more strongly expressed in the rat 
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amygdala, thalamus and hypothalamus and it is suggested that this receptor 
may regulate endogenous CRF release in the amygdala (Miyata et al., 2001). 
 
 A role for CRF1 in the regulation of HPA axis activity has been clearly 
demonstrated by studies using selective CRF1 antagonists, such as 
CRA0450/R278995 (Chaki et al., 2004), CRA5626 (Steckler et al., 2006), CP-
154, 526 (Schulz et al., 1996), antalarmin (Webster et al., 1996; Bornstein et al., 
1998), SSR125543A (Gully et al., 2002), R121919 (Gutman et al., 2003), 
DMP696 (Maciag et al., 2002), DMP904 (Lelas et al., 2004) and CRA1000 
(Pournajafi et al., 2001), which reduced CRF-induced increases in plasma ACTH 
and/or corticosterone. Indeed CRF1 is the main CRF receptor subtype at the 
anterior pituitary level (Chalmers et al., 1995) and was therefore expected to 
have a strong influence on HPA axis activity (Steckler, 2001), while CRF2(a) 
predominates at the level of the PVN (Chalmers et al., 1995). 
 
 Stress-induced corticosterone levels were reduced in CRF1-deficient mice 
(Timpl et al., 1998). Basal ACTH secretion in these mice is normal, while stress-
induced heightened ACTH levels are reduced (Timpl et al., 1998). Unaltered 
basal ACTH may be explained by the influence of other hormones stimulating 
ACTH release, such as vasopressin, which acts synergistically with CRF on 
ACTH release, but in contrast to CRF, is unable to increase ACTH synthesis 
under acute stress conditions (Aguilera et al., 1983; De Bold et al., 1984). In a 
second line of CRF1-deficient mice (Smith et al., 1998), stress-induced ACTH 
and corticosterone responses were also reduced. 
 
 In addition to these two major CRF receptors expressed in the brain, a 
CRF binding protein (CRF-BP) exists. In the brain, CRF-BP is hypothesised to 
serve as a regulatory factor in HPA activation, as well as extrahypothalamic CRF 
neurotransmission (Kemp et al., 1998). Indeed, it has been shown to function as 
an endogenous buffer for CRF and related peptides (Behan et al., 1996). CRF-
BP binds both native rat/human CRF and Urocortin 1 (discussed below) with 
higher affinity than CRF receptors (Vaughan et al., 1995). As Urocortin 1 also 
binds CRF-BP with high affinity, albeit less than CRF itself (Behan et al., 1996), it 
has been proposed that Urocortin 1 may act endogenously to elevate CRF levels 
through competition at CRF-BP. 
Chapter 1  Introduction 
 11 
 
 A number of other peptides related to CRF and endogenous to various 
species have also been discovered. Some of these peptides have been used in 
the production of research tools (e.g. frog sauvagine (Erspamer et al., 1980) was 
used in the production of the selective CRF2 antagonist antisauvagine-30 
(Ruhmann et al., 1998)), and those endogenous to both rodents and humans 
have received particular interest. These peptides have been dubbed the 
Urocortins.  
 
The Urocortins 
 
 Urocortin 1 (Vaughan et al., 1995) has 45% homology to human CRF 
(Table 1) and has a high affinity for both CRF1 and CRF2 receptors, greater than 
CRF itself, with approximately equal affinity for CRF1 and CRF2(a) (Table 2) 
 
Mouse Urocortin 2 (Reyes et al., 2001) (mUrocortin 2) is a 38 amino acid 
peptide with 34% amino acid identity with rat CRF (Table 1) and is highly 
selective for CRF2 (Table 2). Human Urocortin 2 (hUrocortin 2; also known as 
Stresscopin-related peptide) was originally identified along with hUrocortin 3 
(also known as Stresscopin) from Takifugu rubripes (Japanese pufferfish), and 
Tetraodon nigroviridis (a freshwater pufferfish) (Hsu and Hsueh, 2001). 
hUrocortin 3 shares 32% amino acid identity with human CRF (Table 1), and 
hUrocortin 2 shares 34% homology to human CRF. Both hUrocortin 2 and 
hUrocortin 3 are highly selective for CRF2, though hUrocortin 3 is less potent at 
CRF2 than mUrocortin 3 (Lewis et al., 2001).  
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Table 1: Sequence comparison of CRF peptides. Identical amino acids in all 
peptides are underlined (Abbreviations: r, rat; h, human; o, ovine; m, mouse) 
(Adapted from Dautzenberg et al., 2001; Lewis et al., 2001) 
 
Peptide Amino acid sequence Length Homology (%) 
rhCRF SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII 41 100 
oCRF SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA 41 83 
rUrocortin 1 DDPPLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV 40 45 
hUrocortin 1 DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV 40 43 
hUrocortin 2 IVLSLDVPIGLLQILLEQARARAAREQATTNARILARV 38 34 
mUrocortin 2 VILSLDVPIGLLRILLEQARYKAARNQAATNAQILAHV 38 34 
hUrocortin 3 FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI 38 32 
mUrocortin 3 FTLSLDVPTNIMNILFNIDKAKNLRAKAAANAQLMAQI 38 26 
 
 
Table 2: Inhibitory binding constants (Ki) (nM) of CRF peptides at human CRF 
receptors 
 
Peptide hCRF1 hCRF2(a) hCRF2(b) Reference 
rhCRF 1.5 42 47 
oCRF 1.1 230 320 
rUrocortin 1 0.3 0.4 0.4 
hUrocortin 1 0.4 0.3 0.5 
Dautzenberg et al., 2001 
hUrocortin 2 >100 1.7                0.5 
mUrocortin 2 >100 2.1 0.66 
hUrocortin 3 >100 21.7 13.5 
mUrocortin 3 >100 5.0 1.8 
Lewis et al., 2001 
 
 
In the rat, Urocortin 1 expression has been found in the Edinger-Westphal 
nucleus, the lateral superior olive, the lateral hypothalamus and the supraoptic 
nucleus (all regions that have not been shown to express CRF mRNA) the 
cholinergic laterodorsal tegmental nucleus, the serotonergic dorsal raphe 
nucleus, and the PAG (Kozicz et al., 1998) (Figure 2d). Moderate levels of 
Urocortin 1 mRNA are also found in the hippocampus, the basal ganglia, the 
medial septum, the medial and cortical amygdaloid nuclei, the PVN and the 
VMH, the superior colliculus, the red nucleus, the substantia nigra, and the 
cerebellar cortex (Wong et al., 1996). A much more uniform distribution of 
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Urocortin 1 has been reported in the human brain, with Urocortin 1-like 
immunoreactivity in the frontal, temporal and occipital cortices, the thalamus, 
hypothalamus, pons, medulla oblongata and cerebellum (Takahashi et al., 1998). 
Direct comparison by Morin et al. (1999) of CRF and Urocortin 1 
immunoreactivity in the rat brain revealed limited overlap of CRF and Urocortin 1 
expression, only overlapping in the supraoptic nucleus and the hippocampus, 
potentially suggesting that the peptides have distinct functions. 
 
 Urocortin 2 mRNA expression is primarily subcortical, with major sites of 
expression in stress-related cell groups such as the PVN, supraoptic and arcuate 
nuclei of the hypothalamus, and the LC. Secondary sites of expression were 
observed in the motor nuclei of the brain stem (trigeminal, facial, hypoglossal), 
as well as in the spinal ventral horn (Reyes et al., 2001) (Figure 2d). 
 
 Urocortin 3 mRNA expression has been reported in the median preoptic 
nucleus, fornix, BNST, anterior and lateral hypothalamus and just lateral to the 
PVN, the dorsomedial hypothalamic nucleus, the ventral part of the anterior 
periventricular nucleus, the retrochiasmatic area, the medial amygdala and the 
auditory-related superior paraolivary nucleus (Lewis et al., 2001) (Figure 2d). 
Immunohistochemistry confirms this distribution (Li et al., 2002), and revealed 
Urocortin 3-immunoreactive fibres in the VMH, the predominant site of CRF2 
receptor (discussed below) expression within the hypothalamus (Chalmers et al., 
1995; Van Pett et al., 2000), extending to the lateral arcuate nucleus, and from 
the rostral arcuate nucleus into the retrochiasmatic area. A small number of 
fibres were found in the dorsomedial nucleus and the lateral hypothalamus, while 
abundant fibres were present in the anterior hypothalamus. Fibres were also 
found in the medial preoptic area, and in the posterior hypothalamus. Urocortin 
3-immunoreactive fibres extended through the supramammillary nucleus to the 
ventral premammillary nucleus. In the median eminence fibres were present in 
the internal zone. Outside the hypothalamus, fibres were present in the lateral 
septum, posterior BNST and medial amygdala, all CRF2 expressing areas 
(Chalmers et al., 1995; Van Pett et al., 2000), and extended into the ventral 
hippocampus. In the thalamus, fibres were found in the posterior paraventricular 
nucleus and the lateral habenula. In the midbrain and brainstem, low numbers of 
fibres were found in areas with low CRF2 expression, including the dorsal and 
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dorsolateral periaqueductal grey, the superior and inferior colliculi and the ventral 
lateral leminiscus (Li et al., 2002). 
 
 Based on the central distribution of the Urocortins and CRF2 expressing 
neurons (discussed below), it has been suggested that Urocortin 1 may serve as 
the major endogenous CRF2 ligand in the hindbrain, whereas Urocortin 3 may 
serve as the major CRF2 ligand in the forebrain (Hauger et al., 2003). Urocortin 
2, on the other hand, may signal at CRF2 receptors expressed in regions lacking 
Urocortin 1 or Urocortin 3 innervation, e.g., hippocampus and certain regions of 
the cerebral cortex (Hauger et al., 2003). 
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CRF and its relationship with other systems 
 
 The distribution of the CRF-system components discussed so far overlaps 
with numerous regions and neuronal pathways associated with other 
neurotransmitter systems. In addition to such suggestive evidence for 
interactions with other neurotransmitter systems in the brain, many studies have 
provided further anatomical and functional evidence. 
 
Glutamatergic System 
 
 Interaction between the CRF and glutamatergic systems appears to be 
both region and receptor dependent. Activation of CRF1 receptors in the rat 
lateral septum with CRF facilitates glutamatergic synaptic transmission, while 
activation of CRF2 receptors with Urocortin 1 depresses this transmission (Liu et 
al., 2004; Liu et al., 2005). Conversely, in the CeA, CRF depresses glutamatergic 
transmission, while Urocortin 1 facilitates it (Liu et al., 2004). Glutamatergic 
transmission in these nuclei appears to be tonically modulated through these 
receptors, as CRF receptor antagonists also modulated transmission (Liu et al., 
2004). 
 
Noradrenergic System 
 
CRF projections originating in the CeA, the PVN and the BNST terminate 
in the noradrenergic LC, which may have a role in arousal in response to 
emotional stressors, and possibly affect attentional processes (Carli et al., 1983; 
Cole and Robbins, 1992; Usher et al., 1999). Noradrenergic projections return to 
the BNST and the CeA (Heinrichs et al., 1991; Koob and Heinrichs, 1999), 
raising the possibility of feedback loops. 
 
Centrally administered (intracerebroventricular, or ICV) CRF, or CRF 
infused directly into the LC increases the firing rate of the LC (Curtis et al., 1997), 
and increases the release of noradrenaline in LC projections (Smagin et al., 
1995). Infusion of CRF into the LC also produces an increase in catecholamine 
activity and turnover in the frontal cortex along with increased anxiety-related 
behaviour (Butler et al., 1990). ICV CRF and Urocortin 1 increased hippocampal 
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levels of noradrenaline and its metabolite 3-methoxy-4-hydroxyphenylglycol, 
whereas Urocortin 2 and Urocortin 3 elevated 3-methoxy-4-hydroxyphenylglycol, 
but not noradrenaline levels (de Groote et al., 2005). Activation of the LC by 
stress has also been prevented by administration of CRF antagonists directly 
into the LC region (Valentino et al., 1991; Curtis et al., 1994; Lechner et al., 
1997). In addition, stressors increase the concentration of CRF in the LC 
(Chappell et al., 1986), and noradrenergic antagonists have been shown to 
reverse some of the stress-like effects of ICV CRF (Cole and Koob, 1988). 
Stress has also been shown to induce noradrenaline release in the PVN (Pacak 
et al., 1995b) and the BNST (Pacak et al., 1995a). Noradrenaline in the PVN and 
CeA  may also be involved in stimulating the release of CRF (Raber et al., 1995). 
 
A feed-forward system of interactions between the CRF and 
noradrenaline systems has been proposed (Koob, 1999), in which, after 
stimulation of the LC by CRF, as described above, noradrenaline is capable of 
stimulating CRF release in terminal projections of the forebrain noradrenergic 
systems, such as the PVN, the BNST and the CeA. It has been hypothesised 
that such a system may be an important link between activation of the HPA axis 
and the central nervous system, although such a system may also be vulnerable 
to dysfunction (Koob, 1999).  
 
Serotonergic (5-Hydroxy-tryptamine; 5-HT) System 
 
CRF interacts with the serotonergic system at the level of the dorsal raphe 
nuclei (DR) (Price et al., 1998), which provides one of the major sources for 
forebrain 5-HT innervation (Azmitia and Segal, 1978), and also affect a wide 
range of different types of behaviour (Soubrie, 1986; Steckler and Sahgal, 1995; 
Lucki, 1998). ICV injection of CRF or Urocortin 1, 2, or 3 has been shown to 
increase levels of 5-HT and its metabolite 5-HIAA in the hippocampus (Linthorst 
et al., 2002; de Groote et al., 2005), and the increase in hippocampal 5-HT 
associated with diving during forced-swim could be antagonised by the CRF 
antagonist D-Phe-CRF12-41 (Linthorst et al., 2002). Mutant mice deficient for 
CRF1 receptors have altered levels of 5-HIAA although not serotonin (Penalva et 
al., 2002). Further evidence supports effects of ICV CRF on 5-HT levels in other 
brain regions. ICV CRF has also been shown to influence 5-HT and 5-HIAA 
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levels in the DR and MR of previously stressed rats (Summers et al., 2003), and 
ICV CRF is reported to increase 5-HT and 5-HIAA levels in the dorsomedial 
hypothalamus (Lowry et al., 2001). Co-localisation of 5-HT and CRF receptors 
has been demonstrated in the DR (Day et al., 2004), and both ICV CRF, and 
CRF injected into the DR inhibit neuronal activity (although high doses may even 
increase activity) (Price et al., 1998; Kirby et al., 2000). The inhibitory effect of 
CRF in the DR could be blocked by CRF1 antagonists (Kirby et al., 2000). 
However, in vitro, CRF has been reported to increase the firing rates of neurons 
from the ventral portion of the DR (Lowry et al., 2000). Injection of Urocortin 2 
into the DR increased 5-HT efflux in the basolateral amygdala, a projection 
region of the DR, and increased c-fos expression in raphe serotonergic neurons, 
and these effects were blocked by the CRF2 antagonist antisauvagine-30, 
suggesting that the effects are CRF2-mediated (Amat et al., 2004). In the DR 
itself, low doses of Urocortin 2 actually appear to reduce the activity of 
serotonergic neurons through CRF2, although at high doses of Urocortin 2, 
CRF2-mediated deactivation of GABA-ergic neurons in the same region may lead 
to non-specific activation of the same serotonergic neurons (Pernar et al., 2004). 
Furthermore, chronic administration of either ovine CRF (which has a higher 
affinity for CRF1 than CRF (Hauger et al., 2006)) or Urocortin 2 to the DR have 
been demonstrated to produce similar alterations in expression of genes 
associated with components of the  serotonergic system in the DR (Clark et al., 
2007). Injection of Urocortin 1 into the basolateral amygdala has been reported 
to increase the number of c-Fos-immunoreactive serotonergic neurons within 
subdivisions of both the dorsal raphe nucleus and median raphe nucleus (Spiga 
et al., 2006). Furthermore, ICV Urocortin 2 has been reported to increase c-Fos 
expression in serotonergic neurons of the DR (Staub et al., 2005; Staub et al., 
2006). Overall, the evidence suggests a complex interaction between the CRF 
and 5-HT systems, perhaps more explicitly neuronal-dependent than CRF 
receptor-dependent. Such interactions may be of relevance to the 
pathophysiology underlying depression, and support a role for drugs altering 
activity of the CRF system in the (co)treatment of this disorder. 
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Dopaminergic System 
 
In addition to their potential role in interactions between noradrenergic and 
CRF systems, CRF neurons in the CeA and BNST innervate dopaminergic 
neurons in the substantia nigra (Gray, 1993). Centrally administered CRF has 
been shown to increase concentrations of a dopamine metabolite in a number of 
brain regions (Kalivas et al., 1987; Dunn and Berridge, 1987), suggesting an 
increased drive for dopamine production. This is supported by in vitro evidence, 
as CRF has been reported to activate striatal tyrosine hydroxylase, the crucial 
enzyme in the production of dopamine (Olianas and Onali, 1988; Olianas and 
Onali, 1989). It has also been demonstrated that ICV CRF increases the activity 
of dopaminergic projections to the prefrontal cortex (Lavicky and Dunn, 1993). In 
a behavioural model believed to reflect stress- and anxiety-related states, the 
CRF-enhanced acoustic startle, a dopamine receptor antagonist has been 
demonstrated to inhibit the startle-enhancing effects of CRF (Meloni et al., 2006). 
In the same study, CRF neurons in the BNST, a region linked to the CRF-
induced effects on startle (Lee and Davis, 1997), were found to be closely 
surrounded by dopaminergic neurons, providing anatomical evidence for 
interaction of these two systems. 
 
Cholinergic System 
 
 A combination of evidence suggests intricate interactions between the 
CRF and cholinergic systems. Interaction between these two systems may be 
involved in cognitive function (see Warnock et al., 2006 for review). 
 
 Coexpression of elements of the CRF and cholinergic systems has been 
reported in cholinergic forebrain nuclei (medial septum, ventral and horizontal 
limbs of the diagonal band of Broca, substantia inominata, but not the nucleus 
basalis magnocellularis), and cholinergic brainstem nuclei (pendunculopontine 
and laterodorsal tegmental nuclei) (Crawley et al., 1985; Austin et al., 1995; 
Sauvage and Steckler, 2001). 
 
Intracerebroventricular (ICV) infusions of CRF have been reported to 
increase hippocampal acetylcholine (ACh) release (Day et al., 1998a; Day et al., 
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1998b), an effect which is likely to be CRF1-mediated (Gully et al., 2002). There 
is evidence that interactions between these two systems are reciprocal, with both 
CRF capable of affecting cholinergic activity and acetylcholine capable of 
modulating CRF activity (see Warnock et al., 2006 for review), as for example, 
chronic treatment with the non-selective muscarinic antagonist atropine 
produced an increase in CRF1 in frontoparietal cortex in rats (De Souza and 
Battaglia, 1986), and acetylcholine induces CRF release from the amygdala in 
vitro (Raber et al., 1995). 
 
 Clearly there is a sizeable body of literature supporting interactions 
between the CRF system and a number of other neurotransmitter systems in the 
brain, with far-reaching implications in a range of behaviours and pathological 
states, including (e.g.) arousal/attention (noradrenaline/acetylcholine), 
reward/addiction (dopamine), anxiety/depression (serotonin). Furthermore, 
complex interactions exist between not only CRF and the systems discussed 
above, but also between those other neurotransmitters, with the consequence 
that the effects of CRF could be wide-reaching, and that endpoint responses 
could involve multiple neurotransmitter systems. 
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Implication of CRF in stress-related disorders 
 
Alterations in CRF activity have been described in a range of 
neuroendocrine, neurological and psychiatric disorders, including major 
depressive disorder, post-traumatic stress disorder (PTSD), schizophrenia and 
dementia (Steckler, 2005). This makes the CRF system an interesting target for 
the development of novel treatments for these disorders. 
 
 CRF1 antagonists are implicated in the potential treatment of PTSD, as 
studies have shown basal cerebrospinal fluid (CSF) CRF levels to be elevated in 
patients with the disorder, although low glucocorticoid levels have also been 
observed (see Kasckow et al., 2001 for a review). This surprising discrepancy 
has led to speculation of an adrenocortical insufficiency in these patients 
(Kasckow et al., 2001), supported by studies of cortisol secretion and 
glucocorticoid receptors (Yehuda et al., 1991a; Yehuda et al., 1991b; Yehuda et 
al., 1993; Yehuda et al., 1996). Neuroimaging studies have revealed functional 
impairment and shrinkage of the medial prefrontal cortex in PTSD (Rauch et al., 
2003; Shin et al., 2005), a region which may be involved in negative feedback on 
the HPA axis (Diorio et al., 1993). 
 
In depression, an increased number of CRF-immunoreactive neurons has 
been reported at the level of the PVN (Raadsheer et al., 1994), and in situ 
hybridisation revealed markedly elevated CRF mRNA levels in the PVN of 
depressed patients (Raadsheer et al., 1995). Chronic antidepressant treatment 
has been demonstrated to decrease CRF mRNA in the rat PVN (Brady et al., 
1992), and decrease CRF1 mRNA levels in the amygdala (Aubry et al., 1999), 
providing animal model support for these clinical findings. An increased CRF-like 
immunoreactivity in the cerebrospinal fluid of depressed patients has been 
reported in some studies (Banki et al., 1987; Nemeroff et al., 1988; Wong et al., 
2000), which seems to decrease after successful antidepressant treatment (De 
Bellis et al., 1993; Heuser et al., 1998), while lack of normalisation of 
cerebrospinal fluid CRF levels during antidepressant treatment may predict early 
relapse (Banki et al., 1992).  
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Variations in the CRF-BP gene have been associated with major 
depression (Claes et al., 2003). A failure of CRF-BP levels to adapt to rising CRF 
levels, associated with depression (Mitchell, 1998), may contribute to increased 
“free” CRF levels and therefore the development of heightened stress responses 
or even psychopathology (Herringa et al., 2006a). Indeed, a recent post-mortem 
study of depressed suicide victims demonstrated increased CRF levels in the 
frontal cortex, whereas CRF-BP mRNA remained unchanged (Merali et al., 
2004), and reductions in basolateral amygdala CRF-BP mRNA have been found 
in schizophrenic and bipolar patients (Herringa et al., 2006b), although the 
translation of these changes into protein levels was not confirmed. 
 
Depressed patients have been reported to have a blunted ACTH 
response to exogenous CRF challenge (Gold et al., 1986; von Bardeleben and 
Holsboer, 1988) and to show an abnormal response to combined 
dexamethasone/CRF challenge, which has been reported in up to 80-90% of 
patients (Heuser et al., 1994). There is also evidence that these abnormalities 
can be normalised by antidepressant treatment, though differences in the onset 
of normalisation are apparent, and the recovery may only be temporary (Schule 
et al., 2006). In healthy volunteers, the HPA response to CRF challenge could be 
attenuated by antidepressant treatment (Michelson et al., 1997), and certain 
selective serotonin reuptake inhibitors (SSRIs) have been reported to reduce the 
activity of CRF neurons (Nemeroff and Owens, 2004). A decrease in CRF 
binding sites has been measured in the frontal cortex of suicide victims 
(Nemeroff et al., 1988), possibly secondary to elevated CRF levels (Steckler, 
2005). In support of this, CRF has been demonstrated to downregulate CRF1 
binding in cortical areas of rats, although this was only after acute ICV 
administration (Brunson et al., 2002), and CRF1 mRNA, but not CRF2 mRNA has 
been found to be downregulated in the frontal cortex of depressed patients 
(Merali et al., 2004).  
 
The precise reasons for HPA hyperactivity and, in particular, for enhanced 
production and release of CRF in depression remain unknown. It has been 
suggested that once the balance of corticosteroid receptor mediated events is 
disturbed, an individual loses the ability to maintain homeostasis if challenged, 
for example by an adverse life event, such as severe stress (De Kloet et al., 
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1998). This leads to disturbed neuroendocrine regulation and impaired 
behavioural adaptation, which after a certain threshold can trigger the onset of a 
psychiatric disorder (Holsboer, 1999). Clinical studies support the theory of 
impaired glucocorticoid receptor function leading to insufficient cortisol-mediated 
negative feedback on CRF expression (Modell et al., 1997; Modell et al., 1998; 
Holsboer, 2000). Furthermore, in a rat model of social instability during 
adolescence, subsequent stress exposure induced abnormal HPA responses, 
both centrally and peripherally (increased plasma corticosterone and PVN CRF 
mRNA levels) (McCormick et al., 2007). The complex regulation of the HPA axis 
provides multiple chances for intervention in the event of such impairment 
(Holsboer, 1999). 
 
It has been suggested that the suppression of CRF activity might be the 
final and common step of antidepressant action that is necessary for stable 
remission of major depressive disorder (Holsboer and Barden, 1996), and CRF 
receptor antagonists may provide a method to accelerate normalisation. 
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Local Cerebral Glucose Utilisation (LCGU) 
 
 Glucose is the primary energy source for the mammalian brain, a 
continuous supply being necessary to maintain normal cerebral function (Maher 
et al., 1994). The development of the LCGU technique (Sokoloff et al., 1977) 
provided the demonstration for coupling between synaptic activity and glucose 
use. Thus, with a measure for glucose metabolism in regions of the brain, an 
estimate of synaptic activity in those regions can be obtained.   
 
 The LCGU technique is of particular interest due to its translational nature. 
Translational models are those techniques where the methodology and validity 
can be directly adapted between studies in animals and the clinic. As will be 
discussed here, the theoretical basis of the LCGU technique can be directly 
applied in humans, using positron emission tomography (PET). 
 
 Sokoloff’s LCGU technique relies on the unique properties of the glucose 
analogue 2-deoxy-D-glucose (2-deoxyglucose; 2DG). This molecule differs from 
glucose by the replacement of the hydroxyl group on the second carbon atom 
with a hydrogen atom. 2DG is transported between blood and brain tissues by 
the same glucose transporters as glucose itself (GLUT1-5, GLUT8; (McEwen 
and Reagan, 2004)), and once in the tissues it competes with glucose for 
hexokinase, which phosphorylates both to their respective hexose-6-phosphates 
(Sols and Crane, 1954). At this point the metabolism of 2DG-6-phosphate (2DG-
6-P) essentially ceases, as 2DG-6-P is not a substrate for the enzyme 
phosphohexoseisomerase, which converts glucose-6-phosphate to fructose-6-
phosphate, allowing further metabolism via the glycolytic and tricarboxylic acid 
pathways (Sokoloff et al., 1977) (Figure 3). By radiolabelling the 2DG molecule 
its accumulation in brain tissues can be measured by conventional techniques, 
such as autoradiography or scintillation counting of homogenates. In the 
originally developed technique [14C]-2DG was used, but since then [3H]-2DG has 
also been made available, which along with improving safety considerations 
increases the resolution of the technique (Gallistel and Nichols, 1983), although 
the reduced specific activity of the latter readioligand could be considered a 
drawback. 
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Figure 3: Schematic illustration of the theoretical model (adapted from Sokoloff et 
al., 1977 and Magistretti and Pellerin, 1999b).  
Glucose and 2DG are transported from the plasma into astrocytes by the same 
glucose transporters (k1 and k1
* represent the rate constants for transport from 
plasma to tissue, k2 and k2
* represent transport from tissue to plasma), once 
inside the cell they are converted to glucose-6-phospate (glucose-6-P) and 2DG-
6-phosphate (2DG-6-P), respectively, by hexokinase (rate constants k3 and k3
*).  
While 2DG-6-P is essentially trapped in the cell, glucose-6-P is metabolised 
further to lactate, which provides an energy source for neurons (see Magistretti 
and Pellerin, 1999b). CP, CE and CM represent the concentrations of plasma 
glucose, intracellular glucose and glucose-6-P, respectively. CP
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 In order to calculate the rate of local cerebral glucose metabolism, 
Sokoloff et al. constructed the model: 
 
 
 Where Ri is the rate of LCGU in a given region (in µmol/100g/min), k1, k1
*, 
k2, k2
*, k3, k3
*, CP, CE, CM, CP
*, CE
*, CM
*, Ci
* represent the parameters detailed 
above, T is the time after which the experiment was ended (0 is zero time), λ is 
the ratio of the distribution space of 2DG in the tissue to glucose, Φ is the 
fraction of glucose that once phosphorylated continues down the glycolytic 
pathway, and Km
*, Vm
*, Vm, Km, represent the Michaelis Menten pharmacokinetic 
constants of hexokinase for 2DG and glucose, respectively. 
 
 This can be generalised to: 
 
 The calculation of actual molar LCGU values (in µmol/100g/min) using this 
equation requires repeated (rapid in the early phase of the protocol) arterial 
blood sampling for the measurement of plasma 2DG and blood glucose levels, 
which represents one of the drawbacks of the originally designed technique, as 
Ri =
Ci*(T) – k1*e
-(k2*+k3*)T
T
0
Cp*e
(k2*+k3*)tdt
T
0
(Cp*/Cp)dt – e
-(k2*+k3*)T
T
0
(Cp*/Cp)e
(k2*+k3*)tdt
∫
∫ ∫λVm*KmΦVmKm*
Ri = 
Total label in 
tissue at time T
Label in precursor 
remaining in 
tissue at time T
-
Isotope effect 
correction 
factor
Integrated 
plasma specific 
activity
Correction for lag in 
tissue equilibration 
with plasma
Labeled product formed in interval of time, 0 to T
Integrated precursor specific activity in tissue
-
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this blood sampling is both labour intensive and risks disturbance of the animal. 
Particularly when studying stress-related effects or the CRF system, disturbance 
of the subject is problematic as this represents a mild stressor in itself, with 
knock on effects on the HPA axis and possibly on central responses. The 
expected plasma curve of 2DG after intravenous (IV) administration is illustrated 
in Figure 4. The rapid repeated sampling in the protocol is necessary to measure 
the rapid peak in plasma 2DG. Also illustrated is the expected cumulative curve 
of 2DG-6-P in the brain. Blood glucose (not illustrated) would in an ideal situation 
be a constant of approximately 150 mg/dl. 
 
Figure 4: Illustrative figure of plasma and brain levels of 2DG and 2DG-6-P, 
respectively, after an IV injection of radiolabelled 2DG (adapted from Sokoloff et 
al., 1977) 
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Cellular mechanisms of LCGU 
 
 Measuring LCGU using 2DG does not reflect synaptic activity directly, but 
measures activity-dependent energy consumption (Magistretti and Pellerin, 
1999b). It has been suggested that astrocytes play a central role in the 
distribution of energy substrates from the circulation to the neurons (Golgi, 1886; 
Sala, 1891; Andriezen, 1893), and the entire surface of central capillaries is 
covered by astrocytic end-feet (Peters et al., 1991). Glucose transporters of the 
GLUT1 type are expressed on these astrocytic end-feet (Morgello et al., 1995). 
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Using cortical glutamate as an example, the drive of glucose metabolism by 
neurotransmission can be illustrated. 
 
 Glutamate released during neurotransmission accumulates in the synaptic 
cleft, from where it is taken up by glutamate transporters in astrocytes, driven by 
an ATP-dependent Na+/K+-ATPase mechanism (Magistretti and Pellerin, 
1999b). Glutamate stimulates the glycolytic processing of glucose in astrocytes, 
as indicated by increased lactate release and 2DG uptake (Pellerin and 
Magistretti, 1994). 
 
 It is suggested that astrocytes preferentially process glucose glycolytically 
into lactate, which once transported into neurons by specific lactate transporters, 
can be transformed by neurons into pyruvate and enter the tricarboxylic acid 
cycle, yielding 17 ATP molecules (Magistretti and Pellerin, 1999b). Indeed, in 
vivo, electrical stimulation resulting in neuronal activitation has been associated 
with increased lactate levels (Hu and Wilson, 1997). 
 
Modifications to the technique 
 
 While Sokoloff et al’s original technique generates a fully quantitative 
measure of LCGU via the collection of repeated data points during the protocol, 
simpler versions of the technique have also been used in the literature to provide 
estimates of LCGU. These modifications typically do not measure plasma 2DG 
or glucose curves, meaning that actual molar LCGU cannot be calculated. 
However, the use of appropriate control groups and methods for standardising 
the protocol maintain the reliability of the technique.  
 
 In the original technique described by Sokoloff et al., the animal was 
placed in a hind-limb plaster cast to facilitate blood sampling, and LCGU was 
measured either in the anaesthetised state or conscious. However, with the aim 
of studying LCGU related to behaviours associated with CRF and stress, for 
example anxiety-related behaviour, it is clearly preferable to measure LCGU in 
the conscious, normally behaving animal. In addition to limiting normal 
behaviour, a hind-limb plaster cast can be compared to half-
restraint/immobilisation stress, which itself is associated with behavioural effects 
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similar to CRF administration, and activates the HPA axis (McBlane and 
Handley, 1994; Jamieson et al., 2006; Rivalland et al., 2007). 
 
 In response to these drawbacks, the method was adapted for freely 
moving rats by Crane & Porrino (Crane and Porrino, 1989), who externalised the 
arterial and venous catheters via the nape of the neck, allowing easy access by 
the experimenter (used, for example, in Sarter et al., 1989). These catheters can 
be connected to a fluid swivel allowing remote infusion and blood sampling while 
maintaining free motion. However, it should be noted that any surgical 
intervention needs to be followed by a suitable period for recovery to an 
unstressed level, during which there is a risk of losing catheter patency through 
clotting. Some studies have measured LCGU within hours of surgery, at which 
point LCGU may be affected by the after-effects of prolonged anaesthesia or the 
physical stress associated with surgery and post-operative pain. 
 
 The technique has also been adapted to remove the need for surgically 
implanted catheters altogether. The function of 2DG as a tracer persists whether 
it is injected intravenously or via another route. Both intraperitoneal and 
subcutaneous administration have been used in the literature (Meibach et al., 
1980; Kelly and McCulloch, 1983b; Kelly et al., 2002), and estimated LCGU after 
intraperitoneal injection of 2DG was found to highly correlate with that after 
intravenous injection (Meibach et al., 1980). While a fully calculated measure of 
LCGU (µmol/100g/min) is lost in the absence of continuous blood sampling, in 
the absence of catheters the animal can be entirely freely moving, remain in its 
home-cage between treatments and generally be less disturbed in the course of 
the protocol, a significant benefit. 
 
 The effect of fluctuating blood glucose is not accounted for in protocols 
without continuous blood sampling. In the original technique it is a requirement 
that blood glucose levels be constant during the protocol. Later, Sokoloff et al 
(1983) reported a modified operational equation which could account for 
changing blood glucose. However, it has also been demonstrated that similar 
patterns of LCGU can be obtained in the absence of repeated blood glucose and 
plasma 2DG measurement, although these representative measurements of 
LCGU cannot be expressed in µmol/100g/min (Meibach et al., 1980). 
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 When using a modification of the technique which is not fully corrected for 
blood glucose and 2DG, efforts have been made to standardise the results in 
another manner. One reported modification measures the ratio of radioactivity in 
grey matter:radioactivity in white matter, i.e. nCi/mg grey matter:nCi/mg corpus 
callosum (Kelly and McCulloch, 1983a; Mitchell and Crossman, 1984). This 
modification assumes that LCGU is unaltered in white matter, but there is 
evidence that this may not be the case (Kennedy et al., 1982), meaning that 
effects may be masked or accentuated by calculating such a ratio. 
 
 Many studies of LCGU use a single dose of 2DG (e.g. 50µCi [14C]-2DG –
Sokoloff et al., 1977) in all animals, regardless of bodyweight, relying instead on 
the equation or ratio calculation to standardise their results. However, it could be 
argued that in studies using inbred rodent strains, with standardised, freely 
available diet, of matching age/bodyweight, that using a per kilogram dose of 
2DG already provides a standardised experimental environment. Furthermore, in 
studies lacking continuous blood sampling, it remains possible to measure blood 
glucose and residual 2DG in the plasma upon sacrifice, and thus ensure that 
treatments have not produced significant changes in either measure, which could 
have knock-on effects on LCGU. 
 
Both autoradiography and brain dissection have been used in studies of 
LCGU, and each has pros and cons. Autoradiography can be a time-consuming 
process, requiring sectioning, exposure to film and densitometry to generate 
data. Using 14C-2DG, imaging requires approximately 5 days, yet does not have 
the resolution of 3H-2DG (Gallistel and Nichols, 1983), which requires 3-4 weeks 
for imaging. Furthermore, the availability of a cryostat for sectioning and a 
computerised system for densitometry can be limited, while the dissection of 
regions of interest from the brain and measurement of LCGU in homogenates 
requires a separate set of instruments, which may be more readily available, and 
dependent on the number of samples can generate data more rapidly than 
autoradiography. However, dissection has a number of clear drawbacks 
compared to autoradiography. Heterogeneous regions such as the thalamus are 
grouped into one dissected region, making it more difficult to draw clear 
conclusions from alterations in LCGU in such regions. Indeed, dissection of 
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these regions may effectively mask changes in LCGU. For example, 
simultaneous increased LCGU in a particular subregion, with reduced LCGU in 
another subregion, grouped by dissection, could be missed through averaging to 
an overall unchanged response. The use of dissection also greatly reduces, and 
in many cases removes, the ability to measure LCGU in small brain regions. This 
effect can be twofold, as while a region may be too small to accurately dissect, 
the amount of radiolabelled 2DG in a small but dissectable region may be too 
low to accurately count. 
 
 Another drawback of techniques to measure LCGU is a lack of cellular 
resolution, or even regional resolution with coarse techniques such as dissection. 
Standard autoradiography, or dissection, allows only regional resolution, and that 
determined also by the size of the region. Sokoloff et al reported their 14C-2DG 
method to have at best a resolution of 200µm (Sokoloff et al., 1983). 
 
 Studies of 2DG uptake at the cellular level have shown that for most brain 
regions, the accumulation of radioactivity per unit area of neuropil and neuronal 
cell bodies is similar (Duncan et al., 1987; Duncan et al., 1990; Duncan and 
Stumpf, 1991). Therefore, at the regional topographic level, the vast majority of 
2DG uptake observed in autoradiograms reflects the uptake of the compound in 
nerve terminals and other neuronal and glial processes that compose neuropil 
(Duncan et al., 1993). 
 
 Itoh et al (Itoh et al., 2004) have brought cellular resolution of LCGU one 
step closer with their development of a fluorescent 2DG analogue, 2-[N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG). Uptake of 
the ligand was demonstrated both in vitro, and in vivo with accumulation of 
phosphorylated 2-NBDG in hippocampal neurons and cerebellar Purkinje cells. 
 
 Translation of preclinical measurements of LCGU to the clinic was made 
possible by the development of a PET (positron emission tomography) ligand - 
18Fluoro-2-Deoxyglucose (FDG) (Reivich et al., 1979), which was successfully 
used to measure LCGU in humans (Phelps et al., 1979; Reivich et al., 1979). 
However, the resolution of this technique is still less than that of detailed 
autoradiography, although constantly improving, with current equipment reaching 
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a spatial resolution of 1.3 mm (microPET Focus, Concorde Microsystems Inc., 
Knoxville, TN, USA; Larobina et al., 2006). 
 
 Recently, an in vivo microprobe capable of locally measuring the time-
concentration curve of a radiolabel has been developed. The “betaP” (Millet et 
al., 2004) is an alternative to 18FDG-PET, capable of acquiring time-
concentration curves with high temporal and spatial resolution (detection with 
18FDG is possible within an 0.8 mm3 area around the probe). 
 
 To summarise, it can be argued that methods for measuring LCGU 
without full calculation do not account for individual subject variability in as much 
detail as the full technique, but these so-called “semi-quantitative” techniques 
can introduce more flexibility to experimental design. 
 
LCGU and Cerebral Blood Flow 
 
 Close links between LCGU and regional cerebral blood flow (rCBF) have 
been demonstrated, with matching effects seen in some studies (Kelly and 
McCulloch, 1983c; Takamatsu et al., 2003a). It has long been postulated that 
increased neuronal energy metabolism is driven by increased cerebral blood flow 
and vice versa (Magistretti and Pellerin, 1999b), and in addition to evidence that 
neuronal glucose supply is regulated by astrocytes (Magistretti and Pellerin, 
1999a), evidence has been found linking astrocytes and rapid changes in rCBF 
(Takano et al., 2006). However, LCGU and rCBF may not always be directly 
linked, as there is also evidence for the uncoupling of these two measures 
(Magistretti and Pellerin, 1999a). The muscarinic receptor antagonist 
scopolamine has been shown to inhibit rCBF in response to somatosensory 
stimulation in rats without affecting LCGU (Villringer and Dirnagl, 1995), and 
conversely, electrical stimulation of the nucleus basalis produced increased 
rCBF without affecting LCGU (Vaucher et al., 1997). Thus, in some cases, the 
study of neuronal activity using both LCGU and rCBF may provide a replication 
of data, though that may not always be the case. 
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LCGU and stress-related disorders 
 
 The value of measuring LCGU in the clinic can be considered two-fold. 
Not only can LCGU be used as a technique to investigate the structures of the 
brain that are involved in stress-related disorders, but the technique can also be 
used in the progression of novel drug candidates. In this latter function, the 
LCGU technique can be used in two ways. As an independent clinical study, the 
technique can be used to demonstrate the penetration of a drug into the human 
CNS in a manner sufficient to alter CNS activity. Secondly, the translational 
nature of the technique allows cross-species replication of drug-induced effects, 
hopefully increasing that drug’s value as a candidate for use in patients. Altered 
LCGU in particular brain regions in patients can be associated with particular 
pathology or successful drug treatment, guiding research in animals. 
 
 Altered LCGU has been shown in depressed patients (Pizzagalli et al., 
2003; Yuuki et al., 2005), along with HPA axis dysfunction (Aihara et al., 2007), 
and evidence has suggested that successful treatment may normalise these 
changes (Navarro et al., 2004; Aihara et al., 2007). The antidepressant fluoxetine 
has been reported to reduce LCGU in the amygdala, hippocampus and ventral 
striatum, all areas implicated in stress-related pathways, and to increase LCGU 
in the right superior parietal lobe (Cook, Jr. et al., 1994; Freo et al., 2000). 
Following tryptophan depletion, patients with major depressive disorder had 
increased LCGU in the orbitofrontal cortex, medial thalamus, anterior and 
posterior cingulate cortices, and ventral striatum compared to sham-depleted 
and normal controls (Neumeister et al., 2004), suggesting a serotonin-related 
trait dysfunction. Increased LCGU has also been reported in areas of frontal, 
cingulate, insula, and temporal cortex in association with different components of 
the severity and course of illness in treatment-resistant unipolar depression 
(Kimbrell et al., 2002). 
 
 Altered LCGU and regional cerebral blood flow has also been reported in 
panic disorder (Reiman et al., 1984; Nordahl et al., 1990; Reiman, 1997; Nordahl 
et al., 1998; Bisaga et al., 1998; Sakai et al., 2005), and LCGU was reduced in 
imipramine-treated panic disorder patients compared to unmedicated patients 
(Nordahl et al., 1990). State LCGU is increased in specific brain regions in 
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patients with panic disorder. Sakai et al (2005) found heightened LCGU by FDG-
PET in the bilateral amygdala, hippocampus, and thalamus, and in the midbrain, 
caudal pons, medulla, and cerebellum compared to normal controls, implicating 
the amygdala-based fear network in panic disorder, and based on the expression 
of CRF and CRF receptors in this region, providing a possible link to CRF. 
Altered LCGU in the hippocampus region has been reported after administration 
of the anxiolytic drugs ipsapirone and buspirone (Wree et al., 1987; Grasby et 
al., 1992; Grasby et al., 1993) implicating the serotonergic system. The septo-
hippocampal system has been linked to anxiety as part of a behavioural 
inhibition system (Gray, 1983; comprehensively discussed in Gray and 
McNaughton, 2000). 
 
 In addition to being implicated in panic disorder, CRF is likely to be 
involved in the amygdala-based fear network. After “priming” (sensitisation by 
repeated treatment) of the basolateral amygdala by CRF or Urocortin 1 infusion, 
Sajdyk et al (Sajdyk et al., 1999) demonstrated behavioural and cardiovascular 
responses to the human panicogenic agent sodium lactate. Furthermore, Choi et 
al (2005) found increased CRF-like immunoreactivity and CRF mRNA in the 
central nucleus of the amygdala after administration of doxapram, which causes 
panic anxiety in humans. Moreover, in addition to reduced fear-like behaviour, 
rhesus monkeys with bilateral lesions of the central amygdala exhibit reduced 
CRF levels in the CSF (Kalin et al., 2004). Increased LCGU in the amygdala, 
among other regions, of panic disorder patients implicates the amygdala-based 
fear network (Sakai et al., 2005). Patterns of altered LCGU after treatment with 
compounds acting on benzodiazepine receptors further support the involvement 
of the amygdala and other limbic regions in anxiety-related behaviour. Diazepam 
reduced LCGU in a range of regions including the amygdala, hippocampus and 
frontal cortex (Ableitner et al., 1985; Eintrei et al., 1999). In contrast, treatment 
with the anxiogenic benzodiazepine partial inverse agonist FG7142 (Corda et al., 
1983; File and Pellow, 1984) has been reported to increase LCGU in limbic 
regions (Ableitner and Herz, 1987), although the amygdala was not studied in 
detail in this study. 
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 Such detectable and reversible alterations in LCGU in stress-related 
disorders suggest that it is a useful paradigm with which to further investigate the 
underlying pathology in these disorders. 
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Using LCGU to Study the CRF system 
 
 Although the anatomy of the CRF system has been studied in detail, and 
the distribution of its components documented, it is particularly difficult to study 
as a whole. There are numerous studies using manipulation of the CRF system 
to study brain areas involved. These can involve lesioning, administration into 
specific brain regions and microdialysis. However, these studies invariably only 
study at most a few regions concurrently, meaning that effects in other regions 
might be missed. An advantage of the LCGU technique is that following a 
manipulation, whether pharmacological or behavioural (e.g. a stressor), the 
number of brain regions in which LCGU can be measured is limited only by the 
resolution of the technique, thus allowing global analysis of effects in the brain. 
What the technique does not allow is the chronological sequence of any 
response to be measured, as at earlier time points in the protocol a combination 
of unmetabolised and metabolised 2DG is present. 
 
 By comparing the effects of targeting either CRF1 or CRF2(a) receptors in 
the brain, it may be possible to further elucidate the roles of the two receptors. 
Furthermore, effects on LCGU can be compared to other measures of brain 
activity, such as increased expression of the immediate-early gene c-fos, which 
is rapidly induced in specific neuronal populations after stress, sensory stimuli, 
pain and pharmacological manipulation (Hughes and Dragunow, 1995), although 
the measurement of LCGU adds the possibility to measure reduced activity in a 
given region, not possible with c-fos. 
 
 The effects of CRF itself on LCGU have been studied, revealing that CRF 
consistently induces increases in LCGU in a wide range of regions in the rodent 
brain. Sharkey et al (1989) reported wide-spread alterations in LCGU following 
ICV CRF administration, including increases in frontal cortex, thalamic areas, the 
lateral hypothalamus and median eminence, the cerebellum, midbrain regions 
including the median raphe and locus coeruleus, regions of the medulla 
oblongata and in the fornix, which may relate to its connections between 
hypothalamus and hippocampus (Sharkey et al., 1989). Interestingly, 
simultaneous reductions in LCGU were seen in an area of the prefrontal cortex 
and the dorsal tegmentum in the same study. In developing rats similar 
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increases in LCGU have been reported in response to central CRF 
administration, and matched to increases in c-fos mRNA expression (Dube et al., 
2000). Additional increases in LCGU were reported in the amygdala and 
hippocampus, and overall prefrontal cortex LCGU was in this case increased. 
Regions exhibiting increased c-fos mRNA expression matched those with 
increased LCGU, with additional increases seen in the PVN and anterior 
hypothalamus. Data reporting that the consistent increases in LCGU in these 
wide-spread regions are dose-dependent has been provided (Freo et al., 2005). 
 
 Studies of the effect of CRF on c-fos expression reveal a pattern of 
activation similar to that seen on LCGU, and indeed similar to that following 
stress. Centrally administered CRF has been reported to induce c-fos mRNA 
expression in limbic structures, including the lateral septum, hippocampus, 
amygdala, hypothalamus (notably the PVN), and in regions of the thalamus and 
brainstem (notably the LC) (Imaki et al., 1993). Increased c-fos immunoreactivity 
has also been reported in a number of these brain regions after either 
intravenous or intraperitoneal administration of CRF or Urocortin 1, including the 
PVN, LC and central amygdala (Wang et al., 2000; Maillot et al., 2003). Urocortin 
2 has been demonstrated to increase c-fos expression in serotonergic neurons in 
the dorsal raphe (DR) after either ICV or direct-DR injection (Amat et al., 2004; 
Staub et al., 2005). C-fos activation after ICV Urocortin 2 administration was 
reported in the bed nucleus of the stria terminalis, central amygdala, PVN, 
parabrachial nucleus and nucleus of the solitary tract (Reyes et al., 2001). 
Notably, there is overlap in the c-fos expression patterns induced by these 
different peptides, suggesting that there may be overlapping function of either 
peptide or receptor in certain regions. 
 
 The different and complementary information obtained by assessment of 
c-fos activity and LCGU illustrates the utility of applying both functional mapping 
approaches to examine neuroanatomical correlates of behavioural states and 
drug treatment (Duncan et al., 1993). 
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Outline and Scope of this Thesis 
 
 Based on the differing distributions of the endogenous CRF-related 
peptides, CRF, Urocortin 1, 2, and 3 in the rodent brain, their differing affinity for 
central CRF receptors, and differing effects of these peptides after acute central 
administration in a range of stress-related paradigms, it was hypothesised that 
these peptides influence neuronal activity in different subsets of rodent brain 
regions. 
 The LCGU paradigm developed by Sokoloff et al. (1977) was chosen for 
its ability to simulataneously measure neuronal activity in numerous brain 
regions after physical or pharmacological manipulation. A number of 
modifications to this method have been reported in the literature, and therefore 
an initial aim of this thesis was to assess the usefulness of these modifications 
and select those which would be used further to study the effects of the 
endogenous CRF-related peptides. 
 After the selection of a suitable version of the LCGU paradigm, the 
primary aim of this thesis was to examine the patterns of neuronal activation 
produced in the rodent brain after acute administration of the CRF-related 
peptides, and to study the involvement of either or both CRF1 and CRF2 
receptors in the LCGU response, using available selective antagonists and 
mutant mice lacking a functional CRF1 receptor. 
 In order to compare the measured LCGU responses to a measure of the 
stress response, it was decided to combine LCGU measurement with 
measurement of plasma corticosterone to provide an indication of HPA axis 
activation. 
 Finally, in order to compare the effects of the CRF-related peptides on 
LCGU with a stressor, the effect of restraint stress on LCGU was studied, also in 
combination with measurement of plasma corticosterone, and the involvement of 
the CRF1 receptor in the response investigated using a selective antagonist. 
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Assessment of the LCGU protocol and modifications 
 
Introduction/Aims 
 
 Prior to using the LCGU technique to study experimental manipulations, it 
was necessary to select and assess modifications to Sokoloff et al.’s original 
technique which may be beneficial. 
 
 These modifications include: the use of 3H-2DG in the place of 14C-2DG,  
major benefits of which include greatly reduced cost and increased safety; “semi-
quantitative” modifications such as calculating grey:white matter ratios or 
dissecting brain regions rather than autoradiography, which can remove the 
need for rapid blood sampling, reducing disturbance to the animal; and 
alternative routes of 2DG administration, as intravenous administration involves 
either surgical intervention or a relatively stressful injection procedure. 
 
 In addition to the LCGU techniques, a method for central 
(intracerebroventricular; ICV) administration of peptides was assessed. This 
method removes the need for surgical implantation of cannulae, while 
maintaining an accurate method for the administration of compounds which 
cannot cross the blood-brain barrier. 
 
 “In-house” assessment of the technique and its modifications allowed the 
selection of a final technique which provided a balance between efficiency and 
experimental power/reliability for further use. In addition, the process allowed 
hands-on assessment of the pros and cons associated with the technique, and 
provided multiple methods of measuring LCGU which could later be used to 
replicate important results. 
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Study 1 - Fully Quantitative Measurement of LCGU with 3H-2DG and 
Phosphoimaging 
 
Introduction 
 
 The use of 3H-2DG for the measurement of LCGU can greatly reduce the 
experimental cost. In addition, this radioisotope is safer than 14C. LCGU 
measured using 3H-2DG has been demonstrated to produce results highly 
correlated to those using 14C-2DG, and furthermore, 3H-2DG may provide higher 
resolution on autoradiographs under the right conditions, although imaging 
requires substantially longer (Meibach et al., 1980). 
 
 Fully quantitative measurement of LCGU was achieved by taking a full 
time course (10 seconds to 45 minutes after 2DG infusion) of blood samples via 
surgically implanted arterial and venous catheters. Measurement of blood 
glucose, plasma 2DG and final brain 2DG content allowed calculation of LCGU 
using Sokoloff et al.’s operational equation. 
 
 An additional modification validated in this study was the use of a 
phosphoimager in the place of traditional autoradiography. Instead of film, the 
Fujix BAS 2000 Phosphoimager uses storage phosphor plates. These plates 
store an image of the radioactive content in sections of the brain, which can then 
be scanned. This process can be completed for 3H-radioligands in approximately 
3 days, compared to 4-6 weeks for autoradiography. 
 
 In order to validate the use of 3H-2DG and the phosphoimager for the 
LCGU technique in our laboratories, a pilot study using three rats was 
performed, to allow comparison to results in the literature. 
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Methods 
 
Subjects 
 
 Three male Sprague-Dawley rats (Charles River Laboratories) were 
individually housed in individually-ventilated cages with food and water available 
ad libitum, under a standard 12h/12h light-dark cycle (lights on 06:00 a.m.), and 
at a regulated temperature of 22 ± 0.5oC and humidity of 50 ± 3% for at least 1 
week prior to surgery. Approximate weight at surgery was 250g. Following 
surgery, rats were housed in standard cages in an automated blood-sampling 
apparatus (Accusampler, DiLab, Sweden), under the same light conditions and 
food and water still available ad libitum. Final testing was carried out between 
0700 and 1200 hours. All testing was conducted according to the European 
Communities Council Directive Nov. 1986 (86/609/EEC) and approved by the 
animal care and use committee of Johnson & Johnson Pharmaceutical Research 
and Development. 
 
Surgery 
 
 Rats were anaesthetised using a mixture of 37.5 mg/kg ketamine (Ketalar, 
Parke-Davis, Belgium) and 0.25 mg/kg metedomidine (Domitor, Pfizer, Belgium) 
at a dose of 1ml/kg injected intraperitoneally (IP), which was sufficient for 
approximately 2h of surgery. Where necessary, small amounts of the anaesthetic 
mixture were subsequently administered IP to maintain a surgical level of 
anaesthesia. 
 
 Once fully anaesthetised, an antibiotic was administered (enrofloxacin 
40mg/kg SC; Baytril, Bayer, Belgium) before surgery commenced. The hair was 
shaved on the belly, left groin area, between the shoulder blades and on the 
throat. 
  
Implantation of arterial/venous catheters 
 
 An incision was made in the skin of the throat to allow blunt dissection of 
the right jugular vein and carotid artery, and a second incision was made in the 
skin between the shoulder blades. Using a trocar two polyurethane catheters 
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were routed subcutaneously from the dorsal incision to the ventral incision. 
These catheters were filled with a heparinized saline solution and implanted in 
the artery and vein, then temporarily plugged. The throat incision was closed with 
absorbable sutures, and a stainless steel coil tether was attached by means of a 
Dacron mesh button sutured with thick gauge non-absorbable sutures between 
the shoulder blades to protect the catheters. The dorsal skin incision was then 
closed with non-absorbable sutures. 
 
 Finally, a post-operative analgesic (buprenorphine 0.5mg/kg SC; 
Temgesic, Schering-Plough, Belgium) and an anaesthesia reversing agent 
(atipamezole 1 mg/kg SC; Antisedan, Pfizer, Belgium) were injected. 
 
 Following surgery the catheters were connected to continuous infusion 
pumps via a mobile swivel (Instech Laboratories Inc., USA), allowing the animal 
to move freely within its home-cage. To maintain the patency of the catheters a 
lightly heparinized saline solution was infused continuously during the week of 
recovery. 
 
Drugs 
 
 2-deoxy-D-[1-3H]-glucose (1.0 mCi/ml, specific activity 14.0Ci/mmol) was 
purchased from Amersham, and administered IV at a dose of 300µCi/kg. 
 
Blood Sampling 
 
 Arterial blood samples were taken manually using a syringe and PE 
tubing from above the swivel at time points t= 0.25, 0.5, 0.75, 1, 2, 3, 5, 7.5, 10, 
15, 25, 35, 45 minutes. Excess blood was drawn into the tubing for sampling in 
order to exclude dead-volume blood (approx. 70µl in the catheters used), and a 
sample of between 100-150µl taken into tubes containing EDTA to prevent 
clotting. The dead-volume blood and saline to replace the volume taken was 
returned to the animal after each sample. 
 
Blood Analysis 
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 10µl of whole blood from each sample was tested for glucose content 
using a commercially available blood glucose meter (Glucotouch ®, Lifescan, 
USA). The samples were then centrifuged (1100g, 4oC, 5 min) to separate the 
plasma. 20µl plasma was taken for scintillation counting to determine 3H content. 
 
Tissue Removal 
 
 After the final blood sample was taken (experimental time 45 minutes) the 
animals were sacrificed using carbon dioxide gas, and the brain removed. Brains 
were frozen in isopentane chilled to approx. –35oC on dry ice, and stored at –
80oC until cutting of sections on a cryostat. 
 
Autoradiography 
 
 20µm brain sections were cut on a Leica cryostat at –20oC, and thaw 
mounted on glass slides, before being dried at room temperature. The slides 
were then exposed for 3 days to Fujifilm BAS TR imaging plates with standards. 
The plates were scanned on a Fujix BAS 2000 Phosphoimager with a resolution 
of 100µm, and images analysed using AIDA 2D densitometry software (Raytest, 
Germany). Regions of interest were drawn and annotated by hand, and 
background subtraction was performed on a section of image not exposed to 
brain sections. 
 
Calculations & Statistics 
 
 With the assistance of Johnson & Johnson Pharmaceutical Research & 
Development’s biostatisticians, measured values for plasma 3H, blood glucose 
and tissue 3H were converted into LCGU values using Sokoloff et al.’s 
operational equation. Calculated values were compared to appropriate literature 
values using Spearman’s Rank correlation coefficient in Graphpad Prism 5.1. 
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Results 
 
 A sample image obtained in the present study is shown in Figure 5. The 
lowest LCGU was measured in white-matter areas, namely the corpus callosum 
and internal capsule (see Table 3), and the highest in the auditory cortex and 
inferior colliculus.  
 
 The data correlated highly with the literature (Rs = 0.87, 95% confidence 
interval 0.6887-0.9493, p < 0.0001, against control values from Sokoloff et al., 
(1977) (N.B. actual LCGU values appear higher in this study due to the higher 
specific activity of 14C-2DG); Rs = 0.90, confidence interval 0.7559-0.9615,  p < 
0.0001, against control values from Sarter (1990), in which 3H-2DG was also 
used). Correlation graphs for the present data against these two cited sources 
are shown in Figure 6 (a) and (b). Comparative values from these studies are 
displayed in Table 3. 
 
 The measured distribution of 3H-2DG in the plasma and blood glucose 
levels used in the calculation of LCGU are shown in Figure 7 and Figure 8). 
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Figure 5: Sample image obtained from the BAS 2000 phosphoimager for a rat 
injected with 2DG. Calibrated standards can be seen in the upper left corner. 
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Table 3: Local cerebral glucose utilisation in test subjects (Mean ± SEM; n=3), 
compared to reference papers (Sarter, 1990; Sokoloff et al., 1977). Missing SEM 
values indicates that LCGU in that region could not be identified in all animals. 
 
 
Region
Amygdala 40  ± 4 48  ± 3 52  ± 2
Arcuate nucleus 28  ± 5
Auditory cortex 56  ± 5 162  ± 5
BNST 26  ± 3
Hippocampus CA1 36 34  ± 2
Hippocampus CA2 37 43  ± 2
Hippocampus CA3 36 42  ± 3
Caudate putamen 41  ± 3 110  ± 4
Central Inferior colliculus 71  ± 4
Cingulate cortex 54  ± 7 82  ± 3
Corpus callosum 12  ± 3 19  ± 2 40  ± 2
Dentate gyrus 34 67  ± 3
Dorsal raphe 39  ± 1 29  ± 2
External inferior colliculus 65  ± 3 197  ± 10
Infralimbic cortex 51
Internal capsule 10  ± 1 33  ± 2
Lateral geniculate body 40  ± 7 45  ± 2 96  ± 5
Lateral globus pallidus 18  ± 2 11  ± 1 58  ± 2
Lateral hypothalamus 32  ± 6 33  ± 3
Lateral Septum 29  ± 5 45  ± 1 64  ± 3
lateral thalamus 51  ± 5 52  ± 3 116  ± 5
Mammillary body 43  ± 7 71  ± 4 121  ± 5
Medial geniculate body 42  ± 4 45  ± 1 131  ± 5
Median raphe 34  ± 1
Motor cortex 48  ± 3 120  ± 5
Nucleus Accumbens 42  ± 4 74  ± 4 82  ± 3
Parietal association cortex 49  ± 6 75  ± 2 112  ± 5
Periaqueductal gray 41  ± 4
Piriform cortex 54  ± 4
Pontine gray matter 22  ± 1 9  ± 1 62  ± 3
Posterior thalamus 51  ± 6
Prelimbic cortex 51  ± 7 119  ± 3
PVN 34  ± 6
Somatosensory cortex 49  ± 2
Substantia nigra 25  ± 1 12  ± 1 58  ± 3
Superior olive 32  ± 5
Ventral tegmentum 46
Ventral thalamus 45  ± 5 56  ± 2 109  ± 5
Ventromedial hypothalamus 33  ± 4
Visual cortex 51  ± 2 49  ± 4 107  ± 6
LCGU µmol/100g/min LCGU Sarter LCGU Sokoloff
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Figure 6: Illustrated correlations between the present data and (a) that of 
Sokoloff et al. (1977); (b) that of Sarter (1990) 
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Figure 7: Plasma 3H (µCi/ml) measured after IV injection of 3H-2DG in the three 
rats studied 
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Figure 8: Blood glucose (mg/dl) measured over the course of the LCGU protocol 
in the three rats studied 
0
20
40
60
80
100
120
140
160
0 10 20 30 40 50
Time (min)
B
lo
o
d
 g
lu
c
o
s
e
 (
m
g
/d
l)
Rat1 Rat2 Rat3
 
 
Chapter 2  Assessment of LCGU protocols 
 49 
Discussion 
 
 This study sought to produce data comparable to that in the literaure, 
utilising the safer, cheaper, tritium-labelled analogue of 2DG and replacing film 
autoradiography through the use of a phosphoimager. The data generated 
correlated to a high degree with the appropriate literature, and those regions with 
the lowest and highest LCGU matched those expected, based upon Sokoloff et 
al.’s (1977) original experiments. A slightly higher level of correlation with the 
data of Sarter (1990) most likely reflects the use of 3H-2DG in both studies, with 
a correspondingly lower specific activity than 14C-2DG as used by Sokoloff et al. 
(1977). 
 
 Although not quantified, for example by measuring plasma corticosterone 
to examine activation of the HPA axis, during the blood sampling process it 
appeared that the presence of two investigators and a degree of movement of 
the swivel was disruptive for the animals. Thus one could expect that these 
aspects of the present protocol may themselves constitute a stress to the 
animals. In order to minimise such an effect, it was decided to consider further 
modifications to the LCGU protocol, reducing the blood sampling load. 
  
 
 
Chapter 2  Assessment of LCGU protocols 
 50 
Study 2 - Administration of 2DG by Subcutaneous and Intraperitoneal 
Routes 
 
Introduction 
 
 In order to simplify the LCGU technique, removing the need for surgical 
implantation of catheters or potentially stressful intravenous (IV) injections (due 
to the increased intricacy of the procedure the animal must be restrained for 
longer than by other routes), both subcutaneous (SC) and intraperitoneal (IP) 
injection of 2DG have been used. The aim of this study was to directly compare 
the pharmacokinetics of 2DG in mice after either SC or IP administration, in 
order to assess the suitability of these routes for use. Mice were selected for use 
in this study in order to reduce the volume of 2DG required, and thus cost. For 
this reason, mice were used predominantly in the remainder of the work 
presented in this thesis. 
 
 Evidence for the suitability of alternate routes of 2DG administration has 
been presented in the literature (Meibach et al., 1980), although a direct 
representation of the pharmacokinetics of 2DG after either SC or IP injection was 
not included. Comparison of IP injection to IV demonstrated very high correlation 
between LCGU values via either route, and further demonstrated that a plateau 
in 2DG uptake was similarly reached regardless of administration route (Meibach 
et al., 1980). An immediate plasma peak following injection, as with IV (see 
Figure 9), is not expected as time for absorption of the 2DG from either SC or IP 
space is required.  
 
  
Chapter 2  Assessment of LCGU protocols 
 51 
Figure 9: Illustration of the expected plasma and brain levels of 2DG and 2DG-6-
P after bolus IV injection (adapted from Sokoloff et al., 1977) 
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 Residual unmetabolised 2DG in the plasma or brain after 45 min should 
also be minimal, assuming that 2DG uptake has reached a plateau. Furthermore, 
residual 2DG could be expected to be lower after IP injection than after SC (Kelly 
and McCulloch, 1983b). Residual 2DG in the system could confound 
measurements of LCGU as it is impossible to dissociate radiolabelled 2DG from 
its metabolite 2DG-6-P via either autoradiography or scintillation counting. 
Central levels of radioactivity are expected to rise continuously throughout the 
45min period, reaching a plateau as plasma levels of 2DG are exhausted. 
 
Methods 
 
Subjects 
 
 Male C57BL/6N mice (Janvier, France) were individually housed in 
individually-ventilated cages with food and water available ad libitum, under a 
standard 12h/12h light-dark cycle (lights on 06:00 a.m.), and at a regulated 
temperature of 22 ± 0.5oC and humidity of 50 ± 3%. The mean bodyweight at 
testing was 25.6 ± 0.7g. Final testing was carried out between 0700 and 1200 
hours. All testing was conducted according to the European Communities 
Council Directive Nov. 1986 (86/609/EEC) and approved by the animal care and 
use committee of Johnson & Johnson Pharmaceutical Research and 
Development. 
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Measurement of 2DG and 2DG-6-P in Brain and Plasma 
 
 2-deoxy-D-[1-3H]glucose (2DG; GE Healthcare, formerly Amersham 
Biosciences UK, specific activity of 2DG unchanged) (300 µCi/kg) was injected 
either intraperitoneally or subcutaneously. Following 2DG injection, mice were 
returned to their home-cage until decapitation. 
 
 Mice were decapitated every 5 minutes (n=3 per time point) from 5 to 45 
minutes after 2DG injection to obtain time-response curves for the level of 2DG 
in the plasma and 2DG/2DG-6-P in the brain (towards the end of the 45 minute 
standard protocol one would expect only negligible amounts of 2DG to remain 
unmetabolised in the brain, but prior to this measurement of total radioactivity 
may include both the unmetabolised and metabolised forms). 
 
 Upon decapitation, the brain was rapidly removed and stored at –20oC, 
trunk blood was collected in BD Microtainer K2E tubes (BD Vacutainer Systems, 
UK), and centrifuged at 1100 g for 10 minutes to separate plasma from red blood 
cells. Plasma samples were collected for measurement of plasma 3H (residual 
2DG) and stored at –80oC. 
 
 Brains were homogenized in phosphate-buffered saline (PBS) using glass 
minibeads and a Mini-BeadBeater-8 (Biospec Products Inc, USA). 3H in plasma 
and brain samples was measured in duplicate in a TopCount NXT (PerkinElmer, 
Belgium) microplate scintillation counter after addition of MicroScint-PS scintillant 
(PerkinElmer, Belgium). 
 
 A relative measure of LCGU was calculated as nCi 3H (metabolised 2DG) 
present per mg of brain tissue. 
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Results 
 
 As expected, a peak in plasma 2DG levels, followed by gradual 
elimination was seen after injection by either route, corresponding with a time-
dependent rise in brain 2DG/2DG-6-P levels reaching a plateau after 
approximately 25 minutes (Figures 10 and 11). 
 
 Also as expected, the peak in plasma 2DG via either injection route 
occurs substantially later than that expected after intravenous injection (compare 
with Figure 10). Plasma 2DG peaked within the first 10 minutes via either route, 
whereas following intravenous injection the peak would be expected within 1 
minute. 
 
 However, a difference in the plasma 2DG curves between the two routes 
can be seen in the later time points. Compared to subcutaneous injection, 
plasma 2DG after intraperitoneal administration appears to reach a lower, more 
stable level from 35 to 45 minutes. 
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Figure 10: Measured plasma and brain levels of 2DG and 2DG-6-P after bolus 
SC injection (data shown: mean lines with individual data, n=3).  
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Figure 11: Measured plasma and brain levels of 2DG and 2DG-6-P after bolus IP 
injection (data shown: mean lines with individual data, n=3).  
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Discussion 
 
 The expected plasma and brain distribution curves were seen following 
both IP and SC 2DG injection. Measured 3H levels in the plasma, representing 
unmetabolised 2DG, peaked early in the 45 minute protocol, and fell with time to 
minimal levels. Brain 3H levels, eventually representing 2DG metabolised to 
2DG-6-P, plateaued after approximately 25 minutes in both cases, indicating that 
the duration of the 45 minute protocol is sufficient to reach a steady state, in 
agreement with Sokoloff et al’s (1977) original assumptions. Based on the 
literature (Kelly and McCulloch, 1983b), it was expected that the IP route would 
produce lower levels of residual 2DG in the plasma, perhaps due to more 
complete diffusion and uptake of the ligand via this route. Indeed, in the present 
study, residual 2DG levels in the plasma speculatively appear lower and more 
consistent after IP 2DG injection, although this could only be confirmed in a 
larger-scale study by statistical analysis. 
 
 This study has illustrated that the distribution of 2DG and 2DG-6-P in 
plasma and brain appear to be as expected after either SC or IP administration. 
Thus, it could be expected that in future studies, a measure of LCGU could be 
obtained after the injection of 2DG by these routes. 
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Study 3 - Measurement of LCGU in Dissected Brain Regions by Scintillation 
Counting 
 
Introduction 
 
 As previously discussed, both autoradiography and brain dissection have 
been used in studies of LCGU, and each has pros and cons.  
 
Autoradiography can be a time-consuming process, requiring sectioning, 
exposure to film and densitometry to generate data. Using 14C-2DG, imaging 
requires approximately 5 days, yet does not have the resolution of 3H-2DG 
(Gallistel and Nichols, 1983), which requires 3-4 weeks for imaging. The 
availability of a cryostat for sectioning and a computerised system for 
densitometry was limited within Johnson & Johnson Pharmaceutical Research & 
Development, due to ongoing internal projects.  
 
In contrast, the equipment required for dissection of regions of interest 
from the brain and measurement of LCGU in homogenates was more readily 
available. In addition to this technical issue, dissection can generate data more 
rapidly than autoradiography, dependent on the number of samples. However, 
dissection has a number of clear drawbacks compared to autoradiography. 
Heterogeneous regions such as the thalamus are grouped into one dissected 
region, making it more difficult to draw clear conclusions from alterations in 
LCGU in such regions. Indeed, dissection of these regions may effectively mask 
changes in LCGU. For example, simultaneous increased LCGU in a particular 
subregion, with reduced LCGU in another subregion, grouped by dissection, 
could be missed through averaging to an overall unchanged response. The use 
of dissection also greatly reduces, and in many cases removes, the ability to 
measure LCGU in small brain regions. This effect can be twofold, as while a 
region may be too small to accurately dissect, the amount of radiolabelled 2DG 
in a small but dissectable region may be too low to accurately count. 
 
 In the light of these drawbacks, the aim of the present study was to 
confirm that LCGU can be reproducibly measured in dissected brain regions, 
both between different species and by different methods of tissue processing. 
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 For the initial dissection rats were used, due to their larger brain 
compared to mice, providing a larger amount of brain tissue per dissected region 
for homogenisation and counting. In addition to confirming that LCGU can 
successfully be measured in dissected rat brain region, this study compared two 
methods for the extraction of the radiolabel from the tissue in mice (with the aim 
of using this species in further studies, reducing cost). The methods compared 
were mechanical homogenisation and chemical solubilization. Mechanical 
homogenisation was achieved by rapidly shaking the sample in buffer with glass 
minibeads. Solubilisation was achieved using a commercially available tissue 
solubiliser. 
 
 Finally, due to the relatively low beta activity of 3H-2DG for scintillation 
counting, it was confirmed that increasing the administered dose of 2DG (within 
Sokoloff et al.’s assumptions) increases the signal to noise/background ratio for 
counting without further issues. 
  
Methods 
 
 Four male Sprague-Dawley rats (Charles River) were used to assess 
LCGU in dissected brain regions. Housing and treatment was identical to the 
previous studies. Mean bodyweight at testing was 428 ± 49g. Testing was 
carried out between 0700 and 1200 hours. The rats received a subcutaneous 
injection of 3H-2DG (300µCi/kg) and were returned to their home cage until 
decapitation 45 minutes later. Following decapitation the brain was rapidly 
removed and dissected into frontal cortical, septal, hypothalamic, thalamic, 
hindbrain (region encompassing all tissue posterior to the thalamus excluding the 
cerebellum - thus this region includes areas of interest including the locus 
coeruleus, dorsal raphe and other nuclei of relevance to the CRF system), 
hippocampal, and temporal (to include the amygdala) regions. The brain was 
sliced longitudinally along the midline, and the frontal cortex dissected, defined 
as the cortical matter anterior to the corpus callosum. The septum was defined 
as the tissue between corpus callosum and fornix to the depth of the lateral 
ventricle. The hypothalamic region was dissected defined posterior to the fornix, 
anterior to a line between superior colliculus and pituitary, and ventral to the 
thalamus. The thalamus was also defined posterior to the fornix, anterior to a line 
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between superior colliculus and pituitary and dissected to the depth of the 
hippocampus. The hindbrain region was defined as the remaining tissue 
posterior to the dissected thalamic region. With those regions removed, the 
hippocampus could be rolled in its entirety from its position inside the cortical 
fold. Finally the temporal region was defined as a block of tissue taken at the 
temporal cortex level, to include the amygdala. Illustrative diagrams for these 
dissections can be found in Appendix 1. The mean standard deviation in the 
weight of the dissected regions was 6.9 mg. 
 
 The dissected regions were weighed (mg wet weight) and stored in 2 ml 
screw-top plastic vials, initially snap-frozen in liquid nitrogen then stored at –
80oC. 
 
 The brain regions were thawed and homogenised in phosphate-buffered 
saline using glass minibeads and a minibead-beater. Following homogenisation, 
radioactivity levels were counted by liquid scintillation in Microscint 40 
scintillation cocktail (Perkin Elmer). LCGU in nCi/mg tissue was calculated. 
 
 Male C57BL/6 mice (Janvier) were used to compare the two methods for 
tissue processing and doses of 2DG. Again, these mice were housed identically 
to the rats used in the previously described studies. Mean bodyweight at testing 
was 29.1 ± 1.6g. Testing was carried out between 0700 and 1200 hours. 
 
 The regions dissected were the frontal cortex, hypothalamus, thalamus, 
cerebellum, hippocampus, and the same temporal and hindbrain regions as 
outlined for the rat brain dissection above. The mean standard deviation in the 
weight of the dissected regions was 1.9 mg. 
 
 To compare tissue processing techniques, dissected regions were either 
homogenised as previously described for rat brain or solubilised using Solvable 
(Perkin Elmer) (2DG was injected IP at a dose of 300 µCi/kg, and brains 
removed after 45 minutes). To solubilise the tissue, Solvable was added to the 
sample vial, and the samples were incubated at 55oC with regular vortexing until 
the tissue was dissolved. At this point 20 µl 30% hydrogen peroxide was added 
to each sample to reduce colourisation (which could lead to counting errors) and 
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the samples were incubated for a further 30 minutes. The samples were then 
transferred to microplates with Microscint 40 scintillant cocktail (Perkin Elmer) 
and the radioactive content of each sample was then measured in duplicate in a 
TopCount NXT (Perkin Elmer) microplate scintillation counter. 
 
 In their original technique, Sokoloff et al. inject 50 µCi of 14C-2DG to 
measure LCGU. At the typical range of specific activities for this ligand, this 50 
µCi amount equates to approximately 1 µmol of 2DG. This is considered to meet 
the requirements for tracer theory (Sokoloff et al., 1977), i.e. that molecular 
concentrations in blood and/or tissues are quantitatively negligible and 
pharmacologically inactive. At a dose of 300 µCi/kg, a 30 g mouse receives 
approximately 9 µCi of 3H-2DG. At typical specific activity, this equates to 
approximately 0.63 nmol, thus a dose in the range of a thousand fold smaller. 
Therefore the doubling of the 3H-2DG dose to 600 µCi, will not constitute a 
breach of the experimental assumptions, but will benefit the measurement of 
LCGU by scintillation counting, without excessively increasing the amount of 
2DG used. 
 
 To confirm this experimentally, two mice (data missing for mean 
bodyweight at testing; estimate 25-30g) were injected with 2DG at either 300 or 
600 µCi/kg IP, brains removed after 45 minutes and LCGU measured using the 
homogenisation dissection protocol. 
 
Results 
 
 A relative measure of LCGU in nCi/mg could readily be measured in 
dissected rat brain regions, with values ranging from approximately 0.07 to 0.33 
nCi/mg (Figure 12) after the subcutaneous dose of 300 µCi/kg 2DG. 
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Figure 12: LCGU (nCi/mg) measured in homogenised dissected rat brain regions 
(n=4) 
(legend: FrCx – frontal cortex; Sept – Septum; Hy – hypothalamus; Th – 
thalamus; Hb – hindbrain region; Hipp – hippocampus; Temp – temporal region) 
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 Both homogenisation (Figure 13) and tissue solubilisation (Figure 14) of 
dissected mouse brain regions produced values of LCGU similar to those found 
in rat brain. A similar time-scale is required to process the tissue via either 
method. According to the manufacturer of Solvable, Perkin Elmer, this tissue 
processing method should maximise the miscibility of tissue sample and 
scintillant for efficient scintillation counting 
(http://las.perkinelmer.com/content/RelatedMaterials/Brochures/BRO_ 
ScintillationCocktailsAndConsumables.pdf). (Chronological note: this individual 
study was actually conducted after some of the studies investigating the CRF 
system, having learnt of the availability of Solvable. Therefore, earlier studies 
into the effects of CRF system manipulation on LCGU use homogenisation, while 
later studies use Solvable. The confirmed similarity of data produced via either 
method, and the use of an appropriate control group in each study allows the 
comparison of the data.) 
 
 Doubling of the dose of 2DG injected from 300 to 600 µCi/kg increased 
the relative level of LCGU measured by approximately two-fold (Figure 15). 
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Figure 13: LCGU (nCi/mg) measured in homogenised dissected mouse brain 
regions (n=8) 
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Figure 14: LCGU (nCi/mg) measured in solubilised dissected mouse brain 
regions (n=3) 
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Figure 15: LCGU (nCi/mg) measured in homogenised dissected mouse brain 
regions (n=1/dose) 
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Discussion 
 
 This study demonstrated that a measure of LCGU can be reproducibly 
obtained from dissected brain regions in either rat or mouse after peripheral 
administration of 2DG. This is in agreement with previously reported studies, 
where a high correlation between LCGU values obtained through either 
autoradiography or dissection was found (Meibach et al., 1980). The suitability of 
a region for dissection is determined largely by size, of which a consequence is 
containing sufficient metabolised 2DG to be detectable by scintillation counting. 
 
 The levels of LCGU in the dissected regions in relaion to one another 
resemble those reported by Sokoloff et al (1977), when the appropriate individual 
regions are grouped as dissected in the present study. The frontal cortex and 
thalamus are regions with higher metabolism than the hypothalamus and 
hippocampus (Sokoloff et al., 1977). While LCGU in the amygdala is reported by 
Sokoloff et al. (1977) to be approximately half that of the frontal cortex, the 
temporal region dissected presently to include the amygdala also contains 
cortical matter, which typically has a higher LCGU. Thus the mean LCGU for the 
dissected temporal region is higher than that expected for the amygdala alone. 
This highlights a principal drawback of the dissection technique, the loss of 
neuroanatomical resolution. This problem is particularly apparent in the 
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dissected hindbrain region, which amalgamates numerous small brain regions 
and nuclei, many of which are reported to have high LCGU. However, the 
apparent increased hindbrain LCGU found using tissue solubilisation highlights a 
further issue – the effectiveness of dissection and homogenisation techniques in 
measuring the level of 2DG uptake. As a region with an increased mass 
compared to the other dissected regions, the solubilisation method may be more 
effective in recovering 2DG from within the cells. 
 
The reduction in neuroanatomical resolution introduced by dissecting 
brain regions makes it impossible to examine the involvement of small regions, 
either non-dissectable or grouped into larger dissected regions, in changes in 
LCGU. As such small regions may contain large amounts of neurons expressing 
particular neurotransmitters, the opportunity to implicate these particular 
neurotransmitters in LCGU changes is also lost. Dissection does, however, 
remove the need for cryostat and densitometry hardware, which were less 
readily available than homogenisation and scintillation counting equipment. 
 
 In order to avoid accessibility issues with the equipment for 
autoradiography, the dissection version of the original LCGU technique will be 
further used to study the effect of manipulating the CRF system on LCGU. 
However, due to the noted drawbacks of this technique, crucial results will be 
confirmed by autoradiography. 
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Study 4 - The Effect of 2DG on the HPA Axis 
 
Introduction 
 
 Through competition with intracellular glucose, 2DG inhibits 
phosphohexose isomerase (Sols and Crane, 1954; Tower, 1958), the enzyme 
that converts phosphoglucose to phosphofructose, and thereby blocks glycolysis 
at the initiation stage. Therefore, at sufficient doses, 2DG is expected to cause 
depletion of ATP as well as of glucose derivatives required for protein 
glycosylation (Kang and Hwang, 2006). This energy depletion constitutes a 
pharmacological stressor, and it should be noted that in sufficiently high doses, 
2DG itself activates the HPA axis (Weidenfeld et al., 1984; Weidenfeld et al., 
1994; Khan and Watts, 2004). However, the dose required for this effect is 
several hundred-fold greater than the dose used to measure LCGU. 2DG was 
capable of activating the HPA axis at doses >100 mg/kg, while the tracer amount 
of 2DG used to measure LCGU equates to approximately 6 µg/kg (at the 600 
µCi/kg dose). The aim of this study was to confirm that the doses of 2DG used to 
measure LCGU do not affect the HPA axis. 
 
Methods 
 
 To confirm that low doses of 2DG do not affect the HPA axis, 2-Deoxy-D-
glucose (non-radiolabelled; Sigma Aldrich, Germany) was injected 
intraperitoneally in C57BL/6N mice (Janvier; housed identically to those used in 
the previous studies; mean body weight at testing 27.1 ± 0.97g) at doses from 5-
400 mg/kg in saline vehicle. The lowest dose of 5 mg/kg tested is close to one 
thousand times greater than the dose used to measure LCGU, and the higher 
end of the dose range was chosen to include doses expected to increase plasma 
corticosterone, based on studies in the literature (Weidenfeld et al., 1984; 
Weidenfeld et al., 1994; Khan and Watts, 2004). After 45 minutes plasma was 
collected as previously described for the measurement of plasma corticosterone. 
All testing was caried out between 0800 and 1200 hours. Plasma corticosterone 
was measured using ImmuchemTM Double Antibody corticosterone 125I RIA kits 
(MP Biomedicals, USA). Data were statistically analysed non-parametrically 
using the Kruskal-Wallis (KW) test (SPSS v13.0, SPSS Belux, Belgium). Where 
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appropriate, post-hoc comparison was performed by the Mann-Whitney test (2-
sided). 
 
Results 
 
 Intraperitoneal administration of unlabelled 2DG resulted in a dose-
response increase in plasma corticosterone after 45 minutes (Figure 16), only 
reaching statistical significance at the 200 and 400 mg/kg doses (p=0.026 and 
0.015) (equivalent to approximately 20 Ci/kg and 40 Ci/kg, respectively, when 
compared to 2DG used to measure LCGU at a typical specific activity of 8 
Ci/mmol), more than one thousand-fold higher than the dose used to measure 
LCGU (approx 6 µg/kg at an injected dose of 600 µCi/kg). 
 
Figure 16: The effect of intraperitoneally administered 2DG on the HPA axis. 
(n=6/group). *p<0.05. 
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Discussion 
 
 The results of this study clearly demonstrate that 2DG only affects the 
HPA axis, illustrated by increased plasma corticosterone, at substantially higher 
doses than those used to measure LCGU. Thus, effects on the HPA axis in 
subsequent studies cannot be attributed to the use of 2DG to measure LCGU. 
While the present study does not measure other centrally mediated parameters 
that could be altered by 2DG itself, such as LCGU, the experimental design of 
such studies should ensure that any such effects are of negligible consequence. 
The dose of 2DG used to measure LCGU is considered to meet the 
requirements for tracer theory, defined as the presence of the compound at 
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levels below those of pharmacological significance, and furthermore, all 
treatment groups, including control, in subsequent studies will receive an 
identical dose of 2DG. 
 
 The effects of 2DG on the HPA axis in the present study agree with 
previously reported data (Weidenfeld et al., 1984; Weidenfeld et al., 1994; Khan 
and Watts, 2004), in which 2DG was capable of activating the HPA axis at doses 
>100 mg/kg. Through competition with intracellular glucose, 2DG inhibits 
phosphohexose isomerase (Sols and Crane, 1954; Tower, 1958), the enzyme 
that converts phosphoglucose to phosphofructose, and thereby blocks glycolysis 
at the initiation stage. Therefore, at sufficient doses, 2DG is expected to cause 
depletion of ATP as well as of glucose derivatives required for protein 
glycosylation (Kang and Hwang, 2006), constituting a pharmacological stressor 
through energy depletion. The use of a tracer dose of 2DG which is only 
sufficient for the measurement of LCGU ensures that this effect is avoided in 
studies of cenral glucose metabolism.  
Chapter 2  Assessment of LCGU protocols 
 67 
Study 5 - Assessment of a Method for Free-hand ICV Injection in mice 
 
Introduction 
 
 Due to the inability of peripherally injected peptides to cross the blood-
brain barrier, the potential for these peptides to be broken down in the periphery 
and the very limited availability of small molecule agonists and antagonists for 
CRF1 and CRF2 receptors that would negate the problems of stability and the 
blood-brain barrier, it is necessary to administer the CRF peptides and derived 
antagonists directly into the brain. This is most commonly achieved by injecting 
these peptides into the lateral ventricle (intracerebroventricular, or ICV injection) 
through a surgically implanted cannula. This method allows single and repeated 
ICV injections usually through the use of a separate injection cannula and a 
dummy cannula to occlude the guide cannula between uses. Drawbacks of this 
method include: the necessity for surgery and a suitable recovery period, the risk 
of cannula blockage or loss before or during studies, and a degree of stress on 
the animal during the process of injecting compounds through the cannula.  
Experience of surgically implanted cannulas for ICV injection within Johnson & 
Johnson Pharmaceutical Research & Development suggested that the blockage 
of cannulas in mice between surgery and testing was a repetitive problem, and 
that activation of the HPA axis by the handling during injection was often 
sufficient to mask treatment-induced effects. However, a method for the ICV 
administration of compounds without the need for surgery has been reported in 
the literature (Pelleymounter et al., 2000; Pelleymounter et al., 2004). Using this 
method the need to surgically implant cannulas is avoided, although the obvious 
drawbacks include the need to anaesthetise the animal while inserting a needle 
directly through skin and skull into the lateral ventricle, aspects which could 
themselves influence LCGU, and activate the HPA axis. Therefore, the aim of 
this study was to assess the suitability of this method for use in combination with 
measuring LCGU. 
 
Methods 
 
 Male C57BL/6N mice (Janvier, France) were used under the same 
conditions as for previous studies. Mean body weight at testing 26.9 ± 1.0g. All 
testing was caried out between 0800 and 1200 hours. 
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 The freehand ICV procedure was adapted from Pelleymounter et al 
(Pelleymounter et al., 2000; Pelleymounter et al., 2004), who used a Hamilton 10 
µl syringe with a 30 gauge needle (limited to 4mm using polyethylene tubing) to 
inject into the third cerebral ventricle directly under isoflurane anaesthesia. Pilot 
studies suggested that this method of injection risked penetrating the cerebral 
vein running along the midline, so the technique was adapted for injecting into 
the lateral ventricle. 
 
 In the modified technique, the mice were weighed, then briefly (30 
seconds or until a clear change in breathing rhythm was seen) anaesthetized 
using isoflurane (4% in 30% O2, 70% N20) until the change of breathing rhythm 
characteristic of full anaesthesia was apparent. 5 µl of solution was injected 
using a Hamilton 10 µl syringe and 30-gauge needle limited to 2.5 mm length 
using a piece of polyethylene tubing. Using downwards pressure above the ears  
the head was stabilised, and the needle was inserted directly through the skin 
and skull into the lateral ventricle (see Figure 17a), targeted by visualizing an 
equilateral triangle between the eyes and center of skull to locate bregma, then 
inserting the needle 1.5-2 mm laterally to this point (illustrated in Figure 17b). 
This ensures penetration of the skull at the suture line of the skull (Figure 17c) 
plates to minimize necessary force, while avoiding the centrally located vein. 5 µl 
was injected over an approximately 5 sec period, followed by a 10 sec delay to 
allow diffusion and prevent backflow. 
 
Figure 17: Illustrations of the freehand ICV injection technique: a) Paxinos & 
Watson brain atlas slide (at bregma) illustrating the penetration of the needle into 
the lateral ventricle (black space); b) location of the injection site; c) injection site 
relative to skull sutures 
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 In a pilot study injecting methylene blue dye into the lateral ventricles of 
thirty C57BL/6N mice (Janvier, mean body weight 26.6 ± 1.1g) using this 
method, the success rate (as determined by the presence of blue dye in the 
lateral ventricles after removal and slicing of the brain) of injection was 93.3%, 
which corresponds with the values reported in the literature (approximately 95%; 
Pelleymounter et al., 2000). Under normal experimental circumstances an animal 
with any evidence of subdural haemorrhage (altered physical activity, blood upon 
dissection) would be excluded from analysis (as in Pelleymounter et al., 2000; 
Pelleymounter et al., 2004), however in this pilot study no such evidence was 
seen while targeting the lateral ventricle. 
 
 In order to assess the effectiveness of the ICV injection technique for 
compound delivery, the effect of CRF and amphetamine on behaviour in a novel 
open field was measured. 
 
 The open field apparatus consists of four transparent plastic arenas (26 x 
26 x 38 cm) surrounded by infrared beam grids to allow the measurement of 
horizontal and vertical activity. Activity is recorded using Tru-Scan Software 
Version 1.011 (Coulbourn instruments, Allentown, USA). Each arena is 
separated from the others and from the experimenter with opaque panels. 
Parameters of locomotor activity and rearing are recorded over 30 minutes in 6 
minute time bins. 
 
 To examine the effects of the components of the injection procedure, mice 
received either no treatment, anaesthesia only, anaesthesia plus needle 
insertion only or a full ICV injection of 5 µl saline. To assess the effectiveness of 
the method to deliver an active dose of compound, separate groups of mice 
received either ICV injections of 0.5 µg CRF (in 5 µl saline), or 20 µg 
amphetamine (in 5 µl saline). After treatment, mice were returned to their home 
cage for 10 minutes to recover before being placed in the open field apparatus 
for 30 minutes. 
 
 To assess the effects of components of the injection procedure or 
pharmacological treatment on the level of HPA axis activation after exposure to 
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the open field, plasma corticosterone was measured after exposure to the open 
field using ImmuchemTM Double Antibody corticosterone 125I RIA kits (MP 
Biomedicals, USA). 
 
 To assess whether the injection technique produced significant effects on 
LCGU measurements, two groups of mice received either an ICV injection of 
saline using the free-hand method described above, or no injection (i.e no 
component of the ICV procedure), and an IP injection of 300 µCi/kg 3H-2DG. 45 
minutes later the brain was removed and dissected for measurement of LCGU 
using the protocol described above. Blood glucose after the 45 minute protocol 
was measured using a commercially available glucose meter (Lifescan), and 
residual 2DG content is the plasma was measured by scintillation counting. The 
effect of the brief anaesthesia alone, or that of needle insertion, on LCGU was 
not measured in this study as it is the effect of the entire ICV injection procedure 
that must be accounted for in future studies (i.e. in order to later examine the 
effect of ICV CRF compared to ICV saline injection, anaesthesia or needle 
insertion alone will not be of use in delivering the compound). It has been 
established in the literature that prolonged anaesthesia throughout the course of 
measuring LCGU (i.e. at least 45 min) significantly decreases LCGU globally 
throughout the brain (Frietsch et al., 2000). 
 
 Overall effects on LCGU, residual 2DG, blood glucose, total distance 
traveled and total rearing behaviour in the open field, and on plasma 
corticosterone were compared using the Kruskal-Wallis test, and Mann-Whitney 
test for post-hoc comparisons, with a significance level of p=0.05 in SPSS. 
Effects on distance traveled and rearing in the open field by 6 minute time bins 
were analysed using repeated measures ANOVA with Greenhouse-Geisser 
correction for sphericity where appropriate (Mauchly’s W test p<0.05), with t-tests 
for post-hoc comparisons in SPSS with a significance level of p=0.05. 
 
Results 
 
 In the open field, total distance moved was slightly reduced in animals that 
received a component of the ICV injection, compared to untreated animals 
(p<0.009) (Figure 18). However, individual time bin analysis revealed that this 
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reduction was predominantly due to differences during the first 12 minutes in the 
open field (Figure 20; repeated measures ANOVA time effect F4,88=5.794, 
ε=0.655; p=0.002, treatment effect F3,22=12.183; p<0.001, treatment-time 
interaction effect F4,88=9.562, ε=0.655; p<0.001), although reduced locomotion 
continued until the 18 minute time bin (p<0.039). Similar effects were seen on 
overall rearing behaviour, with reduced levels in animals receiving anaesthesia 
plus needle or full ICV injection (p=0.002) (Figure 19), also due to effects in the 
first 12 minutes (Figure 21; repeated measures ANOVA time effect F4,88=10.543; 
p<0.001, treatment effect F3,22=10.291; p<0.001, treatment-time interaction effect 
F4,88=7.030; p=0.002). ICV treatment with 0.5 µg CRF greatly reduced both total 
distance moved and rearing compared to both saline ICV treated and untreated 
animals (p=0.001 vs. saline ICV). In contrast, amphetamine induced a trend for 
increased distance moved (p=0.073) while reducing rearing (p=0.001). These 
effects were present across all time bins (Figures 22 and 23; distance repeated 
measures ANOVA time effect F4,72=6.502, ε=0.535; p=0.003, treatment effect 
F2,18=12.167; p<0.001; rearing repeated measures ANOVA time effect 
F4,72=5.995, ε=0.733; p=0.001, treatment effect F2,18=30.381; p<0.001, 
treatment-time interaction effect F4,72=3.156, ε=0.733; p=0.011). 
 
 Plasma corticosterone after exposure to the open field was unaffected by 
any of the components of the ICV procedure (Figure 24), but was significantly 
increased by either CRF or amphetamine treatment (p<0.005). Plasma 
corticosterone levels in saline-injected mice were 228 ± 23 ng/ml (mean ± SEM), 
while those in CRF- and amphetamine-treated mice were 316 ± 11 and 316 ±6 
ng/ml, respectively. 
 
 The ICV injection procedure had no significant effect on LCGU in any of 
the regions dissected (Figure 25), and no effect on blood glucose (untreated 
mean 125 ± 8 mg/dl, ICV 120 ± 5 mg/dl) or residual plasma 2DG (untreated 
mean 79 ± 21 nCi/ml, ICV 69 ± 5 nCi/ml).  
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Figure 18: The effect of components of the ICV injection procedure, and CRF or 
amphetamine treatment on total distance travelled in the open field apparatus 
(n=6-7/group)  
(None – untreated; Anaesth – anaesthesia only; Needle – anaesthesia plus 
needle insertion) (#: p<0.05 vs. None; *: p<0.05 vs. Saline) 
0
2000
4000
6000
8000
10000
12000
N
on
e
A
na
es
th
N
ee
dl
e
S
al
in
e
C
R
F_
0.
5u
g
A
m
ph
et
_2
0u
g
to
ta
l 
d
is
ta
n
c
e
 (
m
m
)
*
##
#
 
Figure 19: The effect of components of the ICV injection procedure, and CRF or 
amphetamine treatment on overall rearing behaviour in the open field apparatus 
(n=6-7/group) (#: p<0.05 vs. None; *: p<0.05 vs. Saline) 
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Figure 20: The effect of components of the ICV injection procedure on distance 
travelled in the open field apparatus (n=6-7/group) (post-hoc effects - #: 
treatment effect vs. None; *: within-group time effect) 
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Figure 21: The effect of components of the ICV injection procedure on rearing 
behaviour in the open field apparatus (n=6-7/group) post-hoc effects - #: 
treatment effect vs. None; *: within-group time effect) 
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Figure 22: The effect of CRF or amphetamine treatment on distance travelled in 
the open field apparatus (n=6-7/group) (post-hoc effects - #: treatment effect vs. 
None; *: within-group time effect) 
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Figure 23: The effect of CRF or amphetamine treatment on rearing behaviour in 
the open field apparatus (n=6-7/group) (post-hoc effects - #: treatment effect vs. 
None; *: within-group time effect) 
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Figure 24: The effect of components of the ICV injection procedure, and CRF or 
amphetamine treatment on plasma corticosterone levels after exposure to the 
open field apparatus (n=6-7/group) (**: p<0.005 vs. Saline) 
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Figure 25: The effect of the ICV injection procedure on LCGU in dissected 
mouse brain regions (n=11 no treatment, n=16 ICV)  
(legend: FrCx – frontal cortex; Hy – hypothalamus; Th – thalamus; Ce – 
Cerebellum; Hb – hindbrain region; Hipp – hippocampus; Temp – temporal 
region) 
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 Discussion 
 
 This study assessed the effectiveness of a freehand method for ICV 
injection, requiring no surgical intervention. Using this technique it was possible 
to reliably deliver compound into the lateral ventricle of mice, and it was possible 
to detect a pharmacological effect of CRF administration. However, there are 
clear drawbacks of this technique, which were further illustrated in the open field 
paradigm. 
 
 The freehand ICV injection procedure used in the present study can be 
broken down into three component parts: anaesthesia, the penetration of skin 
and skull with a needle, and the injection of saline or another compound. As was 
seen in the open field paradigm, these components either alone or together, 
produced significant effects on behaviour, without the addition of a compound 
with a pharmacological mechanism of action. All of these components reduced 
overall locomotor activity in the open field, predominantly in the first 12 minutes 
after injection, with anaesthesia alone affecting locomotion to a slightly lesser 
degree than the other two components. Anaesthesia alone did not significantly 
affect overall rearing, although there were clear effects in the first 12 minutes as 
for locomotion. However, both needle insertion and further saline injection clearly 
reduced rearing to a greater degree. These effects are comparable to those of a 
stessor on behaviour in the open field (Carli et al., 1989; Broqua et al., 1992), 
which may serve to limit the freehand ICV technique’s usefulness in studying 
stress-related behaviour or components of the stress system. The lack of a 
group with implanted cannulae for comparison is a flaw in the present study. The 
inclusion of such a group in a further study would allow the direct comparison of 
a full ICV injection between the two methodologies. 
 
 While the effects of the ICV injection components diminish with time in the 
open field, it may not be suitable to allow a longer recovery period between 
injection and testing, as it is typically desirable to examine the effects of a 
compound delivered via the ICV route soon after injection (e.g. after 10 minutes 
recovery as used here). Indeed, when using a paradigm such as the 
measurement of LCGU, it is desirable to begin the protocol immediately after 
treatment.  
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 Despite the effects of the ICV procedure itself on behaviour in the open 
field, the effects of CRF treatment were visible throughout the exposure to the 
open field, with further reductions in locomotor activity and rearing, suggesting 
an anxiogenic-like effect. Indeed, CRF has previously been reported to reduce 
locomotor activity in a novel open field environment (Dunn and Berridge, 1990), 
matching the present data. CRF also further activated the HPA axis, above the 
level induced by exposure to the open field or the components of the ICV 
prcocedure, as indicated by increased plasma corticosterone levels, and also in 
agreement with the literature (Dunn and Berridge, 1990). At this point a limitation 
of the present study should be noted, namely that the effects of the ICV 
procedure and those of CRF and amphetmine on the HPA axis were only 
measured after the open field paradigm. As exposure to the open field itself 
activates the HPA axis (as demonstrated by plasma corticosterone levels in the 
unmanipulated control group, which at approximately 200 ng/ml far exceed those 
levels expected at true baseline, of close to zero) the effects of the ICV 
procedure on this measure are likely to be masked.  
 
Based on the literature, amphetamine is expected to produce a non-
specific increase in locomotor activity (Swerdlow et al., 1993). As there was no 
significant effect of amphetamine treatment on locomotor behaviour in the 
present study, only a trend, it is not possible to conclude that a clear 
pharmacological effect was produced, in contrast to the effects of CRF 
treatment. This may indicate that the effects of the ICV procedure on behaviour 
in the open field conflict with those expected after amphetamine administration, 
and could suggest that the presently used ICV injection is not ideal for the study 
of such pharmacological manipulations. However, the failure of amphetamine to 
elicit a significant effect on locomotion in the present study may also represent a 
sub-effective dose, insufficient experimental power or excessive variability 
through insufficient group sizes. The contribution of these issues to the 
measured effect of amphetamine could be investigated in further studies. 
 
 A similar freehand method for ICV injection has been used to study the 
effects of CRF on anorectic behaviour and the effects of Urocortin 2 and 3 on 
anxiety-related behaviour and the HPA axis (Pelleymounter et al., 2000; 
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Pelleymounter et al., 2004). In these studies, the effects of the injected peptides 
were significant when compared to mice receiving ICV injections of vehicle, after 
similar recovery times (15-30 minutes) to those used in the present study. This 
supports the usefulness of this technique in studying the effects of CRF and the 
Urocortins after ICV administration. 
 
 In the present study, the ICV injection procedure did not detectably 
influence LCGU. Stress has been reported to have clear effects on LCGU in the 
literature (Soncrant et al., 1988; Xing et al., 1990; Duncan et al., 1993; Frietsch 
et al., 2000; Takamatsu et al., 2003a, 2003b; and considered later in this thesis). 
Therefore, the lack of a clearly detectable effect of the ICV procedure on LCGU 
suggests that the degree of stress induced by the procedure is not sufficient to 
significantly alter LCGU.  While the effects of components of the ICV procedure 
on LCGU were not individually studied, as the technique in its entirety is required 
for studies into the effects of ICV injected peptides, the effect of anaesthesia on 
LCGU has been considered in the literature. LCGU is greatly reduced in a global 
manner when measured under anaesthesia (Sokoloff et al., 1977; Frietsch et al., 
2000). However, the effects of a brief anaesthesia on LCGU have not been 
studied alone, although in studies utilising Sokoloff et al.’s (1977) original 
method, rats typically have intravenous and arterial catheters implanted under 
anaesthesia hours before the measurement of LCGU, while maintaining 
significant LCGU responses to pharmacological treatment. 
 
 Blood glucose was measured after the LCGU protocol as constant blood 
glucose was a requirement of Sokoloff et al.’s original technique (Sokoloff et al., 
1977). The consequence of large alterations in the level of blood glucose, 
brought about through either physical or pharmacological means, could be 
variation in the level of competition with injected 2DG, leading to incorrect 
estimates of LCGU. Blood glucose at the end of the LCGU protocol was 
unaltered by ICV injection, suggesting that the experimental assumption was 
met. The measurement of residual 2DG in the plasma after the LCGU protocol 
provides a further indication as to whether abnormal competition with glucose 
has occurred, as (for example) increased blood glucose competing with 2DG 
may lead to higher amounts of residual, unmetabolised, 2DG. However, as the 
45 minute protocol is designed to allow ample time for injected 2DG to be 
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metabolised (indicated by the plateau in metabolised 2DG-6-P levels in the brain, 
see Figures 10 and 11), only large variations in blood glucose may be sufficient 
to influence this variable. 
 
 Via the direct penetraion of skin and skull, the freehand ICV technique 
could introduce pathogens into the brain, potentially leading to an immune 
response, itself with consequences on stress levels or LCGU. However, the 
exclusive use of this freehand ICV technique in acute studies lasting up to one 
hour before sacrifice should serve to minimise the size of such an effect. 
Furthermore, the use of surgically implanted cannulae cannot definitively prevent 
this problem, as the presence of a direct channel into the brain over a period of 
(up to) weeks also provides a chance for the introduction of pathogens.  As long 
as the guide cannula is sealed with a dummy cannula the risk is minimised, 
however removal of the dummy cannula to prevent its mechanical seizure within 
the guide, or in the case of damage, or indeed to insert the injection cannula for 
testing, provides a chance for the introduction of pathogens. The introduction of 
pathogens into the animal’s body is a risk during any injection, for example also 
via subcutaneous or intraperitoneal injection, yet this factor is not typically 
considered a serious issue, at least in acute studies. 
 
 In conclusion, the evidence from this study suggests that the freehand 
ICV injection procedure adapted from Pelleymounter et al. (2000; 2004) is an 
alternative to surgically implanted cannulas for the central administration of 
compounds in mice. This freehand method has clear disadvantages, including 
itself affecting behaviour in a stress-related paradigm, the open field, and 
disrupting the expected effects of amphetamine in the present studies. However, 
as no significant effects of an ICV injection using this technique were seen in 
LCGU, and pharmacological effects of CRF administration were detectable, it 
was decided to further use this technique despite its disadvantages, to negate 
the need for surgery. 
 
Chapter 2  Assessment of LCGU protocols 
 80 
Summary & Conclusions 
 
 In this series of experiments a number of modifications to the original 
LCGU technique were examined, ranging from the use of 3H-2DG in the place of 
14C-2DG to the measurement of LCGU in dissected regions of the mouse brain. 
 
 All of the modifications examined here have been successfully used in the 
literature to measure LCGU, as reviewed in the General Introduction. Having 
studied first hand the requirements, advantages and disadvantages of each 
modification, it was possible to select those with which to study the effects of 
CRF system manipulation on LCGU. 
 
 The primary version of the LCGU technique which was used further was 
intraperitoneal injection of 3H-2DG in mice, followed by measurement of LCGU in 
dissected brain regions. The advantages of this version of the technique are the 
removal of the need for any surgery or stressful intravenous injections, a large 
reduction in cost (the tritiated ligand is substantially cheaper than the 14C-labelled 
version, and mice require a ten fold lower dose), and removal of the need for 
equipment specific to autoradiography. However, the disadvantages of this 
version of the LCGU technique are an inability to fully quantify LCGU in 
µmol/100g/min, an inability to repeatedly measure blood glucose, a reduction in 
neuroanatomical resolution and the grouping of heterogeneous brain regions into 
single dissected regions. The inability to fully quantify LCGU removes some 
ability to standardise measured LCGU to individual animal differences, which 
could lead to increased variability within treatment groups, and a possible 
reduction in experimental power. However, a dose of 2DG adjusted to 
bodyweight was used in an inbred mouse strain to keep differences between 
individual LCGU measurements to a minimum. In the absence of fully 
quantitative LCGU measurement, the repeated measurement of blood glucose 
throughout the LCGU protocol is not essential. However a drawback of 
measuring only end point blood glucose is that transient changes in blood 
glucose lasting less than 45 minutes may be missed. The reduction in 
neuroanatomical resolution introduced by dissecting brain regions makes it 
impossible to examine the involvement of small regions, either non-dissectable 
or grouped into larger dissected regions, in changes in LCGU. As such small 
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regions may contain large amounts of neurons expressing particular 
neurotransmitters, the opportunity to implicate these particular neurotransmitters 
in LCGU changes is also lost. Dissection does, however, remove the need for a 
cryostat and film capturing hardware, which are often limited resources. 
 
 This version of the LCGU technique was selected to remove the need for 
surgically implanted catheters and blood sampling, to limit cost through the use 
of the tritiated ligand in mice, and to allow the measurement of 2DG retained in 
the brain without sectioning and autoradiography. However, when drawing 
conclusions from subsequent studies using this version, it is essential to consider 
the disadvantages detailed above. The experimental protocol when using this 
technique in the study of the CRF system and stress is described in detail in the 
following chapter. 
 
 To support any crucial findings in the subsequent studies, it was decided 
to replicate them using autoradiography with 14C-2DG in mice (intraperitoneal 
administration), for precise definition of regions of interest using a widely 
accepted technique. Although not assessed during the studies described in this 
chapter, this version of the LCGU technique has been widely used in the 
literature. The use of the more expensive 14C-labelled ligand in these limited 
cases allows high resolution imaging on film after only 5 days exposure. The 
advantage of using this version of the LCGU technique to replicate important 
results is an increase in regional resolution, although the disadvantages of this 
version are similar to those of the dissection technique, namely, the inability to 
fully quantify LCGU or to repeatedly measure blood glucose. The experimental 
protocol when using this technique in subsequent studies is also described in 
detail in the following chapter. 
 
 To allow any effects on the HPA axis, as expected from CRF and related 
peptides, to be clearly interpreted, it has been confirmed that 2DG does not 
affect the HPA axis itself at the doses used to measure LCGU. 
 
 In order to study the CRF system, the freehand method for ICV injection 
assessed above was used to centrally administer CRF, the CRF-related 
peptides, and the peptide CRF2-selective antagonist antisauvagine-30 (Ruhmann 
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et al., 1998). The advantage of this technique is the removal of the need for 
surgical implantation of cannulas, although there are clear disadvantages such 
as the need to briefly anaesthetise the animal and a degree of stress induced by 
the injection itself. However, despite these drawbacks, it was possible to 
measure the effect of CRF in the open field after administration using this 
technique, and the technique has been used to study the effects of CRF and the 
Urocortins on behaviour and the HPA axis (Pelleymounter et al., 2000; 
Pelleymounter et al., 2004). Thus, it was decided to use this non-surgical 
technique in combination with the non-surgical versions of the LCGU technique 
desribed above in using LCGU to study the CRF system, while taking care to 
consider the drawbacks of both techniques in drawing conclusions from these 
studies. 
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General Methods 
 
 In this chapter those methods selected for further use from the previous 
chapter are described together in detail, as used for the studies in the following 
chapters.  Where required, additional methods are described in the following 
chapters themselves. 
 
Subjects 
 
 Male C57BL/6N mice (Janvier, France) (bodyweight at testing 29-33 g) 
were individually housed in individually-ventilated cages with food and water 
available ad libitum, under a standard 12h/12h light-dark cycle (lights on 06:00 
a.m.), and at a regulated temperature of 22 ± 0.5oC and humidity of 50 ± 3%. All 
testing was conducted according to the European Communities Council Directive 
Nov. 1986 (86/609/EEC) and approved by the animal care and use committee of 
Johnson & Johnson Pharmaceutical Research and Development. All testing was 
carried out between 0800 and 1200 hours, i.e. during the early light-phase. 
 
ICV Injections 
 
 Peptides were injected ICV using the freehand technique modified from 
Pelleymounter et al. (2000; 2004) as described in the previous chapter. In the 
modified technique, the mice were weighed, then briefly anaesthetized using 
isoflurane (4% in 30% O2, 70% N20) until the change of breathing rhythm 
characteristic of full anaesthesia was apparent. 5 µl of solution was injected 
using a Hamilton 10 µl syringe and 30-gauge needle limited to 2.5 mm length 
using a piece of polyethylene tubing. The needle was inserted directly through 
the skin and skull into the lateral ventricle (see Figure 11a), targeted by 
visualizing an equilateral triangle between the eyes and center of skull to locate 
bregma, then inserting the needle 1.5-2 mm laterally to this point (illustrated in 
Figure 11b). This ensures penetration of the skull at the suture line of the skull 
plates (Figure 11c) to minimize necessary force, while avoiding the centrally 
located vein. 5 µl was injected over an approximately 5 sec period, followed by a 
10 sec delay to allow diffusion and prevent backflow. 
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Measurement of local cerebral glucose utilisation (LCGU) 
 
 For dissection studies, 2-deoxy-D-[1-3H]glucose (2DG; GE Healthcare, 
UK) (600 µCi/kg) was injected intraperitoneally immediately after ICV injection. 
Following 2DG injection, mice were returned to their home-cage for 45 min until 
decapitation. For the autoradiography studies, 2-deoxy-D-[1-14C]glucose (GE 
Healthcare, UK) (167 µCi/kg) was also injected intraperitoneally. 
 
 Upon decapitation, trunk blood was collected in BD Microtainer K2E tubes 
(BD Vacutainer Systems, UK), 10 µl whole blood was used to measure blood 
glucose using a Lifescan glucose meter (Lifescan Benelux, Belgium), and the 
remainder was centrifuged at 1100 g for 10 minutes to separate plasma from red 
blood cells. Plasma samples were collected for measurement of plasma 3H 
(residual 2DG) and corticosterone and stored at –80oC. 
 
 In dissection studies the brains were dissected into frontal cortical area 
(anterior to corpus callosum), hypothalamus, thalamus, cerebellum, hindbrain (a 
block defined from the colliculi to the posterior level of the cerebellum), 
hippocampus and temporal region (including the amygdala). Illustrative diagrams 
for these dissections can be found in Appendix 1. Tissue samples were weighed, 
and stored at –80oC until homogenisation. 
 
 Brain samples were either homogenized in phosphate-buffered saline 
(PBS) using glass minibeads and a Mini-BeadBeater-8 (Biospec Products Inc, 
USA), or dissolved using Solvable tissue solubiliser (Perkin Elmer, Belgium). 3H 
in plasma and brain samples was measured in duplicate in a TopCount NXT 
(PerkinElmer, Belgium) microplate scintillation counter after addition of 
MicroScint-PS (homogenised samples) or Microscint-40 (dissolved samples) 
scintillant (PerkinElmer, Belgium). 
 
 A relative measure of LCGU was calculated as nCi 3H (metabolised 2DG) 
present per mg of brain tissue. For comparative purposes, percentage change in 
LCGU was calculated for individual animals against the saline control group 
mean. 
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 In the autoradiography studies, the brains were rapidly frozen in 
methylbutane chilled to –35oC on dry ice, and stored at –20oC. 20 µm sections 
were collected on glass slides using a Leica cryostat (Leica, Germany) and 
exposed for 5 days on Kodak Biomax MR-1 film (Raytest, Germany) with 
calibrated standards. LCGU (also defined as nCi/mg tissue) was measured in 
regions matching those dissected with the addition of the septum and dorsal 
raphe, using an MCID M1 Digital Densitometry System (Interfocus GmbH, 
Germany). 
 
Measurement of plasma corticosterone 
 
 Plasma corticosterone was measured using ImmuchemTM Double 
Antibody corticosterone 125I RIA kits (MP Biomedicals, USA). 
 
Statistical Analysis 
 
 Statistically small (n<30 per treatment group) data sets may violate the 
central limit theorem, i.e. are not normally distributed. Statistical tests for 
normality may also be inaccurate when working with such small data sets. When 
this is the case, the power of parametric statistics is reduced, and non-
parametric analysis may be more suitable. If the The Mann-Whitney U test is 
applied to data which might properly be analysed by the t-test its power 
increases with sample size and is close to 95 % even for moderate-sized 
samples. Therefore it is an excellent alternative to the t-test, and does not have 
the restrictive assumptions and requirements (e.g. normallity and equivalent 
variances) associated with the t-test (Siegel, 1956). Dose-response or single-
dose data were statistically analysed non-parametrically using the Kruskal-Wallis 
(KW) test  or the Mann-Whitney (MW) test, respectively (SPSS v13.0, SPSS 
Belux, Belgium). Where appropriate, post-hoc comparison was performed by the 
Mann-Whitney test (2-sided). However, there is a lack of non-parametric tests 
with supported efficiency suitable for the analysis of dual-treatment data, 
necessitating the use of the parametric 2-way ANOVA for analysis of such data. 
In dual-treatment (mutant mouse/antagonist pre-treatment studies) studies, data 
were analysed using 2-way ANOVA (SPSS). 
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The role of the CRF receptors in the LCGU response to CRF 
 
Introduction 
 
 As described earlier, corticotropin-releasing factor (CRF) is well known as 
the key factor which controls the hypothalamic-pituitary-adrenocortical (HPA) 
axis during basal activity and stress (Vale et al., 1981; Rivier and Plotsky, 1986). 
 
 Alterations in CRF activity have been described in a range of 
neuroendocrine, neurological and psychiatric disorders, including major 
depressive disorder, post-traumatic stress disorder, schizophrenia and dementia 
(Holsboer, 1999; Keck and Holsboer, 2001; Steckler, 2005; Steckler and 
Dautzenberg, 2006). 
 
 CRF and its receptors are widely distributed throughout the rodent brain 
(for overview see Warnock et al., 2006). CRF activates two CRF receptor 
subtypes, CRF1 and CRF2 (Chen et al., 1993; Lovenberg et al., 1995b). CRF1 
has been implicated in the HPA axis response to stress, and in the mediation of 
stress- and anxiety-related behavior (Steckler and Holsboer, 1999), while a clear 
role for CRF2 has yet to be elucidated. Stimulation of CRF2 has been proposed 
to attenuate stress-related behaviour (Bale & Vale, 2004; Skelton et al., 2000) 
but conflicting evidence has also been used to propose a role for CRF2 in 
mediating the delayed effects of stress (Takahashi, 2002; plus Steckler, 2005; 
Steckler & Dautzenberg ,2006 for review). 
 
 This series of studies used the LCGU technique to compare the role of the 
two CRF receptors in neuronal activity. In previous studies, 
intracerebroventricular (ICV) administration of CRF induced widespread 
increases in LCGU throughout the brain, including the frontal cortical, 
hypothalamic, thalamic, cerebellar, midbrain and hindbrain regions (Sharkey et 
al., 1989; Dube et al., 2000; Freo et al., 2005). None of these studies identified 
the CRF receptor(s) involved in this response. 
 
 In order to isolate the involvement of either CRF receptor in the LCGU 
response, a combination of the available endogenous peptides and more specific 
tools were used. Rat/human CRF and human Urocortin 1 were used as non-
Chapter 4  LCGU and the CRF system 
 89 
specific agonists at both receptors, while human Urocortin 2 and human 
Stresscopin were used as selective agonists at CRF2. The role of CRF1 was 
investigated using both an antagonist selective for CRF1, R278995 (Chaki et al., 
2004), and mutant mice lacking the CRF1 receptor. The selective CRF2 
antagonist antisauvagine-30 (Ruhmann et al., 1998) was used to examine the 
role of this receptor. 
 
Materials and Methods 
 
Subjects 
 
 Male C57BL/6N mice were used as described in the General Methods. 
 
Generation of CRF1 knockout mice  
 
 CRF1 knockout mice (CRF1KO) were obtained from stock in the Johnson 
& Johnson Pharmaceutical Research & Development transgenic facility. These 
mutant mice were generated in a similar fashion to those generated by Timpl et 
al (1998), as outlined below. In these mice the final 5 exons of the CRF1 receptor 
gene are deleted, resulting in deletion of the transmembrane regions V, VI and 
VII, including the G-coupling protein domain and the intracellular cytoplasmic tail 
(see ENSEMBL 
http://www.ensembl.org/Mus_musculus/protview?transcript=ENSMUST0000009
3925;db=core). 
 
 CRF1 knockout mice were developed in collaboration with Lexicon 
Genetics Inc.. Using a PCR probe genomic clones were isolated by screening of 
the 129SvEvBrd derived lambda pKOS genomic library (Wattler et al., 1999). A 
9.7 kb genomic clone spanning exon 8 up to the last coding exon 13 was used to 
generate the targeting vector via yeast-mediated homologous recombination. In 
this vector a genomic fragment, spanning exon 8 to exon 13, was replaced by a 
floxed version of exon 8 to exon 13 including a 1.7 kb PGK-neo selection 
cassette flanked by two Frt sites. The NotI-linearized vector was electroporated 
into 129 Sv/Evbrd(LEX1) embryonic stem (ES) cells and G418-fialuridine (FIAU)-
resistant ES cell clones were isolated and analysed for homologous 
recombination by Southern blot analysis. Targeted ES cell clones were injected 
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into C57BL/6(albino) blastocysts, and the resulting chimeras were mated to 
C57BL/6(albino) females to generate animals heterozygote for the floxed CRF1 
allele. These were subsequently crossed to Protamine-Cre mice (O'Gorman et 
al., 1997) and male descendants heterozygote for both the floxed CRF1 allele 
and the Protamine Cre transgene were crossed to C57Bl/6 females to obtain 
heterozygote CRF1 knockout animals. These were subsequently crossed to 
generate homozygote knockout, heterozygote knockout and wild-type littermate 
animals with an overall C57Bl/6 background. The mutant generation process is 
illustrated in Figure 26. Sufficient breeding cycles to generate the required 
experimental animal numbers are necessary due an increased prenatal lethality 
in homozygote CRF1 knockout animals. The expression of CRF1 and CRF2 
receptor mRNA in mutant animals was assessed by quantitative PCR (for 
method and results see Appendix 2). 
 
 For LCGU studies only homozygote knockout males and male wild-type 
littermate controls were used. 
 
Figure 26: Illustration of the targeting vector, subsequent allele and resultant 
allele for generation of CRF1 knockout mice. The targeting vector includes LoxP 
sites and PGK-neo selection cassette for removal of exons 8 to 12 by 
recombinase in Protamine-Cre mice. 
 
Wildtype
LoxP LoxPFrt FrtPGK Neo
Frt Lox PFrtLox P
Targeted allele - Pre-Cre
Targeting vector
Targeted allele - Post-Cre Lox P
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Peptides and ICV Injections 
 
 Peptides were injected ICV using the freehand technique validated and 
described earlier.  
 
 Rat/human CRF (0.1-1 µg), human Urocortin 1 (1, 3 µg), human Urocortin 
2 (1, 10 µg), human Stresscopin (0.1, 1, 10 µg) (Bachem, Germany) and 
antisauvagine-30 (1-5 µg) were dissolved in 0.9% saline and injected in a volume 
of 5 µl. Peptide doses selected were based on those reported to elicit 
behavioural responses (Butler et al., 1990; Dunn and Berridge, 1990; Jones et 
al., 1998; Benoit et al., 2000; Valdez et al., 2002; Valdez et al., 2003). 
 
 For the study combining CRF and antisauvagine-30, the two peptides 
were injected as a mixture dissolved in 0.9% saline and injected in a volume of 5 
µl. The injection of these peptides as a mixture has been shown to produce 
effective antagonism in a behavioural model of anxiety-related behaviour 
(Risbrough et al., 2003). 
 
Compounds 
 
 R278995 is a highly CRF1 –selective antagonist co-developed by Johnson 
& Johnson Pharmaceutical Research & Development and Taisho 
Pharmaceuticals (Japan) with demonstrated pharmocokinetics and 
pharmacological activity (Chaki et al., 2004). Perhaps of note, R278995 also has 
a high affinity for σ1 receptors, which may also have a role in anxiety and 
depression, although studies suggested that these receptors were unlikely to be 
involved in the effects of R278995 (Chaki et al., 2004). In initial studies it 
appeared that after a preinjection (vehicle or compound) the LCGU response to 
CRF in the positive control group was no longer present, making it impossible to 
study the effect of R278995 on this response via this method. This disruption 
may represent the effect of a mild pre-stressor on the subsequent response to 
CRF, which may itself be of interest for future studies. However, in order to study 
the effect of R278995 on the acute effects of CRF on LCGU, it was decided to 
administer the compound through the diet, thus ensuring the presence of 
R278995 in the animal without the need for an injection prior to the ICV 
administration of CRF and 2DG injection. 
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 The efficiency of dietary administration was assessed in a series of pilot 
studies. The data from these pilot studies is presented in Appendix 3. 
 
 The dry compound was administered in a powdered premixed diet from 
Research Diets (http://www.researchdiets.com) to an approximate dose of 40 
mg/kg/day based on mice consuming approximately 4 grams per 24 hours (as 
indicated by pilot studies). The final diet was D12450B. In both pilot and final 
studies the powdered diet replaced the standard diet for 5 days prior to testing. 
In the pilot studies the plasma and brain levels of R278995 were measured by 
Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (LC-MS/MS) 
(method in Appendix 3) on day 6 at three time points to assess the fall in levels 
based upon the 1.8 hour plasma half-life of the compound, and also taking into 
consideration that food consumption effectively stops during the light-phase. 
These time points were selected to examine levels of R278995 at times relevent 
to the measurement of LCGU (i.e. during the early light-phase when all LCGU 
studies were carried out). The occupancy of CRF1 receptors in the frontal cortex 
was also measured on day 6, corresponding to occupancy at 0800 and 1100 
hours (in the early light-phase to match LCGU studies). Both plasma/brain 
compound levels and CRF1 occupancy were compared to those after acute oral 
administration of 40 mg/kg R278995 (1 hour preinjection). 
 
 These pilot studies confirmed that the compound reaches the plasma and 
brain following administration in the diet, and CRF1 occupancy immediately after 
the dark phase reached a similar level to acute administration (82.3 % acute 
versus 72.4 % dietary). Thus, dietary administration of R278995 was used in a 
full scale study to examine the role of CRF1 in the acute LCGU response to CRF. 
 
Measurement of local cerebral glucose utilisation (LCGU) and plasma 
corticosterone 
 
 LCGU and plasma corticosterone were measured as described in the 
General Methods. In order to match the times with optimum occupancy of CRF1 
receptors with R278995, based on the studies described in Appendix 3, all 
testing was carried out between 0800 and 1200 hours, i.e. during the early light-
phase. 
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Statistical Analysis 
 
 Data were analysed as described in the General Methods. Briefly, multiple 
comparisons were made using the Kruskal-Wallis test, followed where 
appropriate by the Mann-Whitney-U test for post-hoc comparisons. Non-
parametric tests were used to account for the possibility that data of this type 
does not meet the central limit theorem. For mutant mouse studies or those with 
dual treatment, two-way ANOVA was used. 
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Results 
 
Local Cerebral Glucose Utilisation 
 
Non-specific CRF1/2 agonists  CRF & Urocortin 1 
 
 In dissected brain regions, CRF increased LCGU in a dose-dependent 
manner in hypothalamic, thalamic, cerebellar and hippocampal areas (Table 4; 
Figure 27). The largest response to CRF was 67 ± 18 % at the 1 µg dose in the 
cerebellar region. A significant increase was seen following the 0.5 µg dose in 
the hypothalamic sample (p<0.01). Similar tendencies were observed at thalamic 
(p=0.072), hippocampal (p=0.054) and cerebellar (p=0.054) levels. A dose of 1 
µg CRF increased LCGU at thalamic (p<0.01), hippocampal (p=0.038) and 
cerebellar (p=0.011) levels, and a similar tendency was seen in the 
hypothalamus (p=0.054). 
 
 When measured by autoradiography, 0.5 µg CRF significantly increased 
LCGU in a number of regions matching those affected in the dissection study. 
LCGU was significantly increased in septal (p=0.017), hypothalamic (p=0.030) 
hippocampal (p=0.004), and cerebellar (p=0.017) regions, with a maximal CRF-
induced effect of 51 ± 8 % in the hippocampus (Table 5; Figure 28; 
representative autoradiographs shown in Figure 29). Similar trends for increased 
LCGU were seen in frontal cortical (p=0.082), amygdala (p=0.063) and hindbrain 
(p=0.052) regions. However, in contrast to the dissection study, no trend-like 
effect on LCGU after CRF treatment was seen in the thalamus at the 
corresponding dose of 0.5 µg. (Note: a higher dose of CRF was not tested by 
autoradiography as this dose corresponded to an an original single dose of CRF 
tested by dissection. The dissection study was later expanded to a dose-
response). 
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Table 4: Changes in LCGU (measured by region dissection) from baseline 
(mean ± SEM) after ICV administration of CRF (Saline n=7, 0.1 µg n=7, 0.5 µg 
n=8, 1 µg n=7). *p<0.05, **p<0.01, (*)p<0.1. (Temporal region dissected to 
include the amygdala). 
               
CRF LCGU (nCi/mg)   
Region Saline 0.1µg 0.5µg 1.0µg 
               
Frontal Cortical 0.12 ± 0.02 0.09 ± 0.02 0.13 ± 0.01  0.14 ± 0.01  
Hypothalamus 0.12 ± 0.01 0.12 ± 0.02 0.17 ± 0.01 ** 0.16 ± 0.02 (*) 
Thalamus 0.18 ± 0.03 0.16 ± 0.03 0.24 ± 0.02 (*) 0.28 ± 0.02 ** 
Cerebellum 0.11 ± 0.02 0.12 ± 0.02 0.17 ± 0.02 (*) 0.19 ± 0.02 * 
Hindbrain 0.08 ± 0.01 0.08 ± 0.01 0.10 ± 0.01  0.11 ± 0.01  
Hippocampus 0.10 ± 0.01 0.10 ± 0.02 0.13 ± 0.01 (*) 0.15 ± 0.01 * 
Temporal 0.12 ± 0.02 0.10 ± 0.02 0.12 ± 0.01  0.14 ± 0.01  
                              
               
CRF % change in LCGU      
Region 0.1µg 0.5µg 1.0µg      
               
Frontal Cortical -19 ± 13 10 ± 8 18 ± 7      
Hypothalamus -3 ± 15 37 ± 7 35 ± 14      
Thalamus -10 ± 16 36 ± 14 59 ± 10      
Cerebellum 3 ± 19 45 ± 16 67 ± 18      
Hindbrain -3 ± 17 26 ± 12 45 ± 14      
Hippocampus -1 ± 16 30 ± 12 51 ± 12      
Temporal -13 ± 16 4 ± 8 14 ± 7      
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Figure 27: Changes in LCGU (measured by region dissection) from baseline 
(mean ± SEM) after ICV administration of CRF (Saline n=7, 0.1 µg n=7, 0.5 µg 
n=8, 1 µg n=7). *p<0.05, **p<0.01, (*)p<0.1. (Region abbreviations match those 
used in Figure 12). 
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Table 5: Changes in LCGU (measured by autoradiography) from baseline (mean 
± SEM) after ICV administration of CRF (Saline n=5, CRF 0.5 µg n=6). *p<0.05, 
**p<0.01, (*)p<0.1. 
 
CRF
Region
Frontal Cortical 1.07 ± 0.06 1.22 ± 0.08 (*) 14 ± 7
Septum 0.82 ± 0.08 1.00 ± 0.03 * 23 ± 3
Striatum 1.17 ± 0.10 1.36 ± 0.06 16 ± 6
Hypothalamus 0.64 ± 0.09 0.89 ± 0.05 * 39 ± 8
Thalamus 1.26 ± 0.09 1.44 ± 0.07 14 ± 5
Amygdala 0.69 ± 0.11 1.02 ± 0.06 (*) 47 ± 9
Hippocampus 0.69 ± 0.08 1.04 ± 0.06 ** 51 ± 8
Cerebellum 1.01 ± 0.11 1.34 ± 0.07 * 34 ± 7
Hindbrain 1.02 ± 0.11 1.24 ± 0.07 (*) 22 ± 6
rLCGU (nCi/mg)
Saline 0.5µg
% change in 
rLCGU
0.5µg
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Figure 28: Changes in LCGU (measured by autoradiography) from baseline 
(mean ± SEM) after ICV administration of CRF (Saline n=5, CRF 0.5 µg n=6). 
*p<0.05, **p<0.01, (*)p<0.1. (Additional abbreviations: Sept – septum, Cpu – 
caudate putamen/striatum, Amyg – amygdala). 
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Figure 29: Split-hemispheric comparisons of representative autoradiographs of 
20 µm coronal sections from (A) ICV saline-treated and (B) 0.5 µg ICV CRF-
treated mice (C) Representative figures from Paxinos & Watson atlas at this 
level. (false colour temperature scale, warmer corresponds to increased LCGU). 
 
 
  
A B C
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 Urocortin 1 (UCN1) dose-dependently increased LCGU in a number of 
brain regions, though to a lesser extent than CRF. The largest increase, 27 ± 6 
%, was seen in the dissected hindbrain region (Table 6; Figure 30), in which 
CRF only induced a trend-like effect, detected only in the autoradiography study. 
LCGU was significantly increased at the 3 µg dose (p=0.005) in the hindbrain, 
with similar trends towards increased LCGU in frontal cortical and hippocampal 
regions (KW p=0.079 and 0.052, respectively). 
 
Table 6: Changes in LCGU from baseline (mean ± SEM) after ICV administration 
of Urocortin 1 (Saline n=7, 1 µg n=5, 3 µg n=5). *p<0.05, (*)p<0.1. 
 
Urocortin 1 LCGU (nCi/mg)   % change in LCGU 
Region Saline 1ug 3ug 1µg 3µg 
                 
Frontal Cortical 0.14 ± 0.00 0.15 ± 0.01 0.17 ± 0.01 (*) 6 ± 7 19 ± 7 
Hypothalamus 0.13 ± 0.01 0.15 ± 0.01 0.14 ± 0.01  13 ± 7 9 ± 5 
Thalamus 0.12 ± 0.01 0.12 ± 0.00 0.14 ± 0.01  2 ± 4 18 ± 9 
Cerebellum 0.06 ± 0.00 0.06 ± 0.00 0.06 ± 0.01  0 ± 4 7 ± 11 
Hindbrain 0.05 ± 0.00 0.05 ± 0.00 0.06 ± 0.00 * 9 ± 5 27 ± 6 
Hippocampus 0.08 ± 0.00 0.09 ± 0.00 0.10 ± 0.01 (*) 9 ± 5 27 ± 9 
Temporal 0.15 ± 0.01 0.16 ± 0.01 0.17 ± 0.01  3 ± 8 10 ± 5 
                                  
 
Figure 30: Changes in LCGU from baseline (mean ± SEM) after ICV 
administration of Urocortin 1 (Saline n=7, 1 µg n=5, 3 µg n=5). *p<0.05, (*)p<0.1. 
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Role of CRF1 and CRF2 in the LCGU  response to CRF 
 
 To examine the involvement of either CRF1 or CRF2 receptors in the 
LCGU response to CRF, a combination of selective antagonists and a mutant 
mouse model were used. To isolate the involvement of CRF1, the effect of CRF 
on LCGU was measured in both mice lacking the CRF1 receptor (CRF1KO), and 
after pretreatment with the selective CRF1 antagonist R278995. To study CRF2, 
the selective antagonist antisauvagine-30 was co-administered with CRF. In 
these studies LCGU was measured in dissected brain regions. 
 
 The LCGU response to 0.5 µg CRF was unaltered in mice lacking the 
CRF1 receptor compared to their wild-type littermates. LCGU was significantly 
increased in thalamic (2-way ANOVA treatment effect, F1,27=4.432, p=0.045), 
cerebellum (F1,27=7.638, p=0.010), hindbrain (F1,27=5.880, p=.022) and 
hippocampal (F1,27=4.332, p=0.047) regions (Table 7; Figure 31). No significant 
2-way ANOVA interaction effect between CRF1KO and CRF treatment was 
found. 
 
Table 7: Changes in LCGU from baseline (mean ± SEM) after ICV administration 
of 0.5 µg CRF in mice lacking the CRF1 receptor (CRF1KO) compared to wild-
type controls (WT) (WT+Saline n=8, WT+CRF n=8, KO+Saline n=8, KO+CRF 
n=7). 
 
                     
CRF in CRF1KO LCGU (nCi/mg)   % change in LCGU 
Region WT+Saline WT+CRF   KO+Saline KO+CRF WT+CRF KO+CRF 
                     
Frontal Cortical 0.22 ± 0.02 0.27 ± 0.03  0.25 ± 0.04 0.30 ± 0.04  27 ± 12 21 ± 16 
Hypothalamus 0.18 ± 0.02 0.21 ± 0.01  0.20 ± 0.02 0.21 ± 0.02  16 ± 6 5 ± 10 
Thalamus 0.14 ± 0.02 0.18 ± 0.01  0.16 ± 0.02 0.19 ± 0.02  29 ± 9 19 ± 11 
Cerebellum 0.08 ± 0.01 0.11 ± 0.01  0.08 ± 0.01 0.10 ± 0.01  31 ± 11 25 ± 11 
Hindbrain 0.09 ± 0.01 0.11 ± 0.01  0.09 ± 0.01 0.12 ± 0.01  31 ± 13 26 ± 12 
Hippocampus 0.17 ± 0.01 0.22 ± 0.01  0.19 ± 0.02 0.21 ± 0.02  27 ± 8 10 ± 10 
Temporal 0.15 ± 0.02 0.20 ± 0.02  0.19 ± 0.03 0.22 ± 0.02  33 ± 13 16 ± 13 
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Figure 31: Changes in LCGU from baseline (mean ± SEM) after ICV 
administration of 0.5 µg CRF in mice lacking the CRF1 receptor (CRF1KO) 
compared to wild-type controls (WT) (WT+Saline n=8, WT+CRF n=8, KO+Saline 
n=8, KO+CRF n=7).  
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 In agreement with the data from CRF1KO mice, the CRF1 antagonist 
R278995 had no effect on the LCGU response to 1 µg CRF (Table 8; Figure 32). 
CRF significantly increased LCGU in both animals that received control diet and 
animals that received compound-treated diet in hypothalamic (2-way ANOVA 
treatment effect, F1,28=4.582, p=0.041), cerebellum (F1,28=5.942, p=.021) and 
hippocampal (F1,28=6.537, p=.016) regions. No significant 2-way ANOVA 
interaction effect between R278995 and CRF treatment was found. 
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Table 8: The effect of R278995 (40 mg/kg/day, 5 days) on changes in LCGU 
from baseline (mean ± SEM) after ICV administration of 1 µg CRF (all treatment 
groups n=8). * 2-way ANOVA treatment effect p<0.05. 
               
R278995/CRF LCGU (nCi/mg)   
Region Ctrl+Saline Ctrl+CRF   R+Saline R+CRF 
               
Frontal Cortical 0.42 ± 0.02 0.42 ± 0.05  0.36 ± 0.04 0.45 ± 0.05  
Hypothalamus 0.39 ± 0.03 0.44 ± 0.05  0.33 ± 0.03 0.46 ± 0.05  
Thalamus 0.43 ± 0.01 0.50 ± 0.06  0.43 ± 0.06 0.54 ± 0.08  
Cerebellum 0.25 ± 0.01 0.30 ± 0.04  0.22 ± 0.03 0.33 ± 0.04  
Hindbrain 0.23 ± 0.01 0.27 ± 0.04  0.20 ± 0.02 0.26 ± 0.04  
Hippocampus 0.25 ± 0.01 0.31 ± 0.03  0.22 ± 0.02 0.31 ± 0.04  
Temporal 0.33 ± 0.02 0.32 ± 0.04  0.27 ± 0.03 0.33 ± 0.04  
                              
                          
R278995/CRF % change in LCGU     
Region Ctrl+CRF R+Saline   R+CRF     
               
Frontal Cortical 0 ± 12 -13 ± 10  8 ± 13     
Hypothalamus 12 ± 12 -15 ± 8  16 ± 13     
Thalamus 16 ± 14 -1 ± 14  25 ± 18     
Cerebellum 18 ± 15 -13 ± 10  32 ± 18     
Hindbrain 16 ± 15 -14 ± 9  12 ± 16     
Hippocampus 22 ± 13 -13 ± 9  22 ± 16     
Temporal -4 ± 12 -20 ± 9  -1 ± 13     
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Figure 32: The effect of R278995 (40 mg/kg/day, 5 days) on changes in LCGU 
from baseline (mean ± SEM) after ICV administration of 1 µg CRF (all treatment 
groups n=8).  
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 In contrast to the continued effect of CRF on LCGU in CRF1KO mice and 
after treatment with R278995, the CRF2-selective antagonist antisauvagine-30 
completely abolished the LCGU to CRF, at both doses tested (Table 9; Figure 
33). Treatment with 1 µg CRF alone significantly increased LCGU in thalamic 
(p=0.029), cerebellum (p=0.001) and hippocampal (p=0.005) regions as reported 
earlier, with the addition of the frontal cortical region (p=0.029) and hindbrain 
(p=0.013). This response was completely abolished by 1 or 3 µg antisauvagine-
30 administered together with 1 µg CRF. 
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Table 9: The effect of antisauvagine-30 (aSVG) (1 and 3 µg) on changes in 
LCGU from baseline (mean ± SEM) after ICV administration of 1 µg CRF (Saline 
n=8, 1 µg CRF n=6, 1 µg CRF + 3 µg aSVG n=8, 1 µg CRF + 3 µg aSVG n=8). 
*p<0.05, **p<0.01. 
              
aSVG vs. CRF LCGU (nCi/mg) 
Region Saline CRF   1µg aSVG 3µg aSVG 
              
Frontal Cortical 0.47 ± 0.05 0.60 ± 0.03 * 0.39 ± 0.05 0.46 ± 0.05 
Hypothalamus 0.43 ± 0.04 0.56 ± 0.03  0.40 ± 0.04 0.45 ± 0.04 
Thalamus 0.51 ± 0.06 0.69 ± 0.03 * 0.40 ± 0.05 0.50 ± 0.05 
Cerebellum 0.32 ± 0.03 0.51 ± 0.03 ** 0.30 ± 0.04 0.35 ± 0.04 
Hindbrain 0.37 ± 0.04 0.51 ± 0.02 * 0.33 ± 0.05 0.36 ± 0.03 
Hippocampus 0.36 ± 0.04 0.50 ± 0.02 ** 0.31 ± 0.04 0.37 ± 0.04 
Temporal 0.33 ± 0.04 0.41 ± 0.02  0.27 ± 0.03 0.32 ± 0.03 
                            
                        
aSVG vs. CRF % change in LCGU    
Region CRF 1µg aSVG   3µg aSVG    
              
Frontal Cortical 29 ± 8 -16 ± 10  -1 ± 10    
Hypothalamus 29 ± 8 -8 ± 10  3 ± 8    
Thalamus 35 ± 6 -22 ± 10  -2 ± 10    
Cerebellum 58 ± 9 -7 ± 12  9 ± 11    
Hindbrain 39 ± 6 -12 ± 14  -4 ± 9    
Hippocampus 39 ± 5 -13 ± 11  2 ± 10    
Temporal 26 ± 7 -17 ± 10  -3 ± 9    
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Figure 33: The effect of antisauvagine-30 (aSVG) (1 and 3 µg) on changes in 
LCGU from baseline (mean ± SEM) after ICV administration of 1 µg CRF (Saline 
n=8, 1 µg CRF n=6, 1 µg CRF + 3 µg aSVG n=8, 1 µg CRF + 3 µg aSVG n=8). 
*p<0.05, **p<0.01. 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
FrCx Hy Th Ce Hb Hipp Temp
n
C
i/
m
g
Saline 1µg CRF 1µg CRF+ 1µg aSVG 1µg CRF + 3µg aSVG
*
*
** * **
 
  
 When administered alone, antisauvagine-30 had no effect on LCGU at the 
dose of either 1 or 5 µg (Table 10; Figure 34). 
 
Table 10: The effect of antisauvagine-30 (aSVG) (1 and 5 µg) on LCGU from 
baseline (mean ± SEM) (Saline n=8, 1 µg aSVG n=8, 5 µg aSVG n=9). 
                
aSVG LCGU (nCi/mg) % change in LCGU 
Region Saline 1ug 5ug 1µg 5µg 
                
Frontal Cortical 0.28 ± 0.01 0.25 ± 0.02 0.24 ± 0.01 -9 ± 7 -15 ± 5 
Hypothalamus 0.22 ± 0.01 0.22 ± 0.02 0.22 ± 0.01 -4 ± 8 -1 ± 6 
Thalamus 0.20 ± 0.01 0.18 ± 0.01 0.18 ± 0.01 -7 ± 7 -11 ± 5 
Cerebellum 0.09 ± 0.00 0.09 ± 0.01 0.09 ± 0.01 -1 ± 12 0 ± 7 
Hindbrain 0.08 ± 0.00 0.07 ± 0.01 0.07 ± 0.00 -4 ± 10 -12 ± 5 
Hippocampus 0.19 ± 0.01 0.19 ± 0.01 0.18 ± 0.01 -2 ± 6 -5 ± 5 
Temporal 0.25 ± 0.01 0.22 ± 0.01 0.23 ± 0.01 -9 ± 6 -8 ± 6 
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Figure 34: The effect of antisauvagine-30 (aSVG) (1 and 5 µg) on LCGU from 
baseline (mean ± SEM) (Saline n=8, 1 µg aSVG n=8, 5 µg aSVG n=9). 
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 In contrast to the effects on LCGU induced by CRF and UCN1, ICV 
administration of the selective CRF2 agonists Urocortin 2 (UCN2) (Table 11; 
Figure 35) and Stresscopin (SCP) (Table 12; Figure 36) had no effect on LCGU. 
 
Table 11: The effect of Urocortin 2 (UCN2) (1 and 10 µg) on LCGU from baseline 
(mean ± SEM) (Saline n=11, 1 µg UCN2n=11, 10 µg UCN2n=10). 
                 
Urocortin 2 LCGU (nCi/mg)   % change in LCGU 
Region Saline 1µg 10µg 1µg 10µg 
                 
Frontal Cortical 0.17 ± 0.02 0.17 ± 0.01 0.13 ± 0.01  0 ± 9 -19 ± 9 
Hypothalamus 0.15 ± 0.02 0.15 ± 0.02 0.12 ± 0.01  1 ± 11 -20 ± 9 
Thalamus 0.13 ± 0.02 0.14 ± 0.01 0.10 ± 0.01  6 ± 8 -22 ± 10 
Cerebellum 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01  -4 ± 9 -17 ± 11 
Hindbrain 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01  7 ± 9 -16 ± 12 
Hippocampus 0.15 ± 0.02 0.15 ± 0.01 0.13 ± 0.01  3 ± 8 -16 ± 10 
Temporal 0.18 ± 0.02 0.19 ± 0.02 0.15 ± 0.02  3 ± 9 -20 ± 9 
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Figure 35: The effect of Urocortin 2 (UCN2) (1 and 10 µg) on LCGU from 
baseline (mean ± SEM) (Saline n=11, 1 µg UCN2n=11, 10 µg UCN2n=10). 
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Table 12: The effect of Stresscopin (SCP) (0.1, 1 and 5 µg) on LCGU from 
baseline (mean ± SEM) (Saline n=8, 0.1 µg SCP n=8, 1 µg SCP n=8, 5 µg SCP 
n=7). 
             
Stresscopin LCGU (nCi/mg) 
Region saline 0.1 µg 1 µg 5 µg 
             
Frontal Cortical 0.33 ± 0.05 0.31 ± 0.06 0.39 ± 0.07 0.31 ± 0.06 
Hypothalamus 0.34 ± 0.04 0.33 ± 0.05 0.39 ± 0.07 0.31 ± 0.05 
Thalamus 0.35 ± 0.06 0.41 ± 0.07 0.44 ± 0.09 0.31 ± 0.06 
Cerebellum 0.31 ± 0.06 0.30 ± 0.07 0.36 ± 0.07 0.25 ± 0.05 
Hindbrain 0.28 ± 0.05 0.27 ± 0.06 0.35 ± 0.08 0.27 ± 0.06 
Hippocampus 0.30 ± 0.05 0.32 ± 0.06 0.34 ± 0.07 0.26 ± 0.05 
Temporal 0.37 ± 0.07 0.43 ± 0.11 0.43 ± 0.10 0.34 ± 0.08 
                          
                      
Stresscopin % change in LCGU    
Region 0.1 µg 1 µg 5 µg    
             
Frontal Cortical -5 ± 18 17 ± 22 -6 ± 19    
Hypothalamus -3 ± 16 13 ± 19 -11 ± 15    
Thalamus 18 ± 21 26 ± 27 -12 ± 17    
Cerebellum -4 ± 23 16 ± 24 -17 ± 17    
Hindbrain -6 ± 23 23 ± 27 -5 ± 21    
Hippocampus 6 ± 20 13 ± 23 -14 ± 18    
Temporal 14 ± 29 15 ± 26 -8 ± 21    
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Figure 36: The effect of Stresscopin (SCP) (0.1, 1 and 5 µg) on LCGU from 
baseline (mean ± SEM) (Saline n=8, 0.1 µg SCP n=8, 1 µg SCP n=8, 5 µg SCP 
n=7). 
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 Based on the previous studies with CRF and antisauvagine-30, the lack of 
effect of these CRF2-selective agonists was unexpected. Therefore, the effects of 
Stresscopin on LCGU were studied further, by autoradiography, and in CRF1KO 
mice. Despite its relatively lower affinity for CRF2 (see Table 2), Stresscopin was 
chosen for these further studies as time-dependent behavioural effects have 
been reported for Urocortin 2 (Valdez et al., 2002), complicating the timing of 
injection before measuring LCGU. The delayed effects of Urocortin 2 in vivo may 
reflect its lack of a consensus site for proteolytic cleavage (Hauger et al., 2003). 
Stresscopin has not been reported to lack such a site, and direct behavioural 
effects after administration have been reported (Valdez et al., 2003), although 
the possibility of further time-dependent effects cannot be fully excluded. 
 
 0.1 µg Stresscopin had no effect on LCGU measured by autoradiography 
(Table 13; Figure 37), and had no effect on LCGU in mice lacking the CRF1 
receptor or their wild-type littermates (Table 14; Figure 38). 
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Table 13: The effect of Stresscopin (SCP) (0.1 µg) on LCGU (measured by 
autoradiography) from baseline (mean ± SEM) (Saline n=12, 0.1 µg SCP n=11). 
          
Stresscopin LCGU (nCi/mg) % change in 
LCGU 
Region Saline 0.1 µg 0.1 µg 
          
Frontal Cortical 0.95 ± 0.06 1.03 ± 0.07 9 ± 7 
Septum 0.70 ± 0.05 0.74 ± 0.06 6 ± 8 
Striatum 1.04 ± 0.07 1.15 ± 0.08 10 ± 8 
Hypothalamus 0.58 ± 0.04 0.68 ± 0.05 17 ± 8 
Thalamus 1.07 ± 0.07 1.20 ± 0.08 13 ± 8 
Amygdala 0.66 ± 0.05 0.79 ± 0.06 20 ± 9 
Hippocampus 0.65 ± 0.04 0.72 ± 0.04 12 ± 6 
Cerebellum 0.83 ± 0.07 0.91 ± 0.07 9 ± 8 
Hindbrain 0.84 ± 0.07 0.93 ± 0.06 11 ± 7 
                    
          
 
Figure 37: The effect of Stresscopin (SCP) (0.1 µg) on LCGU (measured by 
autoradiography) from baseline (mean ± SEM) (Saline n=12, 0.1 µg SCP n=11). 
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Table 14: Changes in LCGU from baseline (mean ± SEM) after ICV 
administration of 0.1 µg SCP in mice lacking the CRF1 receptor (CRF1KO)  
compared to wild-type controls (WT) (WT+Saline n=6, WT+SCP n=6, KO+Saline 
n=5, KO+SCP n=6). 
 
 
 
Figure 38: Changes in LCGU from baseline (mean ± SEM) after ICV 
administration of 0.1 µg SCP in mice lacking the CRF1 receptor (CRF1KO) 
compared to wild-type controls (WT) (WT+Saline n=6, WT+SCP n=6, KO+Saline 
n=5, KO+SCP n=6). 
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SCP in CRF1KO LCGU (nCi/mg) % change in LCGU 
Region WT+Saline WT+SCP KO+Saline KO+SCP WT+SCP KO+SCP 
                   
Frontal Cortical 0.19 ± 0.02 0.16 ± 0.03 0.14 ± 0.03 0.17 ± 0.03 -12 ± 17 17 ± 19 
Hypothalamus 0.13 ± 0.01 0.12 ± 0.01 0.11 ± 0.02 0.12 ± 0.02 -11 ± 9 11 ± 15 
Thalamus 0.13 ± 0.01 0.12 ± 0.02 0.10 ± 0.02 0.11 ± 0.02 -11 ± 16 6 ± 21 
Cerebellum 0.07 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 -24 ± 9 9 ± 18 
Hindbrain 0.07 ± 0.01 0.06 ± 0.01 0.05 ± 0.01 0.06 ± 0.01 -17 ± 17 5 ± 19 
Hippocampus 0.14 ± 0.01 0.11 ± 0.01 0.10 ± 0.02 0.11 ± 0.01 -19 ± 9 11 ± 15 
Temporal 0.18 ± 0.02 0.14 ± 0.03 0.13 ± 0.03 0.15 ± 0.03 -20 ± 14 14 ± 19 
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Residual plasma 2DG and Blood glucose 
  
 The effects of the treatments in the above studies on the control 
parameters of residual 2DG in the plasma and blood glucose after the LCGU 
protocol are summarized in Table 15.  
 
 Residual 2DG in the plasma was increased by CRF treatment in four of 
the described studies: CRF treatment alone (0.5 µg, dissection (p=0.009) and 
autoradiography (trend p=0.052) studies); CRF treatment combined with 
R278995 (2 way ANOVA treatment effect, F3,28=5.018, p=0.033); and CRF 
treatment alone in the study combining CRF and antisauvagine-30 (p=0.020). 
 
 R278995 induced an increase in blood glucose independent of CRF 
treatment (2 way ANOVA treatment effect, F3,28=19.070, p<0.001). Increased 
blood glucose was also seen in mice lacking the CRF1 receptor, independent of 
treatment in the Stresscopin study (2 way ANOVA treatment effect, F3,19=11.639, 
p=0.003), but a similar increased level was not seen in the earlier study using 
these mutant mice (CRF treatment). When CRF treatment was combined with 
antisauvagine-30, blood glucose was reduced, at both the 1 and 3 µg dose (p= 
0.003 and 0.010, respectively). 
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Table 15: The effects of CRF system manipulations, alone and in combination, 
on parameters measured in the blood: residual plasma 2DG, blood glucose and 
plasma corticosterone. Data are shown as mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, (*)trend p<0.06. a dissection study, b autoradiography study, NM not 
measured.  
LCGU study Treatment
CRF
a
Saline 84 ± 8 163 ± 9 117 ± 14
CRF 0.1µg 84 ± 9 160 ± 10 336 ± 15 **
CRF 0.5µg 144 ± 25 ** 159 ± 11 331 ± 14 ***
CRF 1µg 108 ± 11 163 ± 16 356 ± 43 **
CRF
b
Saline 162 ± 12 NM 172 ± 20
CRF 0.5µg 248 ± 28
(
*
)
NM 358 ± 11 ***
Urocortin 1 Saline 53 ± 5 135 ± 6 161 ± 54
UCN1 1µg 66 ± 9 133 ± 8 347 ± 38 **
UCN1 3µg 60 ± 8 118 ± 9 341 ± 71 **
CRF in CRF1KO WT+Saline 169 ± 15 154 ± 7 218 ± 23
WT+CRF 188 ± 11 166 ± 16 305 ± 32
KO+Saline 202 ± 13 176 ± 10 5 ± 2
KO+CRF 225 ± 27 183 ± 22 7 ± 3
R278995/CRF Ctrl+Saline 148 ± 38 131 ± 6 107 ± 12
Ctrl+CRF 203 ± 38 121 ± 6 344 ± 12
R+Saline 109 ± 8 168 ± 8 103 ± 12
R+CRF 199 ± 35 187 ± 20 332 ± 15
antisauvagine-30/CRF Saline 131 ± 9 174 ± 10 121 ± 11
CRF 1µg 183 ± 18 * 142 ± 13 325 ± 17 ***
CRF+1µg aSVG 151 ± 13 124 ± 10 * 315 ± 13 ***
CRF+3µg aSVG 133 ± 16 133 ± 9 * 304 ± 9 ***
antisauvagine-30 Saline 71 ± 5 128 ± 8 102 ± 9
aSVG 1µg 70 ± 8 130 ± 6 95 ± 9
aSVG 5µg 71 ± 7 126 ± 7 86 ± 8
Urocortin 2 Saline 151 ± 13 125 ± 8 164 ± 11
UCN2 1µg 184 ± 13 123 ± 6 265 ± 14 **
UCN2 10µg 188 ± 21 127 ± 5 250 ± 6 ***
Stresscopin
a
Saline 223 ± 46 168 ± 12 117 ± 13
SCP 0.1µg 183 ± 23 144 ± 8 161 ± 11 *
SCP 1µg 250 ± 31 138 ± 7 274 ± 6 ***
SCP 5µg 246 ± 56 159 ± 6 306 ± 11 ***
Stresscopin
b
Saline 173 ± 7 NM NM
SCP 0.1µg 185 ± 20 NM NM
SCP in CRF1KO WT+Saline 164 ± 19 150 ± 8 287 ± 14
WT+SCP 122 ± 20 134 ± 13 281 ± 39
KO+Saline 142 ± 20 176 ± 8 10 ± 5
KO+SCP 144 ± 8 187 ± 14 13 ± 5
Residual plasma 
2DG (nCi/ml)
Blood glucose 
(mg/dl)
Plasma cortico- 
sterone (ng/ml)
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Effects on the HPA axis 
 
 Unexpectedly, plasma corticosterone levels were increased by all four of 
the endogenous CRF-related peptides (Table 15; Figure 39). In the dissection 
study, CRF induced a greater than twofold increase in plasma corticosterone at 
all doses (all p<0.01). In the autoradiography study, a similar effect was seen 
(p<0.001). UCN1 also increased plasma corticosterone at both doses (both 
p<0.01). The effect of UCN2 on plasma corticosterone was less pronounced, but 
still highly significant at both doses tested (both p<0.01). SCP induced a dose-
dependent increase in plasma corticosterone, with greater than two-fold 
increases after treatment with 1 and 5 µg (0.1 µg p<0.05, 1 and 5 µg p<0.01). 
 
 In CRF1KO mice, the increase in plasma corticosterone after 0.5 µg CRF 
treatment in wild-type mice (p<0.05) was abolished, and plasma corticosterone in 
saline-treated mice was greatly diminished (2-way ANOVA geneotype effect, 
F1,27=4.511, p=0.043). This genotype effect was mimicked in the second study 
with these mutant mice, although in this study 0.1 µg SCP did not affect plasma 
corticosterone in either wild-type or mutant mice. 
 
 Neither the CRF1-selective antagonist R278995 or the CRF2-selective 
antagonist antisauvagine-30 had any effect on the CRF-induced increases in 
plasma corticosterone. 1 µg CRF treatment increased plasma corticosterone in 
both saline- and R278995-pretreated animals (2-way ANOVA treatment effect 
F3,28=328.174, p<0.001). 1 µg CRF increased plasma corticosterone in both 
saline- and antisauvagine-30-pretreated animals (p<0.001 for all treatment 
groups). 
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Figure 39: The effects of the endogenous CRF-related peptides CRF, UCN1, 
UCN2 and SCP on plasma corticosterone. Data are means ± SEM. *p<0.05, 
**p<0.01, ***p<0.001 as determined by Kruskal-Wallis followed by Mann-Whitney 
U tests. (n=5-11 mice per group). 
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Discussion 
 
 The present study aimed to investigate the hypothesis that CRF and the 
Urocortins induce differing patterns of local cerebral glucose utilisation (LCGU), 
an indicator of neuronal activity, after central administration, and to further 
investigate the role of the CRF1 and CRF2 receptors in these responses. This 
was achieved using CRF and the CRF-related peptides, selective antagonists 
and mutant mice as pharmacological tools. The non-specific CRF1/CRF2 
agonists CRF and Urocortin 1 both induced increases in LCGU after ICV 
administration, although with differing LCGU patterns, and the CRF-induced 
increase in LCGU could be antagonised by the CRF2-selective antagonist 
antisauvagine-30, but not the CRF1-selective antagonist R278995. However, the 
CRF2-selective agonists Urocortin 2 and Stresscopin had no significant effect on 
LCGU. 
 
 An increase in LCGU after central administration of CRF is in direct 
agreement with previous studies in developing and adult rats (Sharkey et al., 
Chapter 4  LCGU and the CRF system 
 115 
1989; Dube et al., 2000; Freo et al., 2005), although the present studies have 
identified significant effects in multiple regions at a far lower dose. At doses in a 
similar range to ours (0.1-1 µg), Freo et al. (2005) found LCGU increases only in 
prefrontal cortex, cerebellum and some brainstem regions. At a higher dose of 
10 µg, more widespread increases in LCGU were found, including hippocampus, 
amygdala, subthalamic nucleus, hypothalamus and in further brainstem regions. 
At a dose of approximately 3 µg CRF in developing rats, Dubé et al. (2000) 
reported increases in LCGU in frontal cortical, amygdala, hippocampal, thalamic 
and brainstem regions, but not the hypothalamus. At the very high dose of 
approximately 25 µg CRF, Sharkey et al. (1989) found increased LCGU in frontal 
cortical, thalamic, hypothalamic (in particular in the lateral hypothalamus, a 
region with CRF projections to the thalamus), cerebellum and a number of mid- 
and hindbrain regions. The widespread effect of CRF on LCGU revealed in the 
present studies may reflect a drawback of the modifications to the technique 
used here. A number of the regions studied are components of the limbic 
system, and indeed all regions studied express CRF or related peptides and 
CRF receptors. Thus it could be expected that a measurement such as LCGU, 
taken at the end of a period of receptor stimulation, would show effects in many 
regions, as the technique cannot delineate whether regions are activated in a 
particular order. 
 
 The complete antagonism of CRF-induced increases in LCGU by the 
CRF2-selective antagonist antisauvagine-30 clearly implicates the CRF2 receptor 
in this LCGU response. The failure of the CRF1-selective antagonist R278995 to 
attenuate the CRF-induced increases in LCGU, and the continued LCGU 
response to CRF in mice lacking a functional CRF1 receptor, support this 
conclusion and further suggest that any involvement of CRF1 in the LCGU 
response to CRF is a small one. However, the failure of the CRF2-selective 
agonists Urocortin 2 and Stresscopin to alter LCGU contradicts a hypothesised 
primary role of CRF2 in LCGU increases. 
 
The use of a stressful technique for the ICV injection (see Chapter 2, 
Study 5) of CRF and the Urocortins may have adversely the LCGU results 
obtained, although a clear effect of the ICV injection technique alone on LCGU 
was not seen (Chapter 2, Study 5). It is possible that the effects of CRF on 
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LCGU seen in the present studies represent a potentiation of stress-induced 
effects on LCGU brought about by the freehand ICV injection procedure. 
However, as stress has been reported to have clear effects on LCGU in the 
literature (Soncrant et al., 1988; Xing et al., 1990; Duncan et al., 1993; Frietsch 
et al., 2000; Takamatsu et al., 2003a, 2003b; and considered later in this thesis), 
the lack of a clearly detectable effect of the ICV procedure on LCGU found in 
Chapter 2 suggests that the degree of stress induced by the procedure is not 
sufficient to significantly alter LCGU.  Despite these considerations, the clear 
effect of antisauvagine-30 on CRF-induced changes in LCGU continues to 
implicate CRF2 receptors in the LCGU response to CRF, in contrast to the effects 
of Urocortin 2 and Stresscopin. The extent of any influence of the ICV procedure 
used could be investigated through the replication of the key elements of the 
present data using pre-implanted cannulae for ICV injection, which under well-
controlled conditions constitute a minimal stressor for the animal. 
 
 Ligand-specific receptor populations within overall CRF1 or CRF2 
populations may explain the lack of effect of Urocortin 2 and Stresscopin on 
LCGU despite the evidence that CRF-induced changes in LCGU are CRF2-
mediated. Indeed a new concept of ligand-dependent differential regulation of 
receptor-coupled effector pathways specifically includes agonist-specific 
signaling (Urban et al., 2007). Such functional selectivity has been suggested for 
a range of neurotransmitter-receptor systems, including in the serotonergic, 
opioid, dopaminergic, vasopressin and adrenergic systems (Urban et al., 2007). 
Urocortin 1 and CRF have been shown to regulate G-protein receptor kinase 
activity differently in human retinoblastoma Y79 cells (Dautzenberg and Hauger, 
2002). Such a difference may account for the differing effect size of Urocortin 1 
on LCGU compared to CRF, and allows speculation that further differences in 
receptor activation may be present for Urocortin 2 and Stresscopin. Ligand 
binding in CRF1 requires ligand-receptor interaction at four points: between the 
ligand C-terminal and the receptor N-terminal, and between the ligand N-terminal 
and the receptor juxtamembrane (J)-domain (Perrin and Vale, 1999; Beyermann 
et al., 2000; Hoare et al., 2004). Whether a similar dual domain model exists for 
CRF2 has not yet been clarified (Hoare et al., 2005). The J-domain in CRF1 has 
been linked to coupling with either Gs or Gi through ligand-induced 
conformational changes (Berger et al., 2006). G-protein interaction with the CRF2 
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J-domain has also been reported to affect the affinity of Urocortin 2 and 
Stresscopin (Hoare et al., 2005), although the effects on CRF or Urocortin 1 
binding were not included in this study for comparison. Therefore it is possible 
that different interaction with the CRF2 J-domain for the different CRF-related 
peptides studied presently may explain the discrepancies between the effects on 
LCGU via CRF2. 
 
Further studies are necessary to determine the rate at which Urocortin 2 
and Stresscopin diffuse from the ventricles after ICV administration, as while it 
has been shown that CRF and Urocortin 1 access cognate receptors after ICV 
injection (Bittencourt & Sawchenko, 2000), it is possible that Urocortin 2 and 
Stresscopin do not diffuse as readily. Indeed, delayed permeation of Urocortin 2 
from the ventricles to sites of CRF2 expression has been proposed (Bale & Vale, 
2004) as a mechanism explaining the delayed effects of this peptide on anxiety-
related behaviour (Valdez et al., 2002). Such time-dependent effects may also 
be present in the LCGU response to Urocortin 2 or Stresscopin, an aspect that 
could also be studied further, although the clear effects of Urocortin 2 or 
Stresscopin on the HPA axis indicate that these peptides have reached CRF2 
receptors in the hypothalamic paraventricular nucleus (PVN) or regions 
projecting to the PVN.  
 
 Ligand-specific receptor activation may also explain the differences in the 
LCGU response to Urocortin 1 compared to CRF, despite Urocortin 1’s higher 
affinity for both CRF1 and CRF2 compared to CRF. A subpopulation of the brain’s 
CRF receptors may be selective for Urocortin 1, and this subpopulation may 
correspond to the endogenous distribution of Urocortin 1. As this endogenous 
distribution is substantially smaller than that of CRF, the effect of exogenous 
Urocortin 1 applied to the brain may also be expected to be less widespread. It 
has also been suggested that Urocortin 1 may act to displace CRF from the 
CRF-binding-protein (CRF-BP) (Behan et al., 1996). Such a mechanism could 
also be involved in Urocortin 1-induced increases in LCGU. 
 
 Chen et al (2005) have identified a soluble version of the CRF2 receptor in 
the brain, expressed in areas that also express CRF1. This variant of the CRF2 
receptor binds Urocortin 2 and 3, but also CRF and Urocortin 1 with high affinity, 
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and the authors propose that it may modulate ligand activity by either competing 
with the full-length, membrane-bound receptors, by presenting the ligand or by 
prolonging its action. Furthermore, the existence of alternative receptors with 
distributions different to those of the membrane-bound receptors may account for 
some of the complex and often varied effects of CRF ligand administration. 
 
 The CRF1 receptor has consistently been implicated in the anxiogenic 
effects associated with CRF through a combination of several antagonist and 
mutant mouse studies (comprehensively reviewed in Steckler, 2005 and 
Takahashi,  2001). Thus, it is possible that the clear involvement of CRF2 in the 
LCGU response could reflect a specific CRF2-mediated glucose metabolism 
pathway, linking with reports of peripheral glucose homeostasis mechanisms 
involving CRF2 (Chen et al., 2006), rather than the LCGU responses measured 
here reflecting a state during (e.g.) anxiety-related behaviours. However, studies 
have shown that CRF2 may also be involved in anxiety-related behaviour that 
can also be CRF1-mediated (Risbrough et al., 2003; Risbrough et al., 2004), and 
have further shown that stimulation of CRF2 in the lateral septum affects anxiety-
related behaviour (Todorovic et al., 2007), although CRF2 stimulation in this 
region can either increase or decrease anxiety-related behaviour depending on 
the basal stress-state of the animal (Henry et al., 2006). Therefore an alternative 
explanation is that some or all of the effects of CRF on LCGU in the present 
studies propagate from CRF2-mediated effects in the lateral septum, which would 
explain their antagonism by antisauvagine-30. 
 
 In those studies examining the effects of CRF on LCGU, CRF consistently 
increased LCGU in multiple brain regions. However, while LCGU was increased 
in the cerebellum and hippocampus in all CRF studies, effects in the frontal 
cortex, hypothalamus and thalamus were less robust. For example, while the 
effect of CRF on LCGU in dissected thalamus was large, in the same region 
measured using autoradiography (although actual nCi/mg values differed due to 
the varying specific activity of the two radioactive isotope forms of 2DG used, 3H 
and 14C) no significant effect was found. This may simply be dose related, as at 
the 0.5 µg dose used in the autoradiography study, only a trend was seen in 
dissected thalamus. However, in the later study examining the effects of 
R278995 on CRF-induced LCGU changes, no significant effect was found in the 
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dissected thalamus even at the 1 µg dose used. This discrepancy may be due to 
increased variation between individual responses in the latter study. However, 
increased experimental variation may also have been introduced by the stressful 
nature of the freehand ICV injection procedure. While the overall effect of CRF in 
increasing LCGU is supported by studies using pre-implanted, less-stressful, 
cannulae (Sharkey et al., 1989; Dube et al., 2000; Freo et al., 2005), the 
robustness of the CRF effect in particular regions may have been reduced 
through the freehand ICV procedure. 
 
 CRF increased hypothalamic LCGU in three out of five studies. While the 
lack of a robust effect in this region may again be due to the techniques used, a 
CRF-induced increase in hypothalamic LCGU is consistent with activation of the 
HPA axis, confirmed by the large increase in plasma corticosterone. However, 
hypothalamic LCGU was not significantly increased in Urocortin 1-, Urocortin 2- 
or Stresscopin-treated animals, despite increased plasma corticosterone, also 
suggesting HPA axis activation. Thus, altered hypothalamic LCGU may be 
unrelated to activation of the HPA axis, although effects purely in the 
paraventricular nucleus (PVN; the source of CRF signaling to the pituitary) could 
be masked by effects in other hypothalamic regions in the dissected sample. 
Indeed, CRF1-mediated neuronal activation and CRF2-mediated neuronal 
suppression has also been reported in the ventromedial hypothalamus 
(McCrimmon et al., 2006), illustrating the possibility that the effects measured in 
complete hypothalamus do not necessarily represent the PVN. 
 
 As described earlier (Introduction) central administration of CRF has also 
been reported to increase c-Fos expression in widespread regions throughout 
the rodent brain (Bittencourt and Sawchenko, 2000), and matching the regions 
exhibiting increased LCGU after CRF administration in the present studies. 
Notably, the effects of central Urocortin 1 administration on c-Fos expression 
closely resembled those to CRF (Bittencourt and Sawchenko, 2000), though to a 
slightly reduced degree at a matching dose. This is in contrast with the effects on 
LCGU seen in the present studies, in which the effects of Urocortin 1 on LCGU 
were much less widespread, despite testing at a higher dose. 
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 LCGU increases after ICV CRF may correspond to behavioural activation, 
which is a reported effect of ICV CRF when the animal is in a familiar 
environment (Dunn and Berridge, 1990), as was the case here, where the 
animals were kept in their home cage during the experimental protocol. As a 
region implicated in the motor control of movement, the increased LCGU seen in 
the cerebellum could support this hypothesis. LCGU in the cerebellum could be 
directly mediated by CRF2, as evidence for expression of this CRF receptor 
subtype in this region has been provided (Bishop et al., 2000; Gounko et al., 
2006), although contradictory findings reporting an absence of CRF2 in the 
cerebellum have also been published (Van Pett et al., 2000). CRF-induced 
LCGU increases may also reflect increased arousal, also associated with central 
administration of CRF (Warnock et al., 2006; Sauvage and Steckler, 2001), and 
with a number of brain regions, including the laterodorsal and pendunculopontine 
tegmental nuclei, dorsal raphe and locus coeruleus, regions included in the 
dissected hindbrain region, which showed up to 40% increase (though reaching 
only trend-like significance in the autoradiography study, although this 
discrepancy may reflect technical issues as discussed above) in LCGU after 
CRF administration. This highlights one of the discussed drawbacks of 
measuring LCGU in dissected brain regions as used presently, as the dissection 
of large brain regions can lead to the amalgamation of small, but interesting, 
regions. 
 
 Also of note, the regions displaying altered LCGU in the present study 
after CRF-related peptide treatment do not entirely correspond to regions 
predominantly expressing either CRF1 or CRF2 receptors. For example, CRF 
induced an increase in thalamic LCGU in most studies, mediated by CRF2 
receptors, despite no reported expression of these receptors in the thalamus 
(reviewed in Warnock et al., 2006). This would suggest changes in LCGU 
downstream of CRF-related peptide-induced effects at CRF receptors in other 
brain regions. Projections from regions directly activated by CRF2 may propagate 
CRF's effects to other regions, and interactions with other neurotransmitter 
systems may also lead to effects in regions not directly stimulated. Indeed, there 
are numerous CRF projections to the thalamus, originating from regions 
including the central amygdala and lateral hypothalamus (reviewed in Warnock 
et al., 2006). As a site of CRF2 expression, LCGU in the hippocampus may be 
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directly influenced by CRF administration. In addition, as discussed above, the 
cerebellum may also be a site of direct CRF2-mediated influence. Although the 
expression of CRF2 in the cerebellum is contested, as discussed above, in the 
absence of CRF2 expression and as a region displaying one of the most robust 
CRF-induced LCGU increases, the cerebellum becomes a likely candidate for 
effects downstream of effects in other regions. 
 
 In addition to the putative links with behavioural activation and motor 
activity through CRF-induced increased LCGU in the cerebellum, a number of 
the other regions displaying altered LCGU after CRF administration in the 
present studies have been implicated in stress-related function.  
 
 Increased LCGU in the dissected hindbrain region may include altered 
LCGU in regions such as the LC, and PPTg, both regions linked to arousal and 
attention (Carli et al., 1983; Steckler et al., 1994; Usher et al., 1999; Inglis et al., 
2001), and sites through which CRF may interact with noradrenaline and 
acetylcholine to modulate these processes (reviewed in Warnock et al., 2006). 
Furthermore, the cholinergic PPTg and LDTg project to the cerebellum, raphe 
nuclei, thalamus, hypothalamus, basal forebrain and medial prefrontal cortex 
(Satoh and Fibiger, 1986; Butcher, 1992; Steckler et al., 1994), providing further 
possibilities of CRF-induced secondary effects on LCGU, through interaction with 
other neurotransmitter systems. Furthermore, a feed-forward loop originating in 
the LC and projecting through the noradrenergic system to the PVN, BNST and 
CeA has been suggested, with a hypothesised involvement in central activation 
during stress-related situations (Koob, 1999). In turn, the PVN, BNST and CeA 
have been implicated as a source of CRF innervation to the ventral tegmental 
area (Rodaros et al., 2007), where CRF release has been linked to stress-
activation of appetitive behaviour (Wang et al., 2005). Also included in the 
dissected hindbrain regions, are the ventrolateral medulla, dorsomedial 
medulla/NTS and ventrolateral pons which have been implicated in several 
integrative functions, including the relaying of primary viscerosensory information 
and in sympathetic activation (Ingram, 2005). 
 
 CRF also induced a trend towards increased LCGU in the amygdala when 
this region was examined more specifically by autoradiography. The CeA and 
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MeA are involved in the processing and relaying of stress signals to other limbic 
and brainstem areas (Davis et al., 1994), and the CeA has also been linked to 
the autonomic effects of CRF through activation of the sympathetic nervous 
system (Dunn and Berridge, 1990; Gray, 1993; Gray and Bingaman, 1996). The 
BLA plays an important role in the integration of inputs from various cortical and 
thalamic sites and may also play an important role in associative learning which 
underlies fear conditioning and anxiety (Ingram, 2005). 
 
 The hippocampus, which exhibited clear, robust, increases in LCGU in 
response to CRF, has a role in episodic memory, particularly for the emotional 
context of memories, and plays a role in regulating behavioural responses to 
threatening environmental contexts (Phillips and LeDoux, 1992). As a part of the 
septo-hippocampal system, the hippocampus may be also involved in anxiety 
through a behavioural inhibition system (Gray, 1983; Gray and McNaughton, 
2000). This region is also a likely site of interaction between the CRF and 
cholinergic systems and their involvement in the modulation of cognitive 
behaviour (reviewed in Warnock et al., 2006). 
 
 In addition to the postulated role of CRF2 receptors in the septum in the 
propagation of CRF-induced effects on LCGU, above, the septal area is involved 
in the regulation of hippocampal function through the septohippocampal 
pathway, a connection that is important in controlling the termination of stress 
responses (Ingram, 2005). 
 
 The dissected frontal cortical region also contained aspects of the 
prefrontal cortex. This region may be involved in the integration of both stress-
induced activation of the HPA axis and gluocorticoid negative feedback with 
executive function and cognitive processing (Sullivan and Gratton, 2002b), and is 
implicated in generating an active coping strategy in response to a stressful 
stimulus (Giorgi et al., 2003), perhaps setting an emotional tone to information 
processing (Ingram, 2005). 
 
 The effects of the endogenous CRF-related peptides tested on LCGU do 
not support theories of opposing roles for these receptors in the brain (Skelton et 
al., 2000; Chen et al., 2003), although care must be taken without direct 
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translation of effects on LCGU into behaviour. It may also be prudent to examine 
the effects of Urocortin 2 and Stresscopin on LCGU using an alternative method 
for ICV injection, as the freehand technique used presently reflects one of the 
largest drawbacks and potential confounds in the present studies. When one 
considers the somewhat unclear literature on the role of CRF2 in e.g. anxiety-
related behaviour (Takahashi, 2001; Takahashi, 2002), it is possible that LCGU 
simply represents one physiological measurement which can be altered by CRF-
related peptides. This particular parameter may not be directly translatable to 
behavioural effects, despite its demonstrated ties to neuronal activation (see 
Introduction), and may be affected through unrelated mechanisms and different 
signaling pathways. Indeed, increased HPA axis activity, as demonstrated by 
increased plasma corticosterone, after stimulation of either CRF receptor, 
despite otherwise unmatching central effects on LCGU, suggests an uncoupling 
of HPA axis and central responses. As 2DG itself only increased plasma 
corticosterone at doses hundreds-fold greater than that used to measure LCGU 
(see Chapter 2), the corticosterone responses to CRF and the Urocortins can not 
be attributed to this aspect of the protocol. 
 
 CRF has been reported to increase blood glucose in the literature (Brown 
et al., 1982a), although the dose used in this study (>25 µg) was much larger 
than those necessary to exert behavioural effects (<1 µg). Sufficient changes in 
blood glucose could violate the assumptions of the LCGU model, leading to 
unreliable conclusions. No effect on blood glucose at the end of the LCGU 
protocol after CRF treatment was found in the present studies, suggesting that 
the assumptions were fulfilled. However, the small increases in residual plasma 
2DG seen after CRF treatment may indicate transient changes in blood glucose 
during the LCGU protocol, not detected by end point measurements. Increased 
blood glucose would compete with 2DG as an energy source for neurons, thus 
effectively reducing measured LCGU as the effective dose of 2DG is reduced. 
Therefore, the detection of increased LCGU after CRF treatment in the present 
studies, despite this minor evidence of changing blood glucose (including the 
state increase in blood glucose found after R278995 treatment), further indicates 
the robustness of the overall LCGU response to CRF (despite less robustness in 
the LCGU effects in particular regions as discussed above). Furthermore, the 45 
minute duration of the LCGU protocol was chosen to allow nearest-to-full 
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metabolism of the injected dose of 2DG, meaning that a large increase in 
competition between endogenous glucose and 2DG would be necessary to 
influence measurements to a physiologically significant level. Assuming an 
approximate injected dose of 18 µCi 2DG (at the 600 µCi/kg dose used), residual 
2DG levels of even 200 nCi/ml (compare to Table 15) represent less than 2 % of 
the initial dose.  
 
 Reduced blood glucose in combined CRF and antisauvagine-30 treated 
groups agrees with the literature for the periphery, in that peripheral Urocortin 2 
and the CRF2 receptor in skeletal muscle are reported to be involved in the 
negative regulation of glucose uptake (Chen et al., 2006). Antisauvagine-30 
increased skeletal muscle glucose uptake, leading to reduced blood glucose 
(Chen et al., 2006). However, it should be noted that this study administered 
Urocortin 2 or antisauvagine-30 peripherally, compared to the ICV route used in 
the present studies. Centrally, Urocortin 3 has been reported to increase 
sympathetic activity in a similar fashion to CRF (Brown et al., 1982b; Dunn and 
Berridge, 1990), including increasing blood glucose (Jamieson et al., 2006). 
Therefore, in the present studies, reduced blood glucose in antisauvagine-30 
treated mice may support a mild, CRF2-mediated, effect on sympathetic activity. 
 
 Increased plasma corticosterone levels after Urocortin 2 or Stresscopin 
administration suggests that CRF2 plays a role in HPA axis activation. In support 
of this, de Groote et al. (2005) found increased levels of corticosterone in the rat 
hippocampus after not only CRF and Urocortin 1 but also after Urocortin 3 
treatment. In contrast, some studies have suggested that CRF2 does not play a 
major role in the acute response of the HPA axis to stress. A number of studies 
have reported that baseline plasma ACTH levels were unaltered by either 
Urocortin 2, Stresscopin or the selective CRF2 antagonist antisauvagine-30 
(Ruhmann et al., 1998), administered either peripherally (Hsu and Hsueh, 2001) 
or centrally (Pelleymounter et al., 2002; 2004), although antisauvagine-30 slightly 
attenuated the ACTH response to ICV injection alone (Pelleymounter et al., 
2002). However, Urocortin 2 mRNA is up-regulated in the parvocellular part of 
the rat PVN following immobilisation stress and in the magnocellular part 
following water deprivation, raising the possibility that this highly selective CRF2 
agonist may be involved in stress-induced HPA axis responses (Tanaka et al., 
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2003). A greater impairment of the HPA axis response to stress has also been 
reported in mice lacking both CRF1 and CRF2, compared to mice lacking CRF1 
alone (Bale et al., 2002b), further supporting a role for CRF2 in the HPA axis. 
Most recently, clear CRF2-mediated activation of the HPA axis, demonstrated 
though increased CRF heteronuclear RNA in the PVN and increased plasma 
ACTH, has been reported after central administration of Urocortin 2 or Urocortin 
3 (Stresscopin) (Maruyama et al., 2007), in direct agreement with the HPA axis 
activation demonstrated by increased plasma corticosterone found in the present 
studies. 
 
 Despite a lack of effect in the present LCGU model, Urocortin 2, as a tool 
for agonism of CRF2 receptors, may affect other factors linked to neuronal 
activation. Indeed, Urocortin 2 has been reported to increase extracellular 
serotonin in the basolateral amygdala (Amat et al., 2004), and also in the 
hippocampus (de Groote et al., 2005), a site of reported CRF2 expression (see 
Warnock et al., 2006). Furthermore, Urocortin 2 has been reported to increase c-
Fos expression in subpopulations of serotonergic neurons within specific 
subdivisions of the rat dorsal raphe nucleus (Amat et al., 2004; Staub et al., 
2005; Staub et al., 2006), a part of the dissected hindbrain region, and reported 
site of CRF2 expression. Furthermore, a number of regions contained in the 
dissected hindbrain regions are sites of Urocortin 1, 2 and 3 expression, 
suggesting endogenous CRF2-related activity in this part of the brain. These 
findings support the hypothesised role of CRF2 in the mediation of neuronal 
activation, despite the lack of activity of this ligand in the present model.  
 
 However, it has been reported that direct administration of Urocortin 2 into 
the dorsal raphe inhibited neuronal activity at low doses, while a higher dose of 
Urocortin 2 showed mixed effects, activating some neurons, while inhibiting 
others (Pernar et al., 2004). These effects could be blocked with the CRF2-
selective antagonist antisauvagine-30, but not the CRF1-selective antagonist 
antalarmin (Webster et al., 1996), indicating that the effects are CRF2 mediated. 
A bimodal mechanism for CRF2-induced neuronal inhibition or activation such as 
this may mask effects on LCGU, meaning that changes in LCGU in particular 
regions could be missed. 
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 The present findings add useful information to the body of literature on the 
function of CRF1 and CRF2 receptors, and CRF-related peptides. In conclusion, 
a role for the CRF2 receptor in the modulation of central glucose utilisation is 
postulated, but the similar effects of the CRF-related peptides on plasma 
corticosterone suggest that the HPA axis response may be uncoupled from the 
central effects of CRF receptor activation. 
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The Effect of Restraint Stress on LCGU and Comparison to The Effects of 
CRF 
 
Introduction/Aims 
 
 As discussed earlier, the CRF system has been implicated in the stress 
response, both in the context of stress-related behaviour and in the activation of 
the hypothalamic-pituitary-adrenal (HPA) axis. Thus, in order to compare the 
effects of direct manipulation of the CRF system on LCGU to those induced by a 
stressor, it was decided to study the effect of restraint stress on LCGU. 
 
 Restraint stress has been reported to activate the HPA axis (Crine et al., 
1983; Odio and Maickel, 1985; Hauger et al., 1988; Rowland and Dunn, 1995; 
Torres et al., 2001; Rivalland et al., 2007), and has also been reported to 
increase c-fos expression in regions that express components of the CRF 
system (Funk et al., 2003; Crane et al., 2005; Funk et al., 2006), such as the 
hypothalamus, amygdala and locus coeruleus, and specifically including CRF-
expressing neurons in the paraventricular nucleus of the hypothalamus (PVN) 
(Rivalland et al., 2007). 
 
 Restraint in cold water has been reported to markedly reduce LCGU 
globally in rats (Xing et al., 1990), and reductions in LCGU in the dorsal 
hippocampus and anteroventral thalamic nucleus were also seen after another 
stressor similar to restraint stress, four limb immobilisation (Soncrant et al., 
1988), although an increase was seen in the lateral habenula. However, it should 
be noted that restraint (and other stressors) have been reported to increase 
blood glucose levels (Odio and Maickel, 1985; Soncrant et al., 1988; Rowland 
and Dunn, 1995; Brown et al., 1996; Torres et al., 2001). As has been discussed 
previously, sufficient variations in blood glucose may influence the measurement 
of LCGU. The measurement of blood glucose as part of the LCGU protocol 
allows for the control of this variable. 
 
 To study the effects of restraint stress on LCGU and the HPA axis, these 
parameters were first measured after restraint during the LCGU protocol, and the 
involvement of the CRF1 receptor assessed using the selective CRF1 antagonist 
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R278995 (Chaki et al., 2004). To further investigate the effects of the restraint 
stress on LCGU, the effects of various durations of restraint were compared. 
 
Methods 
 
Subjects 
 
 Male C57BL/6N mice were used as described in the General Methods. 
 
Compounds 
 
 The selective CRF1 antagonist R278995 (Chaki et al., 2004) co-developed 
by Johnson & Johnson Pharmaceutical Research & Development and Taisho 
Pharmaceuticals (Japan) was used to assess the involvement of CRF1 receptors 
in the LCGU response to restraint. R278995 or solvent (saline plus 10% 
cyclodextrin and tartaric acid) was injected subcutaneously (SC) at a dose of 40 
mg/kg, 1 hour before the injection of 2DG. The formulation of R278995 in 
solution was carried out by the J&JPRD Internal Pharmacy. 
 
Measurement of local cerebral glucose utilisation (LCGU) and plasma 
corticosterone 
 
 LCGU and plasma corticosterone were measured as described in the 
General Methods. 3H-2DG was injected immediately before restraint stress. 
 
Restraint Stress 
 
 For the restraint stress, mice were removed from their home cage, 
injected with 2DG then placed in well ventilated stainless steel restraining tubes 
for between 2 and 45 minutes. Mice receiving restraint stress for less than the 
full 45 minute duration of the LCGU protocol were returned to their home cage 
for the remainder of the protocol duration. 45 minutes after 2DG injection, the 
mice were either removed from their home cages or the restrainers and 
decapitated in accordance with the LCGU protocol. 
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Statistical Analysis 
 
 Data were analysed as described in the General Methods. Briefly, the 
influence of the selective CRF1 antagonist R278995 on LCGU after restraint 
stress was analysed by 2-way ANOVA, while the LCGU response to varying 
durations of restraint stress was analysed by the Kruskal-Wallis test, followed by 
the Mann-Whitney U-test for post-hoc comparisons. 
 
Results 
 
 45 minutes of restraint stress significantly reduced LCGU in all regions 
studied (2-way ANOVA restraint effect F3,26=7.962-29.44, all p<0.01) (Table 16; 
Figure 40), and significantly increased plasma corticosterone levels (2-way 
ANOVA restraint effect F3,26=343.206, p<0.001), but had no effect on either 
residual plasma 2DG or blood glucose (Table 17; Figure 41). 
 
 The effects of restraint on LCGU and corticosterone were unaffected by 
pre-treatment with R278995, as were residual plasma 2DG or blood glucose 
(Table 16, 17; Figure 40, 41). 
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Table 16: The effect of 45 minutes restraint stress, and pre-treatment with 40 
mg/kg R278995 on LCGU (mean ± SEM) in mice (control-control n=8 , control-
restraint n=8 , R278995-control n=6 , R278995-restraint n=8) 
R278995/Restraint
Region
Frontal Cortical 0.36 ± 0.03 0.28 ± 0.02 0.32 ± 0.02 0.25 ± 0.01
Hypothalamus 0.27 ± 0.02 0.22 ± 0.02 0.27 ± 0.02 0.22 ± 0.01
Thalamus 0.33 ± 0.03 0.22 ± 0.02 0.30 ± 0.02 0.21 ± 0.01
Cerebellum 0.22 ± 0.02 0.15 ± 0.01 0.20 ± 0.01 0.13 ± 0.01
Hindbrain 0.15 ± 0.01 0.11 ± 0.01 0.14 ± 0.01 0.12 ± 0.01
Hippocampus 0.26 ± 0.02 0.20 ± 0.02 0.26 ± 0.02 0.20 ± 0.01
Temporal 0.34 ± 0.02 0.25 ± 0.02 0.31 ± 0.02 0.26 ± 0.02
R278995/Restraint
Region
Frontal Cortical -24 ± 5 -12 ± 5 -30 ± 2.2
Hypothalamus -18 ± 7 -2 ± 8 -20 ± 2.6
Thalamus -32 ± 7 -10 ± 8 -35 ± 2.7
Cerebellum -33 ± 4 -10 ± 7 -42 ± 4.8
Hindbrain -29 ± 5 -7 ± 9 -25 ± 4.5
Hippocampus -23 ± 6 -2 ± 6 -24 ± 3
Temporal -36 ± 11 -10 ± 5 -26 ± 5.1
Saline+Restraint R+Ctrl
LCGU (nCi/mg)
Saline+Ctrl Saline+Restraint R+Ctrl R+Restraint
R+Restraint
% change in LCGU
 
Figure 40: The effect of 45 minutes restraint stress, and pre-treatment with 40 
mg/kg R278995 on LCGU in mice (mean ± SEM) (control-control n=8 , control-
restraint n=8 , R278995-control n=6 , R278995-restraint n=8) (Region 
abbreviations as in previous Figures) 
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Table 17: The effect of 45 minutes restraint stress, and pre-treatment with 40 
mg/kg R278995 on residual plasma 2DG, blood glucose and plasma 
corticosterone in mice (mean ± SEM) (control-control n=8 , control-restraint n=8 , 
R278995-control n=6 , R278995-restraint n=8) 
LCGU study Treatment
R278995/ Saline+Ctrl 39 ± 6 135 ± 8 98 ± 22
Restraint Saline+Restraint 36 ± 6 156 ± 16 331 ± 8
R278+Ctrl 37 ± 8 157 ± 12 55 ± 4
R278+Restraint 38 ± 7 176 ± 23 326 ± 10
Residual plasma 
2DG (nCi/ml)
Blood glucose 
(mg/dl)
Plasma cortico- 
sterone (ng/ml)
 
 
Figure 41: The effect of 45 minutes restraint stress, and pre-treatment with 40 
mg/kg R278995 on plasma corticosterone in mice (mean ± SEM) (control-control 
n=8 , control-restraint n=8 , R278995-control n=6 , R278995-restraint n=8) (key: 
Sal – saline; Ctrl – control; Res – restraint; R27 – R278995) 
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When the effect of varying restraint time on LCGU was measured, 
significant reductions in LCGU were only seen after 45 minutes of restraint in the 
frontal cortical, thalamic, hippocampal and temporal dissected regions (p<0.05) 
(Table 18; Figure 42). 
 
 No changes in residual plasma 2DG or blood glucose were found after 
any duration of restraint stress studied (Table 19). Plasma corticosterone levels 
were increased in a restraint-duration dependent manner (Table 19). 
 
Table 18: The effect of different durations of restraint stress on LCGU (mean ± 
SEM) in mice (group sizes n=8-10) (*p<0.05) 
Restraint Stress
Region
Frontal Cortical 0.27 ± 0.02 0.24 ± 0.03 0.22 ± 0.01 0.30 ± 0.02 0.24 ± 0.01 0.21 ± 0.02 *
Hypothalamus 0.20 ± 0.01 0.19 ± 0.02 0.18 ± 0.01 0.22 ± 0.01 0.20 ± 0.02 0.18 ± 0.01
Thalamus 0.22 ± 0.02 0.19 ± 0.02 0.18 ± 0.02 0.24 ± 0.02 0.20 ± 0.02 0.15 ± 0.01 *
Cerebellum 0.13 ± 0.01 0.11 ± 0.02 0.12 ± 0.02 0.13 ± 0.02 0.10 ± 0.01 0.09 ± 0.01
Hindbrain 0.10 ± 0.01 0.08 ± 0.01 0.08 ± 0.02 0.09 ± 0.01 0.07 ± 0.01 0.06 ± 0.01
Hippocampus 0.15 ± 0.01 0.13 ± 0.01 0.13 ± 0.01 0.16 ± 0.00 0.14 ± 0.01 0.12 ± 0.01 *
Temporal 0.18 ± 0.01 0.15 ± 0.01 0.15 ± 0.01 0.25 ± 0.06 0.16 ± 0.01 0.15 ± 0.01 *
Restraint Stress
Region
Frontal Cortical -12 ± 10 -18 ± 5 12 ± 7 -12 ± 4 -22 ± 6
Hypothalamus -8 ± 11 -13 ± 7 11 ± 6 -2 ± 9 -13 ± 5
Thalamus -14 ± 11 -19 ± 8 6 ± 9 -11 ± 8 -32 ± 5
Cerebellum -18 ± 13 -13 ± 12 -6 ± 13 -23 ± 10 -30 ± 7
Hindbrain -20 ± 12 -13 ± 16 -2 ± 15 -22 ± 11 -33 ± 10
Hippocampus -11 ± 10 -16 ± 6 4 ± 3 -8 ± 6 -19 ± 4
Temporal -16 ± 8 -16 ± 6 42 ± 32 -9 ± 6 -17 ± 6
% change in LCGU
2 min 5min 10 min
LCGU (nCi/mg)
20 min 45 min
10 min 20 min 45 min2 min 5min
Control
 
 
Chapter 5  LCGU and restraint stress 
 134 
Figure 42: The effect of different durations of restraint stress on LCGU (mean ± 
SEM) in mice (group sizes n=8-10) (*p<0.05) 
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Table 19: The effect of different durations of restraint stress on residual plasma 
2DG, blood glucose and plasma corticosterone in mice (mean ± SEM) (group 
sizes n=8-10) (*p<0.05) 
LCGU study Treatment
Multiple- Control 44 ± 3 135 ± 9 65 ± 15
Duration 2 min 57 ± 12 163 ± 9 127 ± 23 *
Restraint 5 min 57 ± 10 154 ± 12 112 ± 17 *
10 min 49 ± 3 136 ± 11 146 ± 23 *
20 min 50 ± 3 154 ± 8 188 ± 18 *
45 min 49 ± 6 144 ± 22 323 ± 11 *
Residual plasma 
2DG (nCi/ml)
Blood glucose 
(mg/dl)
Plasma cortico- 
sterone (ng/ml)
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Discussion 
 
 The present studies aimed to compare the effects of an acute stressor, in 
this case restraint, to the effects of manipulating the CRF system on LCGU and 
the HPA axis, as described in the previous chapter. 
 
 Restraint stress activated the HPA axis, in a duration-dependent manner, 
indicated by increased levels of plasma corticosterone. This activation of the 
HPA axis after restraint stress agrees with reports from the literature (Crine et al., 
1983; Odio and Maickel, 1985; Hauger et al., 1988; Rowland and Dunn, 1995; 
Torres et al., 2001; Rivalland et al., 2007), is similar to that seen after central 
administration of CRF or the related endogenous peptides Urocortin 1, 2 and 3, 
and indicates the activation of the CRF system at least at the level of the 
paraventricular nucleus of the hypothalamus (PVN).  
 
 However, in contrast to the apparent CRF2-mediated increases in LCGU 
demonstrated after the administration of CRF and Urocortin 1, LCGU was 
reduced after 45 minutes of restraint stress by up to 42 % (in the cerebellum). 
This is in agreement with previous reports in the literature (Soncrant et al., 1988; 
Xing et al., 1990), but indicates that restraint stress-induced changes in LCGU 
are unlikely to be mediated by a similar mechanism involving CRF2. The failure 
of the CRF1 antagonist R278995 to ameliorate the effects of restraint stress on 
LCGU suggests that in this case this receptor is not the primary component in 
the LCGU response, perhaps implicating other neurotransmitter systems, 
discussed further below.  
 
 Many areas involved in stress processing receive noradrenergic 
innervation, generally arising from hindbrain regions and projecting to limbic and 
cortical regions (Cunningham, Jr. and Sawchenko, 1988). As a result of this 
widespread innervation many stressful stimuli will stimulate noradrenergic activity 
in stress-related areas (Pacak et al., 1995b). For example, noradrenaline release 
occurs in the hippocampus in response to restraint stress (Vahabzadeh and 
Fillenz, 1994) and several other stressors will increase noradrenaline release in 
the medial prefrontal cortex (mPFC), including immobilisation, novel environment 
and conditioned fear (McQuade and Stanford, 2000; Swanson et al., 2004). 
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Furthermore, any one particular stressor will cause noradrenaline release across 
several stress-related areas. For example, microdialysis studies have shown that 
electric footshock induces noradrenaline release in the PVN (Yokoo et al., 1990; 
Ishizuka et al., 2000), amygdala (Quirarte et al., 1998; Williams et al., 1998), 
hippocampus (Hajos-Korcsok et al., 2003) and mPFC (Ishizuka et al., 2000), 
encompassing a number of the regions exhibiting reduced LCGU in the present 
studies. 
  
 Activation of the serotonergic system also occurs during stressor 
exposure, and a variety of stressors can evoke release or turnover of 5HT in the 
PFC, hippocampus, amygdala, nucleus accumbens and LC (Pei et al., 1990; 
Shimizu et al., 1992; Kawahara et al., 1993; Inoue et al., 1994; Linthorst et al., 
1995; Adell et al., 1997; Amat et al., 1998; Kaehler et al., 2000; Funada and 
Hara, 2001), which may influence LCGU. Indeed, acute inhibition of central 
serotonin reuptake using the selective serotonin reuptake inhibitor (SSRI) 
fluoxetine has been reported to decrease LCGU in a widespread manner 
throughout the rat brain (Freo et al., 2000). Evidence for interactions between the 
serotonergic and CRF systems, particularly in the dorsal raphe (DR) (Price et al., 
1998, and briefly reviewed in Chapter 1) also supports the possibility that while 
the present studies do not directly implicate CRF receptors in restraint stress-
induced changes in LCGU, they may still be involved to some degree. 
 
 The acute stress of restraint or footshock has been reported to activate 
the mesolimbic dopamine system (Puglisi-Allegra et al., 1991), and restraint 
stress has also been reported to increase concentrations of the dopamine 
metabolite dihydroxyphenylacetic acid (DOPAC) in the PFC and accumbens, 
and induce Fos immunoreactivity in dopamine neurons of the VTA (Deutch et al., 
1991). However, mixed effects on LCGU, with increases in some regions, such 
as the substantia nigra, have been reported after direct stimulation of dopamine 
receptors (Levant et al., 1998), which may suggest that this system could also be 
limited to a minor role in restraint stress-induced LCGU changes. 
 
 Both restraint stress and swim stress have been reported to induce 
widespread release of glutamate in the mPFC, hippocampus, striatum and 
nucleus accumbens (Moghaddam, 1993). However, the mechanistic links 
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between glutamate and LCGU suggest that this may not be directly linked to the 
effects seen on LCGU in the present studies, as glutamate stimulates the 
glycolytic processing of glucose in astrocytes, which is indicated by increased 
LCGU (Pellerin and Magistretti, 1994), rather than the reductions seen presently 
after restraint stress. 
 
 The near ubiquitous inhibitory effect of GABA on neural activity has made 
it difficult to attribute the effects of this neurotransmitter system on specific 
aspects of the stress response (Ingram, 2005). However increased GABA has 
been measured in the LC after immobilisation stress (Singewald et al., 2000) and 
in the amygdala in response to noise (Singewald et al., 1995), and furthermore 
strong reductions in LCGU have been reported after chronic infusion of GABA 
into the nucleus basalis magnocellularis (Majchrzak et al., 1992), indicating one 
possible mechanism for the reductions in LCGU seen in the present studies. 
 
 While in the first of the present studies restraint stress significantly 
reduced LCGU in all dissected regions, significance was only reached in the 
second study in four of the seven regions. This discrepancy may be explained by 
the differing experimental design between the two studies, necessitating different 
methods of statistical analysis. 
 
 LCGU was reduced in the dissected frontal cortical region. Evidence 
suggests that the mPFC plays an important role in regulating the HPA response 
to emotional stress (Diorio et al., 1993; Figueiredo et al., 2003; Spencer et al., 
2005). From lesion studies, the literature generally suggests that the mPFC 
influences on stress-induced HPA responses are inhibitory (Diorio et al., 1993; 
Brake et al., 2000; Figueiredo et al., 2003; Spencer et al., 2005), although some 
studies suggest altered basal but not stress-induced HPA responses after 
lesioning of the mPFC (Sullivan and Gratton, 2002a), which also suggests a role 
for this region in basal HPA axis regulation. Furthermore, the role of the mPFC in 
modulating HPA activity appears to be subregion specific, as lesions of the 
dorsal mPFC led to exaggerated HPA responses to stress, but ventral mPFC 
lesions led to mildly suppressed HPA responses (Radley et al., 2006). 
 
Chapter 5  LCGU and restraint stress 
 138 
 In studies of LCGU in response to other stressors, effects on LCGU other 
than reductions have been reported. In agreement with the present, and 
reported, data for restraint stress, reduced LCGU has been reported during 
hypothermia (Frietsch et al., 2000) in all regions measured. Although 
hypothermia was induced under anaesthesia, which itself affected LCGU, the 
changes found were still significant when compared to an anaesthetised 
normothermic control group. However, increases in LCGU after swim stress have 
been reported in prefrontal cortical areas, motor cortex and lateral septum, and 
these effects matched with increased fos-like-immunoreactivity in these areas 
(Duncan et al., 1993). Differences in the physical context of the stressor could 
explain such contradictory findings. For example, restraint/immobility and 
hypothermia (in the context above) could be considered to reflect stressors with 
(imposed) limited physical activity, while clearly forced swim stress requires a 
large activity component. Interestingly, the forced swim stress-induced increase 
in LCGU in the lateral septum was blocked by treatment with imipramine 
(Duncan et al., 1993), which in this acute context implicates the serotonergic and 
noradrenergic systems in these LCGU changes. 
 
 Contrasting effects on LCGU have also been reported after treatment with 
pharmacological stressors, perhaps in a species-dependent manner. Injection of 
the pharmacological stressor FG7142, a benzodiazepine partial inverse agonist, 
in rhesus monkeys reduced LCGU in all regions measured (including the frontal 
cortex, thalamus and cerebellum), and plasma cortisol levels were increased 
(Takamatsu et al., 2003a) and reduced LCGU after FG7142 has been reported 
in anxious humans (Gur et al., 1987). Also in rhesus monkeys, the anxiety-
inducing agent mCPP induced global reductions in LCGU (Takamatsu et al., 
2003b). In contrast, FG7142 administration in rats increased LCGU in 
predominantly limbic structures (Ableitner and Herz, 1987), and the anxiolytic 
diazepam decreased LCGU in matching regions (Ableitner et al., 1985). FG7142 
has also been reported to increase c-fos mRNA expression in rats in regions 
including frontal cortical regions, accumbens, medial septum and the ventral 
hippocampus (Funk et al., 2006), matching those regions with altered LCGU in 
reported and present studies, although c-fos techniques can only indicate a 
response in immediate-early gene transcription, and thus cannot help 
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differentiate the contrasting increases or decreases in LCGU seen after FG7142 
administration. 
 
 LCGU can also be estimated by measurement of extracellular lactate 
release (Kuhr and Korf, 1988), using in vivo microdialysis. As discussed in the 
General Introduction, lactate release after glycolytic processing of glucose in 
astrocytes is a likely cellular mechanism quantified in the measurement of LCGU 
(Pellerin and Magistretti, 1994). It has been shown that lactate release in the rat 
medial prefrontal cortex is immediately and transiently increased by 
immobilisation for 5 min, and indeed also after noise or tail-pinch stressors 
(Takita et al., 1992). During 90 min of restraint lactate release was increased 
initially (approx 15 min) before falling gradually to baseline levels. Increased 
LCGU (as estimated by lactate release) during the first minutes of immobilisation 
stress may reflect an active coping response, while a reduction in LCGU after 
continuous restraint (as measured in the present studies using 2DG) may reflect 
an inability of an active coping response to manage continued restraint, perhaps 
even reflecting a change to passive coping. The effect of stress on the HPA axis 
would not appear to be affected by such a differential mechanism, as attested to 
by the clear restraint-duration-dependent gradual increase in plasma 
corticosterone. 
 
 Glucocorticoid feedback may play a role in LCGU changes during 
activation of the HPA axis, particularly in regions associated with the HPA axis 
negative feedback loop, such as the hippocampus (Herman et al., 1992; Cullinan 
et al., 1993). A classic catabolic action of glucocorticoids in numerous peripheral 
tissues is to inhibit glucose uptake into cells (Munck, 1971; Horner et al., 1990), 
and studies have shown that in hippocampal cell cultures glucocorticoids 
significantly inhibit glucose uptake and oxidation both by neurons and astrocytes 
(Horner et al., 1990; Virgin, Jr. et al., 1991), although exposure for at least 4h 
appears to be necessary. LCGU was increased following acute adrenalectomy in 
rats, further indicating a negative modulatory role of glucocorticoids on cerebral 
glucose metabolism (Kadekaro et al., 1988), and acute hydrocortisone challenge 
has been shown to reduce hippocampal LCGU in elderly patients (de Leon et al., 
1997). Whether such a mechanism is involved in the LCGU changes after 
restraint stress in the present studies is unclear. While reduced hippocampal 
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LCGU with simultaneous increased plasma corticosterone is in agreement with 
the hypothesised mechanism, the increased hippocampal LCGU with 
concomitant increased plasma corticosterone after CRF treatment as described 
in the previous chapter is in direct contrast with this theory. Indeed this may 
highlight a drawback of the LCGU technique. It is possible that glucocorticoid 
feedback does induce a reduction of LCGU in a specific subset of hippocampal 
neurons, however when LCGU is measured in the complete hippocampus, 
increased LCGU in a separate neuronal population after CRF treatment may 
mask this effect. 
 
 Lastly, a proteomic analysis of rat hippocampus after repeated 
psychosocial stress revealed (among others) changes in proteins involved in 
energy metabolism, including pyruvate kinase (Carboni et al., 2006), an enzyme 
involved in the glycolysis of glucose to pyruvate, and thus involved in the one of 
the likely cellular mechanisms behind the measurement of LCGU (Pellerin and 
Magistretti, 1994), and thus providing a further link between stress and changes 
in LCGU. 
 
 In conclusion, the present studies suggest that restraint stress does not 
induce similar effects to CRF or Urocortin 1 on LCGU, indicating differing central 
mechanisms, although one cannot preclude that the specific LCGU response to 
CRF2 receptor stimulation is not a part of a more widespread neurotransmitter 
system response to stress. The clear HPA axis response to stress, however, 
indicates the involvement of at least this part of the CRF system in the measured 
responses to restraint stress. 
Chapter 6  General discussion 
 141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 – General Discussion 
Chapter 6  General discussion 
 142 
General Discussion 
 
 
 The aim of this thesis was to test the hypothesis that CRF and the related 
endogenous peptides, Urocortin 1, 2, and 3, induce different patterns of neuronal 
activation after central administration. This was achieved using modified versions 
of Sokoloff et al.’s technique for the measurement of local cerebral glucose 
utilisation (LCGU), and the involvement of CRF1 and CRF2 receptors in the 
LCGU response to CRF was examined using selective antagonists and mutant 
mice lacking a functional CRF1 receptor.  
 
 The measurement of LCGU provides a brain region specific estimate of 
neuronal activity (Sokoloff et al., 1977), and the technique can be applied in a 
translational manner across a range of species, including rodents, primates and 
humans, through the use of different radioligands. 
 
 Two modified versions of the original LCGU technique were chosen after 
experimental examination of a range of modifications, as described in detail in 
Chapter 2.  
 
 The first of these versions, and the one primarily used for the study of the 
CRF system, was a protocol using the cheaper, safer, 3H-2-deoxyglucose (2DG), 
injected intraperitoneally in mice, and with the dissection of a number of brain 
regions. Reports in the literature suggested that these modifications could 
reliably be used to measure LCGU, with results strongly correlating to those 
obtained using the originally described technique (Meibach et al., 1980; Kelly 
and McCulloch, 1983b), and this was supported by the results of the studies 
described in Chapter 2. LCGU measured using 3H-2DG correlated highly with 
that measured by Sokoloff et al. using 14C-2DG, and furthermore the combination 
of using the tritiated ligand in mice serves to significantly reduce cost compared 
to 14C-2DG in rats. The dissection of specific brain regions does not have the 
same resolution for small regions as autoradiography, and groups heterologous 
populations of neurons into given dissected regions, but allows the rapid 
measurement of LCGU without the need for sectioning or the repeated 
delineation of brain regions after autoradiography. 
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 The second version, used for the verification of important experimental 
results from the first protocol, utilised the 14C-labelled version of 2DG, also 
injected intraperitoneally, in order to allow the measurement of LCGU in sections 
taken from treated mice exposed to film. This protocol allowed the replication of 
important results via an alternative method of measurement. 
 
 When these versions of the LCGU technique were used to study the CRF 
system, an interesting but complex set of results were obtained. The large (up to 
67 % in the cerebellum) CRF-induced increases in LCGU could be abolished by 
the CRF2-selective antagonist antisauvagine-30, and LCGU was also increased  
in a more selective set of brain regions by the CRF-related peptide Urocortin 1, 
which is postulated to function as the endogenous ligand for the CRF2 receptor in 
the hindbrain (Hauger et al., 2003). The involvement of the CRF2 receptor, but 
not the CRF1 receptor to a detectable degree, in the response to CRF was 
further confirmed in studies using mice lacking a functional CRF1 receptor and 
using a selective CRF1 antagonist. However, neither of the CRF2-selective CRF-
related peptide agonists, Urocortin 2 or Stresscopin, had any effect on LCGU, 
which may indicate ligand-specific receptor activation, where CRF and Urocortin 
1 are capable of stimulating CRF2 to influence LCGU, but Urocortin 2 and 
Stresscopin are not, despite their in vitro affinity for CRF2. The concept of ligand-
dependent differential regulation of receptor-coupled effector pathways has 
recently been reviewed (Urban et al., 2007), and specifically includes agonist-
specific signaling. It is also possible that an effect of these peptides on LCGU 
was missed through dosing or time of injection, although a range of doses were 
tested and delayed behavioural effects have only been reported for Urocortin 2 
(Valdez et al., 2002), not Stresscopin. The use of a stressful technique for the 
ICV injection of CRF and the Urocortins may also have adversely affected the 
LCGU results obtained, although a clear effect of the ICV injection technique 
alone on LCGU was not seen. It is possible that the effects of CRF on LCGU 
seen in the present studies represent a potentiation of stress-induced effects on 
LCGU brought about by the freehand ICV injection procedure. However, the 
clear effect of antisauvagine-30 on CRF-induced changes in LCGU continues to 
implicate CRF2 receptors in the response, in contrast to the effects of Urocortin 2 
and Stresscopin. Furthermore, as discussed and demonstrated in Chapter 5, 
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many stressors reduce LCGU in numerous brain regions, which could suggest 
that CRF-potentiation of stress effects on LCGU could be expected to further 
reduce LCGU, in contrast to the increases found in the present studies. The 
extent of such an effect could be investigated through the replication of the key 
elements of the present data using pre-implanted cannulae for ICV injection, 
which under well-controlled conditions constitute a minimal stressor for the 
animal.  
 
Thus, in addition to the numerous endogenous CRF-related peptides, 
acting on at least two central CRF receptor subtypes, the further complication of 
the CRF system through postulated ligand-specific effects, may help to explain 
the somewhat unclear literature surrounding the function of the CRF system in 
the brain. While the regions examined in these studies are all sites of CRF 
peptide or receptor expression, these regions are also likely to have an 
involvement in stress-related functions. Whether the present data represent 
direct CRF-related peptide-induced changes in LCGU or a potentiation of ICV-
injection stress-induced changes in LCGU, changes in neuronal activation in 
aspects of the dissected hindbrain region, for example the LC, PPTg and 
aspects of the medulla, suggest links to arousal, attention and autonomic 
regulation, in all of which CRF has been implicated (Dunn and Berridge, 1990, 
and reviewed in Warnock et al., 2006). Increased LCGU in the amygdala and 
hippocampus may relate to their roles in the regulation of the responses to 
stressful situations, while the LCGU changes in the septum and frontal cortex 
may be of functional consequence in stress coping and the termination of stress 
responses. 
 
 The effect of the common stressor, restraint, on LCGU was studied for 
comparison to the effects of CRF on LCGU, as the CRF system has been 
implicated in the stress response (Funk et al., 2003; Crane et al., 2005; Funk et 
al., 2006; Rivalland et al., 2007), particularly for its role in the HPA axis. In 
contrast to the increases in LCGU seen after CRF or Urocortin 1 administration, 
restraint stress reduced LCGU in all regions dissected, an effect that was 
unaffected by pre-treatment with a selective CRF1 antagonist (at a dose 
corresponding to approximately 75% occupancy in the frontal cortex (Chaki et 
al., 2004)). This contrasting response suggested that a mechanism similar to the 
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CRF-induced effects on LCGU involving CRF2 is unlikely, and the failure of the 
CRF1 antagonist to ameliorate the LCGU response to restraint suggested that 
this receptor may not be a principal component of the response, but is perhaps 
part of a response involving numerous neurotransmitter systems. However, as 
the studies into the effects of restraint stress on LCGU did not require the 
administration of compounds by ICV injection, it may be useful to further 
investigate the comparability of the present studies between CRF-related 
peptide-induced effects and restraint stress-induced effects on LCGU. 
 
 Despite the opposing effects on LCGU seen after CRF administration and 
restraint stress, both restraint and the CRF-related peptides had an activating 
effect on the HPA axis, indicating at least one shared component in the response 
to these treatments. In contrast to the differing effects of the CRF-related 
peptides on LCGU, the HPA axis was further activated above the level induced 
by ICV injection stress by not only CRF and Urocortin 1, but also by Urocortin 2 
and Stresscopin (dose-dependently), indicating that activation of the HPA axis 
can be mediated by either the CRF1 or CRF2 receptor. The role of CRF1 in 
activating the HPA axis is well established (reviewed in the Introduction), and 
more recently evidence supporting a role of CRF2 has also been presented in the 
literature (de Groote et al., 2005; Maruyama et al., 2007). Based on the 
distribution of CRF receptors in the hypothalamic paraventricular nucleus (PVN) 
and the anterior pituitary, the two receptor subtypes may exert their influence at 
different levels of the HPA axis. While CRF1 is the predominant subtype 
expressed in the anterior pituitary, CRF2 is the more highly expressed of the two 
subtypes at the level of the PVN (Chalmers et al., 1995). In addition, the 
activation of the HPA axis by Urocortin 2 and Stresscopin despite no effects on 
LCGU, the continued effect of CRF administration on the HPA axis despite 
abolition of this peptide’s effects on LCGU by antisauvagine-30, and indeed the 
restraint stress-induced activation of the HPA axis despite an opposite effect on 
LCGU to that of CRF, combine to suggest that the HPA axis can be uncoupled 
from those central effects measured through LCGU. 
 
 Further studies investigating the possibility of ligand-specific receptor 
activation and second messenger pathways within the CRF system may help to 
draw more detailed conclusions from the present data.  Such mechanisms will 
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most likely be best studied in vitro initially, in order to more readily isolate the 
second messenger systems likely to be involved. The differences in calcium 
signaling in different cell lines expressing CRF receptors is currently being 
investigated (Dautzenberg et al., 2004), although the translation of these effects 
to the endogenous situation is hampered the relative lack of cell lines 
endogenously expressing the CRF2 receptor (Gutknecht, personal 
communication).  
 
 Interactions with other neurotransmitter systems, such as the serotonergic 
and noradrenergic systems, in the LCGU response to the CRF-related peptides 
could be investigated using antagonists selective for components of these 
systems. While the LCGU response in some regions may be a direct effect of 
CRF receptor stimulation, the large body of evidence for interactions between 
the CRF system and other neurotransmitter systems (as discussed in the 
Introduction) tends to suggest that complex interactions, some within specific 
brain regions, could be involved in the effects of CRF on LCGU. The involvement 
of specific brain regions in the LCGU response could also be investigated using 
specific lesion studies. 
 
 While the modified versions of the LCGU technique used here do not 
allow the measurement of changes in LCGU during periods less than 45 
minutes, it may be possible to study the temporal course of changes in LCGU 
produced by CRF-related peptides or restraint stress by measuring extracellular 
lactate release using microdialysis. This technique can be used to estimate 
LCGU (Kuhr and Korf, 1988), and is capable of sampling extracellular lactate 
levels with improved temporal resolution, compared to the measurement of 
LCGU using 2DG. 
 
 In conclusion, the studies comprising this thesis have confirmed the 
hypothesis that central administration of CRF and the Urocortins induces 
differing patterns of neuronal activation, measured through local cerebral glucose 
utilisation. The CRF2 receptor was clearly implicated in the mediation of CRF-
induced increases in LCGU, and a number of brain regions exhibited altered 
LCGU after CRF administration, highlighting the need to further study the role of 
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these regions in the CRF system’s involvement in stress-related disorders such 
as post-traumatic stress disorder and depression.  
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Appendix 1 
 
Brain Region Dissection Illustrations 
 
Figure 43: Diagrams illustrating the definition of brain regions for dissection. 
a) Sagittal definition for frontal cortex, hippocampus, thalamus, hypothalamus, 
hindbrain and cerebellum. b) Coronal definition for septum and caudate 
putamen. c) Coronal definition for thalamus, hypothalamus and temporal region. 
 
a) 
 
b) 
 
c) 
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Appendix 2 
 
Analysis of CRF1 and CRF2 mRNA expression in CRF1KO mice 
 
 This study was carried out to confirm the lack of functional CRF1 receptor 
expression in CRF1 knockout mice that were used to examine the role of CRF1 in 
the LCGU response to CRF. 
 
Methods 
 
 The following analysis was carried out by Ilse Goris (Johnson & Johnson 
Pharmaceutical Research & Development). Tissue from different brain regions 
was disrupted and homogenized using a Mixer Mill MM300 (Quiagen). RNA was 
isolated using an RNeasy Lipid Tissue kit (Qiagen) and First strand cDNA 
synthesis was performed with SuperScript II Reverse Transcriptase (Invitrogen) 
followed by Real time RTQ. Real Time Quantitative RTQ-PCR was performed 
using an ABI PRISM 7900 Sequence Detection System instrument (Applied 
Biosystems) using Assay on Demand primers (Applied Biosystems). In order to 
identify whether a truncated transcript of CRF1 was still expressed in the 
mutants, two primer-probe sets for CRF1 were used, one targeting the deleted 
exons 8-9 (Mm00432675_m1, Applied Biosystems) and another targeting the 
non-deleted exons 3-4 (Mm00432670_m1, Applied Biosystems).  For CRF2 a 
primer-probe set was used targeting exon 13: 
 
Forward primer: GGGAGAACAGAAGCGCCTG 
Reverse primer: CCCTTGTTTCAATCACTCCCA 
Probe: AGAAGGGTGAGGATCCCCCAAATCAGAGT[5']6_FAM [3']TAMRA 
 
 mRNA expression was expressed as a ratio of CRF1 or CRF2 expression 
against beta-actin expression. 
 
Results 
 
 Using the probe set for the deleted exons, 8-9, of CRF1, no expression of 
CRF1 mRNA was found as compared to wild-type littermates (Figure 44). In 
Appendix 2 
 151 
contrast, the probe set for exons 3-4 revealed expression of a CRF1 mRNA-like 
signal similar to that in wild-types (Figure 45). 
 
 CRF2 mRNA expression was unaltered between CRF1KO and wild-type 
littermates (Figure 46). 
 
Figure 44: Expression of CRF1 receptor mRNA in CRF1KO (KO) and wild-type 
(WT) mice as measured using a probe set for exons 8-9.  
(N.B. the CRF1:beta-actin ratio in KO mice was precisely zero, thus is not 
apparent as a column in the Figure below).  
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Figure 45: Expression of CRF1 receptor mRNA in CRF1KO (KO) and wild-type 
(WT) mice as measured using a probe set for exons 3-4. 
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Figure 46: Expression of CRF2 receptor mRNA in CRF1KO (KO) and wild-type 
(WT) mice as measured using a probe set for exon 13. 
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Discussion 
 
 Analysis of CRF1 mRNA expression in CRF1KO mice confirms the knock 
out of exons 8-9 of the CRF1 gene. However, the second probe set targeting 
exons 3-4, which were not targeted in the generation of these CRF1 knockout 
animals, revealed that a truncated transcript of the receptor mRNA is still 
expressed. As exons 8-9 encode a part of the receptor binding domain (Timpl et 
al., 1998), this truncated transcript can be considered inactive. Furthermore, the 
large reduction in HPA axis activation after the ICV injection of CRF in CRF1KO 
mice (Chapter 4, Table 15) supports the expected phenotype (Timpl et al., 1998).  
 
 The unaltered expression of CRF2 mRNA in CRF1KO mice may indicate 
that any compensatory processes do not affect the expression of this CRF 
receptor subtype. 
 
 In conclusion, the measured expression of CRF1 and CRF2 receptor 
mRNA confirms the CRF1 knock-out status of these mice. 
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Appendix 3 
 
Administration of R278995 in the diet 
 
 This pilot study was carried out to confirm the suitability of dietary 
administration to deliver the CRF1 antagonist R278995 (Chaki et al., 2004) in 
sufficient quantity to occupy CRF1 receptors in the mouse brain. 
 
Methods 
 
Basic protocol 
 
 In initial LCGU studies it became clear that a preinjection (vehicle or 
compound) disrupted the LCGU response to CRF in the positive control group, 
making it impossible to study the effect of the CRF1-selective antagonist 
R278995 on this response via this method. For this reason, it was decided to 
administer the compound through the diet. 
 
 The dry compound was administered to male C57Bl/6 mice in a powdered 
premixed diet from Research Diets (http://www.researchdiets.com) to an 
approximate dose of 40 mg/kg/day based on mice consuming approximately 4 
grams per 24 hours (as indicated by pilot studies). The final diet was D12450B.  
 
 The standard VRF1 diet was replaced with the powdered diet containing 
R278995 for 5 days prior to testing. Plasma and brain levels of R278995 were 
measured by Liquid Chromatography/Mass Spectrometry/Mass Spectrometry 
(LC-MS/MS) on day 6 at three time points (0800, 1100, 1500) to assess the fall 
in levels based upon the 1.8 hour plasma half-life of the compound, and taking 
into consideration that food consumption effectively stops during the light-phase 
(confirmed in a separate pilot study). The occupancy of CRF1 receptors in the 
frontal cortex was also measured on day 6 using an ex vivo receptor binding 
protocol utilizing 125I-sauvagine. Both plasma/brain compound levels and CRF1 
occupancy were compared to those after acute oral administration of 40 mg/kg 
R278995 (1 hour preinjection). 
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LC-MS/MS for measurement of compound in plasma and brain 
 
 LC-MS/MS was carried out by the staff of the ADME-Tox department of 
Johnson & Johnson Pharmaceutical Research & Development. Brain samples 
(whole brain) were homogenized in mQ-water (1:10 ratio by weight). After 
solubilisation (with methanol) and  protein precipitation (with acetonitrile), plasma 
and brain samples were quantified on an reversed phase liquid chromatography 
(LC)-column (BDS hypersil C18 3 µm, 50x4.6 mm; Thermo).  Mobile phases 
consisted of  acetonitrile (solvent A) and 0.01M ammonium formiate (pH4) 
(solvent B). Chromatographic separation was obtained by gradient elution (10 % 
solvent A; 90 % solvent B starting conditions to 90 % solvent A; 10 % solvent B 
in 3 min) at a flow rate of 1.2 ml/min. 
 
 LC-MS/MS analysis was carried out on a  API-3000 MS/MS (Applied 
Biosystems, Toronto, Canada), which was coupled to an HPLC-system (Agilent; 
Palo Alto, US). The MS/MS, operated in the positive ion mode using the 
TurboIonSpray™-interface (electrospray ionisation), was optimised for the 
quantification of the compound (MRM transition for R278995: 412.1 > 315). 
 
 The limit of quantification was 5.00 ng/ml for plasma samples and  50.0 
ng/g for brain samples. The accuracy (intra batch accuracy from independent QC 
samples) was between 80% and 120% of the nominal value over the entire 
range for plasma and brain samples. 
 
Measurement of CRF1 occupancy in frontal cortex 
 
 Occupancy of CRF1 receptors was measured in 20 µm frontal cortex 
sections taken on a Leica cryostat. The slides were pre-incubated in rinsing 
buffer (50 mM Tris-HCl, 2 mM EGTA, 10 mM MgCl2, pH 7.4) for 1 minute before 
incubation for either total or non-specific binding. Incubation buffer was prepared 
by the addition of 4 µg/ml leupeptin, 2 µg/ml chymostatin, 40 µg/ml bacitracin, 1 
mg/ml bovine serum albumin, and finally 125I-sauvagine (final concentration 
60258 cpm/50 µl) to the rinsing buffer. Non-specific binding was assessed by the 
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addition of the CRF1 antagonist CRA5626 (10
-5 M) (Steckler et al., 2006) to an 
aliquot of the incubation buffer. After 45 min incubation for either total or non-
specific binding, the slides were washed in rinsing buffer for 5 min in triplicate 
and finally rinsed in distilled water before air drying. The sections were exposed 
to Ektascan films (Kodak) for 10 days with 125I-standards, and the resultant 
autoradiograms were analysed and quantified using a MicroComputer Imaging 
Device (MCID) M1 imaging system. Ex vivo receptor labelling in R278995 treated 
animals was expressed as a percentage of sauvagine binding in control animals. 
 
Results 
 
 R278995 was clearly detectable in both plasma and brain after 5 day 
dietary administration (Figure 47), although at levels up to ten fold lower than 
those seen after acute oral administration (Figure 48). The level of R278995 in 
the plasma after dietary administration declined with time throughout the test day 
(light phase). In contrast, a similar decline in brain R278995 levels was not seen. 
 
 Despite the large difference in detectable plasma and brain compound 
levels between dietary and acute oral routes, CRF1 receptor occupancy was 
similar in acute oral and 0800 sampled dietary groups (Figure 49). Occupancy 
declined by the later (1100) sampling time. 
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Figure 47: Plasma and brain levels of R278995 after 5 days dietary 
administration at 40 mg/kg/day 
0
200
400
600
800
1000
1200
1400
1600
08:00 11:00 15:00
time of sacrifice on day 6
[R
2
7
8
9
9
5
] 
p
la
s
m
a
 n
g
/m
l,
 
b
ra
in
 n
g
/g
plasma brain
 
 
Figure 48: Plasma and brain levels of R278995 1 hour after oral administration of 
R278995 at 40 mg/kg 
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Figure 49: Ex vivo CRF1 receptor binding after either acute oral or 5 day dietary 
administration of R278995 (Key: ctrl – untreated control group; PO – oral dosing; 
D – dietary dosing) 
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Discussion 
 
 This study demonstrated that administration of R278995 in the diet 
produced detectable levels of the compound in plasma and brain, with an 
occupancy of CRF1 receptors similar to that after acute administration of the 
same compound. 
 
 Plasma levels of R278995 declined with testing time. The testing times 
selected all fall within the light-phase, the period in which later studies would be 
carried out. An initial pilot study confirmed that C57Bl/6 mice consume 
approximately 4 g of powdered diet during the dark-phase, but only 
approximately 0.5 g during the light-phase. Thus, based upon the 1.8 hour 
plasma half-life of R278995 (internal communication), a fall in plasma compound 
level during the light-phase was expected. 
 
 In contrast, brain compound levels did not exhibit a similar decay. This is 
supported by initial internal metabolic studies of R278995, which indicated a high 
blood-brain barrier permeability and increased half-life in this organ. 
 
 While the plasma and brain levels of R278995 after dietary administration 
were substantially lower than those after acute oral administration, the 
occupancy data indicates that a similar level of receptor binding compared to 
control animals was obtained. Despite the fall in CRF1 occupancy at the later 
morning time point, it was decided that the receptor occupancy during the testing 
period used in subsequent studies (0730 to 1130) was sufficient to assume 
antagonism at CRF1.  
 
 In conclusion, dietary administration of R278995 was deemed to be a 
suitable route for the use of this compound to study the role of CRF1 in the LCGU 
response to CRF, in order to avoid the disruptive effect of an acute pre-injection 
on the LCGU response. 
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Appendix 4 
 
Publications 
 
 Content from this thesis was presented in Abstract and Poster form at the 
following conference: 
 
- 2007 British Association for Psychopharmacology Summer Meeting, Oxford, 
UK 
 23rd-26th July 2006 
 
CRF-induced increases of relative local cerebral glucose utilisation in the mouse 
brain are mediated by the CRF2 receptor 
 
Geoff Warnock, Dieder Moechars & Thomas Steckler 
 
Corticotropin-releasing factor (CRF) is well known for its role in the hypothalamic-
pituitary-adrenocortical (HPA) axis and its involvement in stress and anxiety, 
among other centrally mediated functions. CRF acts via two main receptor 
subtypes, CRF1 and CRF2. Other endogenous CRF-related peptide ligands for 
the two primary CRF receptors are the urocortins 1, 2 and 3. While CRF is 
thought to mediate its anxiolytic-like properties through CRF1, the role of CRF2 
and its endogenous ligands urocortin 2 and 3 are unclear in the literature. 
 
Measurement of local cerebral glucose utilisation (LCGU) provides an estimate 
of neuronal activity in specific regions of the brain. We have previously shown 
that CRF (and urocortin 1) increase LCGU after intracerebroventricular (ICV) 
administration, while simultaneously activating the HPA axis. Both of these 
peptides are non-specific for either CRF1 or CRF2, although CRF has an 
approximately 28-fold greater affinity for CRF1. 
 
The present studies examine the role of CRF1 and CRF2 in the CRF-induced 
LCGU response, using a modified version of the LCGU technique, in which 3H-2-
deoxyglucose (2DG) was injected intraperitoneally in adult male C57BL/6N mice 
or CRF1-null mutant mice (CRF1KO) and wild-type littermate controls. Selected 
brain regions were dissected 45 minutes after simultaneous administration of 
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peptides and 2DG. Following homogenisation, 2DG levels were measured by 
liquid scintillation counting. 
 
The involvement of CRF1 was examined by measuring CRF-induced changes in 
LCGU in CRF1KO and wild-type mice, while the involvement of CRF2 was 
examined by co-administering the CRF2-selective antagonist antisauvagine-30 
(aSVG) in C57BL/6N mice. 
 
0.5µg CRF increased LCGU in thalamic, cerebellar, hindbrain and hippocampal 
regions in both CRF1KO mice and their wild-type littermates compared to saline-
treated controls (n=7-8/group), while the CRF-induced increase in plasma 
corticosterone in wild-types was greatly diminished in CRF1KO mice. In 
C57BL/6N mice (n=6-8/group), 1µg CRF significantly increased LCGU in frontal 
cortical, thalamic, cerebellar, hindbrain and hippocampal regions. This effect was 
completely abolished by aSVG (1 and 3µg) co-administered with CRF. 
 
The fact that CRF was effective in mice lacking a functional CRF1 receptor 
suggests that the LCGU response is not CRF1 mediated. The abolishment of 
CRF-induced increases in LCGU by the CRF2-selective antagonist aSVG clearly 
suggests a role for this receptor in the response. Continuing studies using a 
selective CRF1 antagonist and co-administration of aSVG with CRF in CRF1KO 
mice will further characterise the complicated interaction between CRF1 and 
CRF2 in cerebral glucose utilisation. 
 
Also published during the course of this thesis: 
 
Interactions between CRF and acetylcholine in the modulation of cognitive 
behaviour 
 
Geoff Warnock, Jos Prickaerts & Thomas Steckler 
 
In: Neurotransmitter Interactions and Cognitive Function (pp. 41-63), Edited by 
Edward D. Levin, © Birkhäuser Verlag/Switzerland 
 
PMID: 17019882 [PubMed - indexed for MEDLINE] 
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